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Background-—The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially
reduce low-density lipoprotein cholesterol (LDL-C) when added to statin therapy in patients who need additional LDL-C reduction.
Methods and Results-—We conducted a systematic review and network meta-analysis of randomized trials of lipid-lowering
therapies from database inception through August 2016 (45 058 records retrieved). We found 69 trials of lipid-lowering therapies
that enrolled patients requiring further LDL-C reduction while on maximally tolerated medium- or high-intensity statin, of which 15
could be relevant for inclusion in LDL-C reduction networks with evolocumab, alirocumab, ezetimibe, and placebo as treatment
arms. PCSK9 inhibitors signiﬁcantly reduced LDL-C by 54% to 74% versus placebo and 26% to 46% versus ezetimibe. There were
signiﬁcant treatment differences for evolocumab 140 mg every 2 weeks at the mean of weeks 10 and 12 versus placebo (74.1%;
95% credible interval 79.81% to 68.58%), alirocumab 75 mg (20.03%; 95% credible interval 27.32% to 12.96%), and
alirocumab 150 mg (13.63%; 95% credible interval 22.43% to 5.33%) at ≥12 weeks. Treatment differences were similar in
direction and magnitude for PCSK9 inhibitor monthly dosing. Adverse events were similar between PCSK9 inhibitors and control.
Rates of adverse events were similar between PCSK9 inhibitors versus placebo or ezetimibe.
Conclusions-—PCSK9 inhibitors added to medium- to high-intensity statin therapy signiﬁcantly reduce LDL-C in patients requiring
further LDL-C reduction. The network meta-analysis showed a signiﬁcant treatment difference in LDL-C reduction for evolocumab
versus alirocumab. ( J Am Heart Assoc. 2017;6:e005367. DOI: 10.1161/JAHA.116.005367.)
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L owering low-density lipoprotein cholesterol (LDL-C)levels with statins reduces the risk of atherosclerotic
cardiovascular disease (CVD).1-6 The IMPROVE-IT trial7 sub-
stantiates that LDL-C reduction with nonstatin therapy further
reduces risk of CVD, although the absolute reduction in
cardiovascular events was small because of modest LDL-C
lowering with ezetimibe on top of a statin.8 There remains,
however, a population of high-risk patients who have elevated
LDL-C despite statin therapy and who have residual risk of
cardiovascular events and mortality.9 As a result, there is an
unmet need for new therapies to provide this high-risk
population with incremental LDL-C reduction beyond that
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which can be achieved by statins and other oral lipid-lowering
therapies. Moreover, there is evidence that the lower LDL-C
achieved provides further risk reduction.10,11
Produced mostly in the liver, proprotein convertase
subtilisin/kexin type 9 (PCSK9) in plasma binds to hepatic
LDL receptors on the cell surface and targets them for
degradation, thereby decreasing the number of LDL receptors
and increasing LDL-C levels. PCSK9 was identiﬁed as a target
when people with variants that upregulated or downregulated
this protein led to, respectively, greater and lesser risk of
cardiovascular events.6 The PCSK9 inhibitors evolocumab and
alirocumab were recently approved for LDL-C reduction when
added to maximally tolerated statin therapy.
To date there are no head-to-head studies comparing the
LDL-C–lowering capacity of PCSK9 inhibitors to each other. In
the absence of such trials indirect treatment comparisons and
network meta-analyses based on a robust systematic litera-
ture review can inform evidence-based healthcare decision
making.12 Within network meta-analyses, indirect treatment
comparison allows the comparison of 2 therapies that share a
common comparator,13 whereas mixed treatment comparison
allows a combination of direct and indirect evidence.14,15
Systematic reviews with subsequent meta-analyses have
been conducted using clinical studies of PCSK9 inhibitors.16-20
However, such studies have either pooled PCSK9 inhibitors
together as a class16-19 or provided pooled efﬁcacy estimates
for evolocumab versus control and alirocumab versus control
without making any formal indirect comparisons.20 Finally,
none of the meta-analyses speciﬁcally focused on patients
whose hypercholesterolemia was not controlled with statin
therapy alone, the primary populations for which evolocumab
and alirocumab are indicated.21-24
We therefore conducted a systematic review and network
meta-analysis to compare LDL-C reduction with evolocumab
to other lipid-lowering therapies (including alirocumab) in
patients receiving statin background therapy.
Methods
Objectives, Study Selection, Quality Assessment,
and Data Abstraction
We conducted this systematic review and network meta-
analysis with a target population of patients with hyper-
cholesterolemia whose condition is not adequately con-
trolled according to European lipid goals25 with moderate- to
high-intensity statin background therapy and who remain at
risk of cardiovascular events. The therapies (ie, interven-
tions) we assessed were evolocumab and other pharmaco-
logic agents for the management of hypercholesterolemia.
The control for each therapy was placebo (ie, background
statin therapy alone) and all other therapies that share a
common comparator. The efﬁcacy outcomes of interest were
percentage change from baseline in LDL-C, high-density
lipoprotein cholesterol (HDL-C), non-HDL-C, apolipoprotein B
(ApoB), and lipoprotein (a) [Lp(a)] and cardiovascular events
(not the focus of this article owing to a lack of available data
for analysis). The safety outcomes of interest were any
adverse event (AE), treatment-related AE, and serious AE.
The systematic review adhered to methods published by
the Centre for Reviews and Dissemination26 and the Cochrane
Collaboration.27 Randomized studies were included if they
enrolled adults (≥18 years) with primary familial or nonfamilial
hypercholesterolemia who were candidates for evolocumab or
other pharmacological lipid-lowering therapies added to
statins. Only studies with ≥12 weeks of follow-up and ≥10
patients per group were included. Studies were excluded if
they included patients with organ transplantations, infectious
diseases such as HIV/AIDS, New York Heart Association
grade III-IV heart failure, or stage 4 or 5 renal dysfunction.
Studies were excluded if patients were only receiving a low-
intensity statin as background, as were those that solely
studied statin therapy. Only doses and frequencies that are
Clinical Perspective
What Is New?
• Patients who need additional lowering of low-density
lipoprotein-cholesterol (LDL-C) despite statin therapy may
beneﬁt from additional lipid-lowering therapy such as
evolocumab or alirocumab (proprotein convertase subtil-
isin/kexin type 9 inhibitors [PCSK9]).
• A systematic literature review found 74 total studies that
explored LDL-C lowering in patients receiving statin back-
ground therapy; of these, 15 were used to conduct a network
meta-analysis of evolocumab, alirocumab, and ezetimibe.
• A network meta-analysis found that evolocumab 140 mg
every 2 weeks reduced LDL-C by 74% versus placebo and
46% versus ezetimibe; alirocumab 75 mg every 2 weeks,
54% and 26%; alirocumab 150 mg every 2 weeks, 60% and
32%; evolocumab 420 mg every month, 72% and 48%; and
alirocumab 300 mg every month, 52% and 28%.
What Are the Clinical Implications?
• Studies of PCSK9 inhibitors in a range of populations and
risk proﬁles have consistently showed a substantial relative
reduction in LDL-C additional to that provided by statins—
often more than 60%, as shown in the present analysis.
• Such incremental LDL-C reduction can allow patients with
high unmet need (eg, those at very high cardiovascular risk)
to achieve LDL-C levels below target, which is expected to
reduce their residual risk of cardiovascular events.
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marketed in the United States or European Union or
investigated in phase 3 studies were included.
We searched MEDLINE, Embase, the Cochrane Databases
of Systematic Reviews and Controlled Trials CENTRAL, the
Database of Abstracts of Reviews of Effects, and the Health
Technology Assessment Database from inception to August
2016. The search strategy was limited where possible to
randomized studies and those in humans but was not limited
by date or language. We searched clinical trial registries and
conference abstracts, presentations or posters, in order to
identify unpublished studies. For studies sponsored by
Amgen, the sponsor of the evolocumab clinical trial program,
we used both publications and clinical study reports.
Keywords for the searches included the hypercholesterolemia
disease state and all therapies used to modify atherogenic
lipids (see Data S1). For quality assurance, the Embase search
strategy was peer-reviewed by a second information specialist
using the Canadian Agency for Drugs and Technologies in
Health peer review checklist.28
Two independent reviewers screened titles and abstracts
to exclude records that obviously did not meet inclusion
criteria; 2 reviewers then obtained and independently
screened full texts for inclusion in the systematic review.
Data were extracted by 1 reviewer and independently
checked for errors by another reviewer. The same process
was used to assess the methodological quality of all included
studies using the Cochrane Collaboration Risk of Bias
Assessment Tool.27 Throughout the screening and data
extraction process, discrepancies between reviewers were
resolved through discussion or by consulting a third reviewer.
Data Synthesis and Analysis
Networks were created including studies that provided
sufﬁcient data for synthesis and with the aim of ensuring as
much homogeneity as possible (eg, based on study design
and clinical characteristics). All available data from the
included studies were incorporated except data from patients
in evolocumab studies with no statin use before enrollment
(30% of LDL-C Assessment w/PCSK9 MonoclonaL Antibody
Inhibition Combined with Statin ThErapy – 2 (LAPLACE-2))29
and patients assigned to diet alone based on their cardiovas-
cular risk (12% of Durable Effect of PCSK9 antibody
CompARed wiTh placEbo Study (DESCARTES)).30
We conducted meta-analyses only if the underlying studies
were considered to be statistically and clinically homogenous.
We assessed statistical heterogeneity with the chi-squared
test (P<0.10 was considered signiﬁcant for heterogeneity)
and the I2 value and by visual inspection of the forest plots.
We could not assess publication bias because there were not
enough studies in each direct meta-analysis to generate a
funnel plot. Stata (StataCorp; College Station, TX) version
13.1 was used to conduct direct meta-analyses using random
effects models. To explore the robustness of results, sensi-
tivity analyses were performed by excluding speciﬁc studies
(eg, if they were associated with heterogeneity in direct meta-
analyses, or unique populations such those enrolled in studies
conducted in Japan) or by relaxing inclusion criteria and
including additional studies.
The network meta-analysis was conducted using Bayesian
models31 in WinBUGS (MRC Biostatistics Unit; Cambridge,
UK) version 1.4.3. We estimated the mean treatment
difference or risk ratio for each comparison after an initial
burn-in of 40 000 Markov chain Monte Carlo simulations,
followed by a further 40 000 simulations. Two chains were
used. We used noninformative normal priors (mean 0,
variance 10 000) for treatment effects and a noninformative
uniform prior (interval 0, 5) to estimate the between-study
standard deviation. We assessed convergence and autocor-
relation by monitoring the trace and autocorrelation plots in
WinBUGS. None of the models showed any problems with
convergence. We obtained the median estimate of the mean
difference or risk ratio from the posterior distribution and
reported it with the 2.5% and 97.5% estimates of the
distribution (the 95% credible interval [CrI]). We assessed
model ﬁt using residual deviance and the deviance informa-
tion criterion. All analyses used random-effects models and
the treatment effect from each study (ie, mean difference,
rather than the mean and standard error for each group).
Within the network meta-analysis, we reviewed assump-
tions of homogeneity based on the I2 statistic from the direct
meta-analyses, similarity using the baseline characteristics
and designs of the included studies, and consistency using
the IFPLOT command in Stata in comparisons with both direct
and indirect comparisons. We conducted sensitivity analyses
to explore any heterogeneity by excluding individual studies or
those in different populations. We also conducted sensitivity
analyses combining both evolocumab dosing groups and
including studies with all background therapies.
We excluded on a post hoc basis nodes in the networks
that included fenoﬁbrate or anacetrapib from this article. The
anacetrapib arm was excluded because this cholesterylester
transfer protein inhibitor’s cardiovascular outcomes trial is
ongoing, and all of the prior trials in this drug class have been
neutral or negative in risk reduction.32 Moreover, a recent
meta-analysis of lipid-lowering therapy found that therapies
that upregulated LDL receptor function were linearly associ-
ated with reductions in cardiovascular events per 1 mmol/L
reduction in LDL-C. This relationship was less consistent with
ﬁbrates and cholesterylester transfer protein inhibitors, and
statin-era trials in particular were negative or neutral in
reducing cardiovascular events.5 We also excluded boco-
cizumab after Pﬁzer announced they were halting clinical and
commercial development of this PCSK9 inhibitor.33 Pﬁzer
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noted in its press release that studies of bococizumab showed
reduced efﬁcacy over time and more injection-site reactions
than evolocumab and alirocumab.33
Evolocumab can be administered as 140 mg every 2 weeks
(Q2W) or 420 mg monthly (QM), and we generated separate
networks for each dosing option. The co–primary end points
for most evolocumab studies were the percentage change in
LDL-C from baseline to the mean of 10 and 12 weeks and to
week 12. The co–primary end point of 10 and 12 weeks allows
a better representation of the efﬁcacy of evolocumab across
the dosing period, particularly for monthly administration, and
is included in international prescribing information. To be
concise, this analysis for evolocumab (140 mg Q2W) is the
focus of the main text and sensitivity analysis. Key results for
week 12 are reported in Figure S1. Because data from some
comparator studies were available only for follow-up of longer
than 12 weeks (eg, up to 78 weeks), we analyzed values using
evolocumab at the mean of 10 and 12 weeks or at week 12
versus comparators at ≥12 weeks. In practice, week-12 data
were available for percentage reduction in LDL-C but less
consistently for other lipid end points.
If the outcome was not available at week 12, we used the
nearest time point after week 12. For alirocumab studies, in
which dose titration is often employed, we speciﬁcally aimed
to analyze patients who were taking only 75 mg Q2W, only
150 mg Q2W, or only 300 mg QM.
Results
Figure 1 displays the systematic review ﬂow diagram. The
systematic review found 45 058 unique records, of which
44 318 were excluded based on the title and abstract. The full
papers of the 740 remaining records were assessed for
eligibility, and 502 were excluded with reasons, leaving 238
records reporting 74 studies (studies and records included and
excluded are displayed in Data S2). These 74 studies had study
data available, and 69 of them focused on a population
requiring further LDL-C reduction while on maximally tolerated
statin therapy. The remaining 5 studies were in statin-
intolerant patients. Table S1 displays population characteris-
tics of the studies.
A total of 54 studies were excluded from all LDL-C
networks (Table S2), and 15 in which patients predominantly
received moderate- or high-intensity statin background ther-
apy were included in the primary networks (ie, those most
closely aligned with the research question) (Table 1, Fig-
ure 2).29,30,34-45 We created separate networks for comparing
evolocumab to other lipid-lowering therapies by dosing
regimen: 140 mg Q2W or 420 mg QM (Figure 2). Both
networks included placebo and ezetimibe (10 mg daily). The
evolocumab 140 mg Q2W network also included alirocumab
75 mg and 150 mg Q2W; the evolocumab 420 mg QM
network included alirocumab 300 mg QM.
There were 4 studies of evolocumab29,34-36 LDL-C Assess-
ment w/PCSK9 MonoclonaL Antibody Inhibition Combined
with Statin ThErapy – Thrombolysis In Myocardial Infarction –
57 (LAPLACE-TIMI-57), LAPLACE-2, StudY of LDL-Cholesterol
Reduction Using a Monoclonal PCSK9 Antibody in Japanese
Patients With Advanced Cardiovascular Risk – 1 (YUKAWA-1),
and YUKAWA-2) in both networks, all of which were 12 weeks
in duration. There was 1 additional study of evolocumab
(DESCARTES30) in the 420 mg QM network that was
52 weeks in duration. All studies compared evolocumab to
placebo, and 1 study29 (LAPLACE-2) also included a compar-
ison with ezetimibe.
In total, there were 9 studies of alirocumab37,38,40,41,45-48 in
the Q2W network (McKenney 2012 and ODYSSEY COMBO I
and II, OPTIONS I and II, CHOICE I, JAPAN, HIGH FH, and LONG-
TERM), of which 2 (McKenney 2012 and CHOICE I) were
included in the QM network.37,41,48 Alirocumab studies were
12 to 104 weeks in duration. All studies reported 12- and
24-week data except 1 that reported 24-week data only (in the
network meta-analyses, the 12-week data were used except for
the study in which it was not available). The alirocumab 75- and
150-mg Q2W doses were included as separate therapies in the
Q2W network, and the 300-mg QM dose was included in the
QM network. Six studies compared alirocumab to placebo, and
3 studies38,47 (ODYSSEY COMBO II and ODYSSEY OPTIONS I
and II) compared alirocumab 75 mg Q2W to ezetimibe.
Finally, there was 1 eligible study44 comparing ezetimibe to
placebo (Masana 2005).
Risk of bias was assessed by judging how well all included
studies reported across 8 domains of the Cochrane Risk of
Bias Assessment Tool (Figure S2). In this article we focus on
those studies that were included in the primary analysis LDL-
C networks. All evolocumab studies29,30,34-36 had low risk of
bias across all criteria. The risk of bias in 5 alirocumab
studies37,38,40,41,46-49 was unclear in at least 1 area. The most
common reason for an unclear risk of bias was insufﬁcient
reporting of allocation of concealment and randomization
methods.
Lipid-Lowering Efﬁcacy of Evolocumab Compared
to Other Therapies
Direct head-to-head comparisons are displayed in Figure S3.
Treatment differences between lipid-lowering therapies for
the percentage reduction in LDL-C from baseline are
displayed in Figure 3 for evolocumab at the mean of weeks
10 and 12 versus comparators at ≥12 weeks and in Figure S3
for evolocumab at week 12 versus comparators at
≥12 weeks. All treatment differences between evolocumab
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140 mg, alirocumab 75 mg, alirocumab 150 mg, or ezetimibe
and placebo were statistically signiﬁcant.
Among PCSK9 inhibitors, evolocumab had a greater LDL-C
reduction than alirocumab. For evolocumab 140 mg Q2W at
the mean of weeks 10 and 12 versus comparators at
≥12 weeks, the treatment difference versus alirocumab
75 mg was 20.03% (95% CrI 27.32% to 12.96%) and
13.63% (95% CrI 22.43% to 5.33%) compared with
alirocumab 150 mg. The treatment difference between evolo-
cumab 420 mg QM and alirocumab 300 mg QM was19.21%
(95% CrI28.52% to10.35%) for evolocumab at the mean of
weeks 10 and 12 and comparators at ≥12 weeks. Treatment
differences were similar for evolocumab at week 12 versus
comparators at ≥12 weeks (Figure S1).
We also conducted a post hoc analysis of evolocumab
140 mg Q2W and 420 mg QM combined as 1 treatment arm
at the mean of weeks 10 and 12 versus alirocumab 75 mg
(18.32%, 95% CrI 24.30% to 12.40%) or 150 mg
(11.06%, 95% CrI 18.72% to 3.73%) Q2W at ≥12 weeks
(Figures S4A and S5A). Another post hoc analysis included all
EXCLUDED PAPERS 
(TITLE/ABSTRACT SCREENING )
TOTAL: 44,318 records excluded
RECORDS RETRIEVED AND SCREENED
(TITLE/ABSTRACT SCREENING)
MEDLINE: 13,884 CENTRAL: 4,500
MEDLINE IN PROCESS & DAILY UPDATE: 584 EMBASE: 20,720
Other Resources and Hand-searching: 10,151 CLINICALTRIALS.GOV: 5,179
Total prior to deduplication: 55,018-
TOTAL: 45,058 records after deduplication
FULL PAPERS ASSESSED
(FULL PAPER SCREENING)
TOTAL: 740 papers
EXCLUDED PAPERS
(FULL PAPER SCREENING)
Not relevant population: 211
Not relevant intervention/comparator: 33
Not relevant outcome: 22
Not relevant study design: 228
Duplicates: 4
Unobtainable: 12
Trials with no data: 50
Note: Papers may be excluded for more 
than one reason
TOTAL: 502 papers excluded 
STUDIES MEETING INCLUSION CRITERIA
TOTAL: 238 papers reporting data for 74 trials
5 trials in statin intolerant patients
69 trials in patients not at LDL-C target while on maximally tolerated statin
STUDIES INCLUDED IN NMA
15 trials in patients not at LDL-C target while on maximally tolerated statin 
Figure 1. Study ﬂow diagram of the systematic review. Articles in the “Excluded Papers”
stage could be excluded for ≥1 reason. The network meta-analysis of statin-intolerant
patients yielded a small sample size and did not include pending results of a phase 3 study
of evolocumab in this population. LDL - C indicates low-density lipoprotein cholesterol;
NMA, network meta-analysis.
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studies that met inclusion criteria, regardless of the back-
ground therapy (eg, ezetimibe, other lipid-lowering therapies,
low-intensity/no statin) (Figures S4B and S5B): evolocumab
140 mg Q2W at the mean of weeks 10 and 12 versus
alirocumab at weeks ≥12 was 16.76% (95% CrI, 22.54% to
11.02%) for 75 mg Q2W and 9.88% (95% CrI, 17.60% to
2.29%) for 150 mg Q2W.
Direct meta-analyses suggested that high statistical
heterogeneity (I2≥70%) was observed for some comparisons.
This was investigated using sensitivity analyses (excluding
studies conducted in Japan35,36,45 [YUKAWA-1, YUKAWA-2,
and ODYSSEY-JAPAN], and also ODYSSEY HIGH FH39).
Sensitivity analyses of direct head-to-head comparisons did
not substantially change the results but did reduce the
statistical heterogeneity (Figure S3). In the network meta-
analysis, moreover, we performed several sensitivity analyses
excluding studies conducted in Japan35,36,45 or ODYSSEY
HIGH FH,39 all of which drove heterogeneity (Figure S6). In
Placebo
EvoMab
140 mg 
Q2W
AliMab
75 mg 
Q2W
AliMab
150 mg 
Q2W
EZE
ODY COMBO II
ODY OPTIONS I and II
LAPLACE-2
Masana 2005
McKenney 2012
ODY HIGH FH
ODY LONG TERM
ODY COMBO I
ODY CHOICE I
ODY JAPAN
LAPLACE-TIMI
LAPLACE-2
YUKAWA 1 and 2
LAPLACE-2
Placebo
EvoMab
420 mg
QM
AliMab
300 mg 
QM
EZE
McKenney 2012
ODY CHOICE I
LAPLACE-2
Masana 2005
DESCARTES
LAPLACE-TIMI
LAPLACE-2
YUKAWA -1 and 2 
LAPLACE-2
A
B
Figure 2. Network of available connections for comparing change in LDL-C. A,
Evolocumab 140 mg Q2W (every 2 weeks). B, Evolocumab 420 mg QM (every month).
Lines between boxes denote direct comparisons. AliMab indicates alirocumab; EvoMab,
evolocumab; EZE, ezetimibe; LDL-C, low-density lipoprotein cholesterol; ODY, ODYSSEY.
DOI: 10.1161/JAHA.116.005367 Journal of the American Heart Association 8
PSCK9 Inhibitors Network Meta-Analysis Toth et al
S
Y
S
T
E
M
A
T
IC
R
E
V
IE
W
A
N
D
M
E
T
A
-A
N
A
L
Y
S
IS
 by guest on O
ctober 20, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
general, the conclusions of these sensitivity analyses with
regard to percentage LDL-C reduction were consistent in
direction and statistical signiﬁcance with the main analyses,
although the magnitudes changed slightly.
Networks were developed for other lipid end points
(Figures S4C through S4E). Network meta-analysis of HDL-C
results demonstrated a moderate increase from baseline
associated with evolocumab and alirocumab compared with
placebo or ezetimibe. Network meta-analysis results for non-
HDL-C were similar in direction and magnitude to LDL-C
results; the same was true of the results for ApoB and Lp(a),
although the networks were smaller for these comparisons
(Figure S7).
Safety
There were no statistically signiﬁcant differences in the risk
of any, treatment-related, or serious AEs between
Table 2. Risk Ratio (95% CI) for Occurrence of Any AE, Treatment-Related AE, and Serious AE
Comparison Any AE Treatment-Related AE Serious AE
Evolocumab 140 mg Q2W vs placebo 1.10 (0.93-1.29) 1.10 (0.42-2.85) 0.96 (0.44-2.09)
Evolocumab 420 mg QM vs placebo 1.03 (0.91-1.18) 1.47 (1.03-2.09) 0.91 (0.38-2.16)
Alirocumab 75 mg Q2W vs placebo 1.06 (0.92-1.22) 1.25 (0.87-1.81) 1.00 (0.74-1.34)
Alirocumab 150 mg Q2W vs placebo 1.25 (0.76-2.08) NR 1.05 (0.40-2.75)
Alirocumab 300 mg QM vs placebo 1.26 (0.89-1.79) 1.17 (1.01-1.35) 1.03 (0.07-15.78)
Ezetimibe vs placebo 1.04 (0.89-1.21) 1.17 (0.68-2.00) 0.77 (0.44-1.36)
AE indicates adverse event; CI, conﬁdence interval; NR, not reported; Q2W, every 2 weeks; QM, monthly.
Evolocumab 140 mg Q2W vs
Placebo
Ezetimibe
Alirocumab 75 mg Q2W
Alirocumab 150 mg Q2W
Alirocumab 75 mg Q2W vs
Placebo
Ezetimibe
Alirocumab 150 mg Q2W
Alirocumab 150 mg Q2W vs
Placebo
Ezetimibe
Ezetimibe vs
-75 -50 -25 0 25 35
Evolocumab at mean of weeks 10 and 12 vs comparator at ≥ 12 weeks
Evolocumab 420 mg QM vs
Placebo
Ezetimibe
Alirocumab 300 mg QM
Alirocumab 300 mg QM vs
Placebo
Ezetimibe
Ezetimibe vs
Change from baseline in LDL-C (%)
(treatment differences of bolded therapy vs comparator)
Change from baseline in LDL-C (%)
(treatment differences of bolded therapy vs comparator)
Evolocumab at mean of weeks 10 and 12 vs comparator at ≥ 12 weeks
-100
-100
-75 -50 -25 0 25 35
Placebo
Placebo
-20.03 (-27.32, -12.96)
-13.63 (-22.43, -5.33)
-74.10 (-79.81, -68.58)
-46.10 (-53.28, -39.06)
-26.06 (-31.19, -20.81)
-54.05 (-59.03, -48.95)
6.39 (-1.72, 14.41)
-32.46 (-40.77, -23.87)
-60.47 (-66.69, -53.89)
-27.99 (-33.51, -22.48)
-19.21 (-28.52, -10.35)
-71.54 (-76.76, -66.39)
-47.52 (-55.22, -39.89)
-28.29 (-38.38, -17.97)
-52.32 (-59.65, -44.71)
-24.04 (-30.86, -17.04)
B
A
Figure 3. Treatment difference in percentage LDL-C change (95% credible interval) in response to
evolocumab 140 mg Q2W network (A) or evolocumab 420 mg QM network (B): evolocumab at the mean of
weeks 10 and 12 vs comparator at ≥12 weeks. LDL-C indicates low-density lipoprotein cholesterol; Q2W,
every 2 weeks; QM, every month.
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evolocumab, alirocumab, or ezetimibe and placebo except
for the QM doses of evolocumab and alirocumab (Table 2).
Evolocumab 420 mg and alirocumab 300 mg QM resulted in
risk ratios of treatment-related AEs of 1.47 (95% conﬁdence
interval 1.03–2.09) and 1.17 (95% conﬁdence interval 1.01–
1.35) compared with placebo. There were, however, very few
treatment-related AEs, and none was considered serious.
Discussion
Our systematic review of lipid-lowering therapies added to
medium- to high-intensity statin therapy and subsequent
network meta-analysis conﬁrms the substantial LDL-C reduc-
tions of PCSK9 inhibitors versus placebo or ezetimibe in
individual trials. Among the PCSK9 inhibitors, evolocumab
appeared to have a greater reduction than alirocumab (75 mg
Q2W, 20%; 150 mg Q2W, 10%; 300 mg QM, 20%).
These treatment differences were directionally consistent in
the various analyses we conducted (ie, exclusion of studies
leading to heterogeneity, variation of dosing amount and
interval, broader background therapy spectrum). There was
also some evidence of proportional treatment differences
between evolocumab and other therapies in HDL-C, non-HDL-
C, ApoB, and Lp(a). The incidence of AEs was similar between
individual therapies and placebo except for signiﬁcantly higher
treatment-related AEs for evolocumab and alirocumab QM
versus placebo.
Our work provides information on PCSK9 inhibitors and
ezetimibe added to statin therapy in those requiring further
LDL-C reduction. The trials generally evaluated patients either
with CVD or at high risk of a CVD event, which is the
expected target population for PCSK9 inhibitors both now
and after cardiovascular outcomes trials for these medica-
tions are completed.50,51 We also characterized the reduc-
tions observed for PCSK9 inhibitors in other parameters
including non-HDL-C and Lp(a). Non-HDL-C is emerging as a
meaningful measure of CVD event risk,52 and Lp(a) is
associated with CVD event risk but is not reduced by
statins.53,54
Finally, we analyzed dose-speciﬁc LDL-C reductions
between PCSK9 inhibitors, which have not been a focus of
published meta-analyses.16-18 The classwide reduction of
LDL-C with PCSK9 inhibitors observed in these meta-
analyses16-18 is consistent with what we observed in the
comparison of individual PCSK9 inhibitors versus placebo or
ezetimibe.
In our network meta-analysis we found evidence of a
signiﬁcantly greater reduction of evolocumab versus alirocu-
mab. The treatment difference of evolocumab 140 mg Q2W
versus alirocumab 75 mg was larger than the comparison to
alirocumab 150 mg. The treatment difference between
evolocumab 420 mg QM versus alirocumab 300 mg QM
reﬂected the fact that more of the study drug was adminis-
tered to patients treated with evolocumab than to those
treated with alirocumab. The treatment difference between
evolocumab and alirocumab was directionally consistent in
the various analyses we conducted. Our approach differed
from that of other meta-analyses by analyzing evolocumab
and alirocumab separately. Lipinski and colleagues17 and Li
and colleagues16 analyzed PCSK9 inhibitors as a class.
Navarese and colleagues’ meta-analysis18 likewise considered
the class in the primary analysis but suggests, in a secondary
analysis, that there was a signiﬁcantly greater reduction in
LDL-C with evolocumab versus placebo than alirocumab
versus placebo.
We studied other atherogenic lipids when the data were
available, and the direction and magnitude of treatment
differences between the lipid-lowering therapies were in line
with those for LDL-C. HDL-C was increased modestly with
evolocumab compared with other therapies, but the differ-
ence was not always signiﬁcant. Non-HDL-C and ApoB were
reduced, as expected, in line with LDL-C. Lp(a) was reduced
by 38% with evolocumab versus placebo, and there was a
modest treatment difference favoring evolocumab versus
alirocumab. This estimated modest 9% to 14% difference in
Lp(a) is of uncertain clinical signiﬁcance. Other meta-
analyses found similar results in the PCSK9 class as a
whole.16-18
There are limitations to this review. In terms of comparing
the LDL-C–lowering capacity of PCSK9 inhibitors to each
other, to date there have been no such head-to-head studies
that would be the best way to remove any potential residual
confounders. Thus, this review is limited by the quantity and
quality of the data available from the included clinical trials.
Additionally, because 75 and 150 mg Q2W were not studied
in a parallel-group trial, FDA review55 concluded that there is
lack of availability of a well-characterized estimate of the
treatment effect for each dose. Another limitation of our
analysis is that most of the studies included in the networks
were relatively short-term (mostly 12 and 24 weeks). Longer-
term follow-up studies of evolocumab and alirocumab have
not shown evidence of loss of efﬁcacy or increased rates of
AEs.30,46,50,56
Conclusions
Based on network meta-analyses, the PCSK9 inhibitors
evolocumab and alirocumab were associated with reductions
in LDL-C of 54% to 74% versus placebo and 26% to 46% versus
ezetimibe in patients not adequately controlled by statins
alone. Recognizing the limitations of indirect comparison, our
synthesis of the available data shows a greater reduction with
evolocumab in LDL-C versus alirocumab 75 mg Q2W with
evidence also suggesting more intense LDL-C reduction
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versus alirocumab 150 mg Q2W. There was some evidence to
suggest that evolocumab may also signiﬁcantly increase HDL-
C and decrease non-HDL-C, ApoB, and Lp(a) levels in
comparison to alirocumab and other treatments. Further
research is needed into the effects of evolocumab and
alirocumab on the risk of cardiovascular events.
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Data S1. Full Search Strategy  
MEDLINE only, others available upon request 
Medline (Ovid): 1946 to July Week 3 2016 
Searched: January 8, 2016 
1     exp hyperlipidemias/ (60308) 
2     (hypercholesterol?emi$ or hypercholesterin?emi$ or cholester?emi$ or 
cholesterin?emi$ or hyperlipid?emi$ or hyperlipoprotein?emia$ or lip?emia$ or 
lipid?emi$ or hyperlip?emi$ or hefh or hofh or fh or hypertriglycerid?emia$ or mckusick 
14575 or triglycerid?emia$ or (triglyceride adj1 storage adj1 disease$)).ti,ab,ot,hw. 
(91009) 
3     ((cholesterol$ or lipid$ or LDL) adj3 (elevat$ or ascend$ or increas$ or high or 
rais$)).ti,ab,ot,hw. (74673) 
4     or/1-3 (150149) 
5     exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/ (33177) 
6     (statin$ or hydroxymethylglutaryl coenzyme A reductase inhibit$ or HMG CoA 
reductase inhibit$ or HMGCoA reductase inhibit$).ti,ab,ot,hw. (30946) 
7     (atorvastatin or Lipitor or torvast or atorlip or atovarol or ci 981 or ci981 or glustar or 
lipibec or lowlipen or sortis or storvas or tahor or ym 548 or ym548 or zarator or 134523-
00-5 or 134523-03-8).ti,ab,ot,hw,rn. (6950) 
8     (Bervastatin or ls 2904 or ls2904 or 132017-01-7).ti,ab,ot,hw,rn. (0) 
9     (crilvastatin or pmd 387 or pmd387 or 120551-59-9).ti,ab,ot,hw,rn. (5) 
10     (dalvastatin or rg 12561 or 132100-55-1 or 135910-20-2).ti,ab,ot,hw,rn. (4) 
11     (fluindostatin or Canef or cranoc or fluindostatin sodium or fluvastatin or fluvastatin 
sodium or fractal lp or lescol or lescol or leucol or lochol or locol or sri 62320 or sri62320 
or vastin or xu 62320 or xu62320 or 93957-54-1).ti,ab,ot,hw,rn. (1761) 
12     (glenvastatin or hr 780 or hr780).ti,ab,ot,hw,rn. (12) 
13     (mevinolin or altocor or altoprev or artein or belvas or Birotin or cholestra or cysin 
or ellanco or elstatin or l 654969 or lipdip or lipivas or lofacol or lomar or lostatin or 
lovacel or lovacol or lovalip or lovalord or lovastan or lovastatin or lovasterol or lovastin 
or lovatadin or lowachol or lozutin or medostatin or mevacor or meverstin or mevinacor 
or "mk 0803" or mk 803 or mk0803 or mk803 or monacolin K or monakolin k or msd 803 
or neolipid or nergadan or ovasta or rodatin rovacor or taucor or 75330-75-
5).ti,ab,ot,hw,rn. (5443) 
14     (mevinolinic acid or mevinolinate or 75225-51-3).ti,ab,ot,hw,rn. (21) 
15     (Monacolin or 76343-78-7 or 79394-47-1).ti,ab,ot,hw,rn. (137) 
16     (pitavastatin or alipza or itavastatin or livalo or livazo or nivastatin or nk 104 or 
nk104 or nks 104 or nks104 or pitava or ribar or vezepra or 147526-32-7).ti,ab,ot,hw,rn. 
(632) 
17     (Pravastatin or astin or bristacol or cholespar or cs 514 or cs514 or elisor or 
epatostantin or eptastatin or eptastatin sodium or eptastatine or kenstatin or lipemol or 
lipidal or liplat or lipostat or liprevil or mevalotin or novales or prareduct or prascolend or 
prastan or prava or pravachol or pravacol or pravaselect or pravasin or pravasine or 
pravator or pravyl or sanaprav or selektine or selipran or sq 31000 or sq31000 or 
stanidine or vasopran or vasten or xipral or 81093-37-0 or 81131-70-6).ti,ab,ot,hw,rn. 
(4390) 
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18     (Simvastatin or Avastinee or cholestat or clinfar or colastatina or colestricon or 
covastin or denan or epistatin or esvat or ethical or eucor or ifistatin or kavelor or 
klonastin or kolestevan or l 644128 or l644128 or lipecor or lipex or lipinorm or liponorm 
or lipovas or lodales or medipo or mersivas or mk 733 or mk733 or nor-vastina or 
normofat or orovas or rechol or simbado or simcard or simchol or simovil or simtin or 
simvacor or simvahex or simvalord or simvastar or simvata or simvatin or simvor or 
simvotin or sinvacor or simvastatin or sinvinolin or sivastin or starzoco or synvinolin or 
torio or valemia or vasilip or vasotenal or vazim or vidastat or zimmex or Zocor or zocor 
forte or zocord or zovast or 79902-63-9).ti,ab,ot,hw,rn. (66137) 
19     (Rosuvastatin or crestor or rosuvas or s 4522 or s4522 or zd 4522 or zd4522 or 
147098-18 or 147098-20-2).ti,ab,ot,hw,rn. (2479) 
20     tenivastatin.ti,ab,ot,hw,rn. (0) 
21     or/5-20 (104468) 
22     (evolocumab or repatha or 1256937-27-5 or AMG-145 or amg145).af. (117) 
23     (ezetimibe or zetia or ezetrol or ezetib or sch 582235 or sch58235 or 163222-33-
1).af. (2149) 
24     (Alirocumab or praluent or regn 727 or regn727 or sar 236553 or sar236553 or 
1245916-14-6).af. (105) 
25     (bococizumab or "pf 04950615" or pf04950615 or rn 316 or rn 316 or 1407495-02-
6).af. (11) 
26     (((PCSK-9 or PCSK9 or PCSK 9) adj2 inhibit$) or (anti-PCSK-9 or anti PCSK-
9)).ti,ab,ot,hw. (245) 
27     or/22-26 (2430) 
28     nicotinic acids/ or niacin/ (16586) 
29     (acipimox or acipemox or olbetam or albermox or 51037-30-0).ti,ab,ot,hw,rn. (299) 
30     (vitamin B3 or vitamin PP or 54-86-4 or 59-67-6 or acido nicotinico or acidum 
nicotinicum or akotin or apelagrin or apo-nicotinic acid or beta pyridine carboxylic acid 
or bionic or davitamon pp or direktan or direktane or efacin or efasin or endur acin or 
enduracin or naotin or natinate or niac or niacin$ or niacor or Niaspan or nicacid or 
nicangin or nico or nicobid or nicocap or nicocidin or nicocrisina or nicodan or nicodane 
or nicolar or niconacid or niconacide or nicoseptin wirkstoff or nicosode or nicospan or 
nicosyl or nicotabs or nicotamin or nicotine or nicotin acid or nicotinat or nicotinate or 
nicotinese or nicotinipca or nicotyl or nicovasen or nicyl or nikacid or nipellan or 
novoniacin or nyacine or nyclin or pellagramin or pellagramine or pellagrin$ or pelonin 
or pelonine or pepevit or peviton or pp factor or "pyridine 3 carbonic acid" or pyridine 
beta carboxylic acid or "s 115" or slo niacin or sodium nicotinate or vasotherm or 
vitaplex n or wampocap or wampopap).ti,ab,ot,hw,rn. (59318) 
31     or/28-30 (64551) 
32     Cholestyramine Resin/ (2587) 
33     (((bile adj2 acid) or anion exchange) adj2 (sequestrant$ or resin$)).ti,ab,hw,ot. 
(2797) 
34     (chol-less or choles or cholesthexal or cholestyramin$ or cholybar or cholytar or 
colestepril or colestiramina or colestran or colestrol or colestyramin or cuemid or lipocol-
merz or lismol or locholest or prevalite or quantalan or questran or resincoles$ or 
vasosan or 11041-12-6 or 58391-37-0).ti,ab,ot,hw,rn. (3358) 
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35     (colestipol or cholestabyl or cholestipol or colestid or lestid or u 26597a or "u 
26797 a" or 25085-17-0 or 37296-80-3 or 50925-79-6).ti,ab,ot,hw,rn. (525) 
36     (Colesevelam or cholestagel or gt 31 104 or gt 31 104hb or gt 31-104 or gt 31-
104hb or gt31 104 or gt31 104hb or gt31-104 or gt31-104hb or welchol or 182815-43-6 
or 182815-44-7).ti,ab,ot,hw,rn. (234) 
37     or/32-36 (6173) 
38     fibric acids/ or bezafibrate/ or fenofibrate/ or gemfibrozil/ (4897) 
39     (fibrate$ or fibric acid$ or arhalofenate or atromid or beclobrate or beclobrinic acid 
or bezafibrate or biclofibrate or binifibrate or choline fenofibrate or ciprofibrate or 
clinofibrate or clofibrate or clofibrate aluminium or clofibric acid or clofibride or 
dulofibrate or eniclobrate or etofibrate or etofylline clofibrate or fenirofibrat or fenofibric 
acid or halofenate or lifibrate or methylclofenapate or nicofibrate or picafibrate or 
pirifibrate or ponfibrate or ronifibrate or salafibrate or serfibrate or simfibrate or 
sitofibrate or tazasubrate or tiadenol diclofibrate or timofibrate or tocofibrate or urefibrate 
or xantifibrate).ti,ab,ot,hw,rn. (9516) 
40     (Bezafibrate$ or befizal or benzafibrate or benzofibrate or bezafibrate retard or 
bezalip or bezatol or bezifal or bezofibrate or bf 759 or bf759 or bm 15075 or bm15075 
or cedur or lo 44 or lo44 or norlip or 41859-67-0).ti,ab,ot,hw,rn. (1552) 
41     (Ciprofibrate$ or lipanor or modalim or win 35833 or 52214-84-3).ti,ab,ot,hw,rn. 
(527) 
42     (Fenofibrate$ or Antara or apo-feno-micro or aterolis or bisterol$ or climage or 
controlip or durafenat or evothyl or fegenor or felosma or fenobrate or fenofanton or 
fenogal or fenoglide or fenox or fibrafen or "grs 001" or hyperchol or katalip or lexemin 
or lipanthyl or lipantil or lipantyl or liparison or lipidax or lipidil or lipilo or lipirex or lipoclar 
or lipofen or lipolin or liposit or lipsin or livesan ge or lofibra or nopid 200 or normalip or 
nubrex or procetofen or procetofenate or procetofene or proketofen or qualipantyl or 
rapidil or redose 200 or rorit or secalip or sigurtil or trichol or tricor or triglide or trolip or 
zerlubron or zumafib or 49562-28-9).ti,ab,ot,hw,rn. (2966) 
43     (gemfibrozil or ausgem or bolutol or brozil or chlorestrol or cholespid or ci 719 or 
ci719 or clearol or decrelip or detrichol or elmogan or fetinor or fibralip or fibrocit or 
gedum or gemfi$ or gemizol or gemlipidor gemnpid or gemzil or genfibrozil or gevilon$ 
or gozid or grifogemzilo or hidil or hipolixan or ipolipid or jezil or lanaterom or lifibron or 
lipazil or lipidys or lipigem or lipira or lipison or lipistorol or lipizyl or lipofor or lipolo or 
lipostorol or lipozid or lipozil or lipur or lopid$ or low-lip or lowin or manobrozil or 
mariston or mersikol or normolipor panazil or polyxit or progemzal or recozil or reducelor 
regulip or synbrozilor triglizil or uragem or zilop or 25812-30-0).ti,ab,ot,hw,rn,tn. (2012) 
44     or/38-43 (12790) 
45     (lomitapide or lojuxta or Juxtapid or 182431-12-5 or 202833-31-6 or 202914-84-9 
or 210823-48-6 or aegr 733 or aegr733 or bms 201038$).af. (91) 
46     exp Blood Component Removal/ or apheresis.ti,ab,hw,ot. (19364) 
47     (anacetrapib or "mk 0859" or mk 859 or mk0859 or mk859 or 875446-37-0).af. 
(153) 
48     (mipomersen or isis 301012 or isis301012 or kynamro or 629167-92-6).af. (153) 
49     21 or 27 or 31 or 37 or 44 or 45 or 46 or 47 or 48 (201944) 
50     4 and 49 (20612) 
51     randomized controlled trial.pt. or "randomized controlled trials as topic"/ (527845) 
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52     controlled clinical trial.pt. (91264) 
53     random$.ti,ot. (131969) 
54     placebo.ab. (162592) 
55     drug therapy.fs. (1887319) 
56     random$.ab. (739171) 
57     trial.ab. (334669) 
58     groups.ab. (1422792) 
59     or/51-58 (3755812) 
60     animals/ not (animals/ and humans/) (4248029) 
61     59 not 60 (3205214) 
62     50 and 61 (13884) 
 
Based on Trials filter: Lefebvre C, Manheimer E, Glanville J. Chapter 6: searching for 
studies. Box 6.4.c: Cochrane Highly sensitive search strategy for identifying randomized 
controlled trials in Medline: Sensitivity-maximizing version (2008 version); OVID format. 
In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of 
Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. 
Available from www.cochrane-handbook.org 
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Data S2. Trials Included/Excluded, Full Paper Selection Stage 
A. List of included trials (74 trials) 
Abbott/NCT00300430 
Abbott. Study to evaluate the long-term safety and efficacy of ABT-335, in 
combination with three different statins in subjects with mixed 
dyslipidemia. NCT00300430. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US). 2009 [accessed June 25, 2014]. 
Available from: http://ClinicalTrials.gov/show/NCT00300430 
Abbott/NCT01674712/EUCTR2011-
005924-16-CZ 
Abbott. A 12-week study to compare the efficacy and safety of fixed 
combinations of fenofibrate/simvastatin 145/20mg and 
fenofibrate/simvastatin 145/40mg tablets versus fenofibrate or 
simvastatin monotherapies in subjects with abnormal blood levels of fats 
(lipids) and at high risk of cardiovascular disease. NCT01674712. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine 
(US).  2013 [accessed July 15, 2015]; Available from: 
http://ClinicalTrials.gov/show/NCT01674712. 
 
Abbott Laboratories Ireland Limited. A 12-week study to compare the 
efficacy and safety of fixed combinations of fenofibrate simvastatin 
145/20mg and fenofibrate simvastatin 145/40mg tablets versus 
fenofibrate or simvastatin monotherapies in subjects with abnormal levels 
of fats (lipids) in the blood and at high risk of cardiovascular disease. 
EUCTR2011-005924-16-CZ.  In: EU Clinical Trials Register (EUCTR) 
[Internet]. London: European Medicines Agency (EMA).  2012 [accessed 
June 4, 2014]; Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2011-005924-16. 
 
 
Foucher C, Aubonnet P, Reichert P, Berli M, Schaeffer A, Calvo Vargas 
CG, et al. New fixed-dose combinations of fenofibrate/simvastatin therapy 
significantly improve the lipid profile of high-risk patients with mixed 
dyslipidemia versus monotherapies. Cardiovasc Ther. 2015;33:329-337. 
ACCORD Lipid Trial 
Accord Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR, 
3rd, Leiter LA, et al. Effects of combination lipid therapy in type 2 
diabetes mellitus. N Engl J Med. 2010;362(17):1563-1574. [Erratum, N 
Engl J Med. 2010;362:1748]. 
ARBITER 2 
Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology 
for the Investigation of the Treatment Effects of Reducing Cholesterol 
(ARBITER) 2: a double-blind, placebo-controlled study of extended-
release niacin on atherosclerosis progression in secondary prevention 
patients treated with statins. Circulation. 2004;110:3512-3517 [Errata, 
Circulation. 2004;110:3615 and Circulation. 2004;110:3512-3517. 
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ARBITER 6-HALTS/NCT00397657 
Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, et 
al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of 
the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment 
Strategies in Atherosclerosis): Final results and the impact of medication 
adherence, dose, and treatment duration. J Am Coll Cardiol. 
2010;55:2721-2726. 
 
Walter Reed Army Medical Center, Abbott. Comparative study of the 
effect of ezetimibe versus extended-release niacin on atherosclerosis. 
NCT00397657. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National 
Library of Medicine (US). 2009 [accessed March 7, 2014]. Available from: 
http://ClinicalTrials.gov/show/NCT00397657. 
 
Devine PJ, Turco MA, Taylor AJ. Design and rationale of the ARBITER 6 
trial (Arterial Biology for the Investigation of the Treatment Effects of 
Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in 
atherosclerosis (HALTS). Cardiovasc Drugs Ther. 2007;21:221-225. 
 
Taylor AJ, Villines TC, Stanek EJ, Devine PJ, Griffen L, Miller M, et al. 
Extended-release niacin or ezetimibe and carotid intima-media thickness. 
N Engl J Med. 2009;361:2113-2122. 
Chen 2013 
Chen YP, Chang KC, Tseng WK, Yin WH, Chen JW, Lee YT, et al. 
Increased rosuvastatin dose versus concomitant fenofibrate and 
rosuvastatin therapy to achieve lipid goal in patients with diabetes or 
atherosclerosis with metabolic syndrome. Acta Cardiol Sin. 2013;29:421-
428. 
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DEFINE/NCT00685776 
Gotto AM, Cannon CP, Shah S, Liu S, Li S, Stepanavage M, et al. Effects 
on lipids and safety following cessation of treatment with cholesteryl ester 
transfer protein inhibitor anacetrapib in patients with or at high risk for 
coronary heart disease. Presented at American Heart Association 
Scientific Sessions; November 12-16, 2011; Orlando, FL, USA. 
Circulation. 2011;124(21 suppl 1). 
 
Merck Sharp Dohme Corp. Study to assess the tolerability and efficacy of 
anacetrapib in patients with coronary heart disease (CHD) or CHD risk-
equivalent disease (MK-0859-019). NCT00685776. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2014 
[accessed July 9, 2014]. Available from: 
http://ClinicalTrials.gov/show/NCT00685776 
 
Cannon CP, Dansky HM, Davidson M, Gotto Jr AM, Brinton EA, Gould 
AL, et al. Design of the DEFINE trial: Determining the EFficacy and 
Tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 
2009;158:513-519.e3. 
 
Merck Sharp Dohme Corp. A 76-week, worldwide, multicenter, double-
blind, randomized, placebo-controlled study to assess the tolerability and 
efficacy of anacetrapib when added to ongoing therapy with a statin in 
patients with hypercholesterolemia or mixed hyperlipidemia. 
EUCTR2007-005839-28-ES.  In: WHO International Clinical Trials 
Registry Platform (ICTRP) [Internet]. Geneva: World Health Organization 
(WHO). 2008 [accessed July 2, 2014]. Available from: 
https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2007-005839-28 
 
Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et 
al. Safety of anacetrapib in patients with or at high risk for coronary heart 
disease. N Engl J Med. 2010;363:2406-2415. 
 
Brinton EA, Kher U, Shah S, Cannon CP, Davidson M, Gotto AM, et al. 
Effects of anacetrapib on plasma lipids in specific patient subgroups in 
the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition 
with AnacEtrapib) trial. J Clin Lipidol. 2015;9:65-71. 
 
Gotto AM, Jr., Kher U, Chatterjee MS, Liu Y, Li XS, Vaidya S, et al. 
Lipids, safety parameters, and drug concentrations after an additional 2 
years of treatment with anacetrapib in the DEFINE study. J Cardiovasc 
Pharmacol Ther. 2014;19:543-549. 
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DESCARTES/Amgen 20110109 
Amgen Inc. Durable effect of PCSK9 antibody compared with placebo 
study. NCT01516879. In: ClinicalTrials.gov [Internet]. Bethesda (MD): 
National Library of Medicine (US). 2014 [accessed May 29, 2014]. 
Available from: http://ClinicalTrials.gov/show/NCT01516879 
 
Amgen Inc. A double-blind, randomized, placebo-controlled, multicenter 
study to evaluate long-term tolerability and durable efficacy of AMG 145 
on LDL-C in hyperlipidemic subjects - DESCARTES, durable effect of 
PCSK9 antibody Compared with placebo study. EUCTR2011-003827-37-
CZ. In: WHO International Clinical Trials Registry Platform (ICTRP) 
[Internet]. Geneva: World Health Organization (WHO). 2011 [accessed 
June 2, 2014]. Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2011-003827-37 
 
Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. A 
52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl 
J Med. 2014;370:1809-1819. 
 
Amgen Inc. A double-blind, randomized, placebo-controlled, multicenter 
study to evaluate long-term tolerability and durable efficacy of AMG 145 
on LDL-C in hyperlipidemic subjects - DESCARTES, durable effect of 
PCSK9 antibody Compared with placebo study [data supplied by 
Amgen]. 2014. 
 
Amgen Inc. Clinical Study Report 20110109: a double-blind, randomized, 
placebo-controlled, multicenter study to evaluate long-term tolerability 
and durable efficacy of AMG 145 on LDL-C in hyperlipidemic subjects. 
Thousand Oaks: 2014. 
 
Blom D, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, et al. 
The double-blind durable effect of pcsk9 antibody compared with placebo 
study (descartes): A 52-week, phase 3, double-blind, randomized, 
placebo-controlled trial of evolocumab (AMG 145) in hyperlipidemic 
patients. Endocr Pract. 2015;21:28A. 
 
Toth PP, Banach M, Djedjos C, Yang X, Elliott M, Davis M, et al. Effect of 
evolocumab on low-density lipoprotein particles. J Am Coll Cardiol. 
2016;67(13 Suppl 1):1909. 
 
Blom D, Djedjos CS, Tsirtsonis K, Wasserman SM, Scott R, Roth E. 
Effects of evolocumab (AMG 145) on vitamin-and serum adrenal and 
gonadal hormone levels; results from the 52-week, phase 3, double-blind, 
randomized, placebo controlled descartes study. Atherosclerosis. 
2015;241:e67. 
EASEGO/NCT00166530 
Merck Sharp Dohme Corp. EASEGO study: doubling of 
atorvastatin/simvastatin or INEGY in patients with hypercholesterolemia 
and coronary artery disease (CAD). NCT00166530. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2008 
[accessed May 29, 2014]. Available from: 
http://ClinicalTrials.gov/show/NCT00166530 
 
Roeters van Lennep HWO, Liem AH, Dunselman PHJM, Dallinga-Thie 
GM, Zwinderman AH, Jukema JW. The efficacy of statin monotherapy 
uptitration versus switching to ezetimibe/simvastatin: results of the 
EASEGO study. Curr Med Res Opin. 2008;24:685-694. 
ENHANCE 
Kastelein JJP, Akdim F, Stroes ESG, Zwinderman AH, Bots ML, 
Stalenhoef AFH, et al. Simvastatin with or without ezetimibe in familial 
hypercholesterolemia. N Engl J Med. 2008;358:1431-1443. 
 
NCT00552097. Effect of Ezetimibe Plus Simvastatin Versus Simvastatin 
Alone on Atherosclerosis in the Carotid Artery (ENHANCE) (P02578). 
2007. 
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ESSENTIAL 
Matsue Y, Matsumura A, Suzuki M, Hashimoto Y, Yoshida M. Differences 
in action of atorvastatin and ezetimibe in lowering low-density lipoprotein 
cholesterol and effect on endothelial function: randomized controlled trial. 
Circ J. 2013;77:1791-1798. 
Ezetimibe Study Group 
Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, et al. 
Achieving lipoprotein goals in patients at high risk with severe 
hypercholesterolemia: efficacy and safety of ezetimibe co-administered 
with atorvastatin. Am Heart J. 2004;148:447-455. 
Farnier 2012 
Farnier M, Retterstøl K, Steinmetz A, Császár A. Comparative efficacy 
and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and 
simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed 
hyperlipidaemia and cardiovascular disease. Diab Vasc Dis Res. 
2012;9:205-215. 
 
Farnier M, Retterstol K, Dluzniewski M, Csazar A, Steinmetz A. 
Comparative efficacy and safety of fenofibrate/pravastatin/ezetimibe 
therapy and simvastatin/ezetimibe therapy in type 2 diabetic patients with 
combined hyperlipidemia and cardiovascular disease. Presented at 
European Society of Cardiology Congress; August 28 – September 1, 
2010; Stockholm, Sweden. Eur Heart J. 2010;31:601. 
 
Farnier M, Steinmetz A, Csaszar A, Retterstol K, Dluzniewski M. 
Comparative efficacy of fenofibrate/pravastatin/ezetimibe and 
simvastatin/ezetimibe therapies in type 2 diabetic patients with combined 
hyperlipidaemia and cardiovascular disease. Presented at 46th Annual 
Meeting of the European Association for the Study of Diabetes; 
September 20-24, 2010; Stockholm, Sweden. Diabetologia. 
2010;53:S512. 
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GAUSS/Amgen 20090159 
Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, et al. Effect of 
a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol 
levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 
2012;308:2497-2506. 
 
Sullivan D, Olsson A, Scott R, Kim JB, Xue A, Liu T, et al. Goal 
achievement after utilizing an anti-PCSK9 antibody in statin intolerant 
subjects (GAUSS): interim results from a randomized, double-blind, 
placebo-controlled study. Presented at American Heart Association 
Scientific Sessions and Resuscitation Science Symposium; November 3-
6, 2012; Los Angeles, CA, USA. Circulation. 2012;126:2782. 
 
Amgen Inc. Goal achievement after utilizing an Anti-PCSK9 antibody in 
statin intolerant subjects. NCT01375764. In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2014 [accessed July 
7, 2014]. Available from: http://ClinicalTrials.gov/show/NCT01375764. 
 
Amgen Inc. Goal achievement after utilizing an anti-PCSK9 antibody in 
statin intolerant subjects -2. NCT01763905. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2014 
[accessed June 7, 2014]. Available from: 
http://ClinicalTrials.gov/show/NCT01763905. 
 
Stein EA, Somaratne R, Schou MB, Civeira F, Sullivan D, Watts GF, et 
al. Efficacy and tolerability of long-term treatment with AMG 145 in 
patients with statin intolerance. Presented at American Heart Association 
Scientific Sessions and Resuscitation Science Symposium; November 
2013; Dallas, TX, USA. Circulation. 2013;128(22 suppl 1). 
 
Amgen Inc. A randomized, multicenter study to evaluate tolerability and 
efficacy of AMG 145 on LDL-C, compared with ezetimibe, in 
hypercholesterolemic subjects unable to tolerate an effective dose of a 
HMG-CoA reductase inhibitor. EUCTR2011-001529-26-ES. In: WHO 
International Clinical Trials Registry Platform (ICTRP) [Internet]. Geneva: 
World Health Organization (WHO). 2011 [accessed June 2, 2014]. 
Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2011-001529-26. 
 
Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, et al. 
Design and rationale of the GAUSS-2 study trial: a double-Blind, 
ezetimibe-controlled phase 3 study of the efficacy and tolerability of 
evolocumab (AMG 145) in subjects with hypercholesterolemia who are 
intolerant of statin therapy. Clin Cardiol. 2014;37:131-139. 
 
Amgen Inc. A double-blind, randomized, multicenter study to evaluate 
safety and efficacy of AMG 145, compared with ezetimibe, in 
hypercholesterolemic subjects unable to tolerate an effective dose of a 
HMG-CoA. EUCTR2012-001364-30. In: EU Clinical Trials Register 
(EUCTR) [Internet]. London: European Medicines Agency (EMA). 2012 
[accessed June 2, 2014]. Available from: 
https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2012-001364-30. 
 
Amgen Inc. Study designed to evaluate the safety and efficacy of AMG 
145 compared with Ezetimibe treatment, in people with high cholesterol 
who have experienced side effects whilst taking existing statin treatment. 
EUCTR2013-000935-29-DE. In: EU Clinical Trials Register (EUCTR) 
[Internet]. London: European Medicines Agency (EMA). 2014 [accessed 
July 9, 2014]. Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2013-000935-29. 
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Amgen Inc. Goal achievement after utilizing an Anti-PCSK9 antibody in 
statin intolerant subjects [data supplied by Amgen]. 2012. 
GAUSS-2/Amgen 20110116 
Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, 
et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with 
statin intolerance: the GAUSS-2 Randomized, placebo-controlled phase 
3 clinical trial of evolocumab. J Am Coll Cardiol. 2014;63:2541-2548. 
 
Amgen Inc. A Double-blind, Randomized, Multicenter Study to Evaluate 
Safety and Efficacy of AMG 145, Compared With Ezetimibe, in 
Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a 
HMG-CoA Reductase Inhibitor. EUCTR2012-001364-30-ES.  In: EU 
Clinical Trials Register (EUCTR) [Internet]. London: European Medicines 
Agency (EMA). 2012 [accessed July 7, 2014]. Available from: 
https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2012-001364-30. 
 
Amgen Inc. A double-blind, randomized, multicenter study to evaluate 
safety and efficacy of AMG 145, compared with ezetimibe, in 
hypercholesterolemic subjects unable to tolerate an effective dose of a 
HMG-CoA reductase inhibitor: GAUSS-2 protocol. Thousand Oaks, 2012. 
 
Amgen Inc. A double-blind, randomized, multicenter study to evaluate 
safety and efficacy of AMG 145, compared with ezetimibe, in 
hypercholesterolemic subjects unable to tolerate an effective dose of a 
HMG-CoA reductase inhibitor: GAUSS-2 [data supplied by Amgen]. 
2012. 
 
Amgen Inc. Clinical Study Report 20110116: a double-blind, randomized, 
multicenter study to evaluate safety and efficacy of AMG 145, compared 
with ezetimibe, in hypercholesterolemic subjects unable to tolerate an 
effective dose of a HMG-CoA reductase inhibitor. Thousand Oaks: 2014. 
 
Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, et al. 
Clinical profile of statin intolerance in the phase 3 GAUSS-2 study. 
Cardiovasc Drugs Ther. 2016;30:297-304. 
GAUSS-3/Amgen 20120332 
Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, 
et al. Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-
intolerant patients: Design of the Goal Achievement after Utilizing an anti-
PCSK9 antibody in Statin-intolerant Subjects 3 (GAUSS-3) trial. Clin 
Cardiol. 2016;39:137-144. 
 
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar 
N, et al. Efficacy and tolerability of evolocumab vs ezetimibe in patients 
with muscle-related statin intolerance: The GAUSS-3 randomized clinical 
trial. JAMA. 2016;315:1580-1590. 
 
Amgen Inc. Study designed to evaluate the safety and efficacy of AMG 
145 compared with Ezetimibe treatment, in people with high cholesterol 
who have experienced side effects whilst taking existing statin treatment. 
EUCTR2013-000935-29-DE. In: EU Clinical Trials Register (EUCTR) 
[Internet]. London: European Medicines Agency (EMA).  2014 [accessed 
July 9, 2014]; Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2013-000935-29. 
 
Amgen Inc. Goal achievement after utilizing an anti-PCSK9 antibody in 
statin intolerant subjects-3. NCT01984424. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US).  2014 
[accessed July 9, 2014]; Available from: 
http://ClinicalTrials.gov/show/NCT01984424. 
Gelabert 2004 
Cabezas Gelabert R. Effect of ursodeoxycholic acid combined with 
statins in hypercholesterolemia treatment: a prospective clinical trial. Rev 
Clin Esp. 2004;204:632-635. 
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Goshima 2010 
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Six Cities Study 
Simons LA. Comparison of atorvastatin alone versus simvastatin +/- 
cholestyramine in the management of severe primary 
hypercholesterolaemia (the six cities study). Aust N Z J Med. 
1998;28:327-333. 
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B. List of excluded trials and reason for exclusion (440 trials) 
Publication citation Reason(s) for exclusion 
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https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-
005924-16 
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Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. Cochrane 
Database Syst Rev. 2014. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Adams SP, Tsang M, Wright JM. Lipid-lowering efficacy of atorvastatin. Cochrane 
Database Syst Rev. 2015. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Aegerion Pharmaceuticals Inc. A safety and efficacy study of AEGR-733 to treat 
homozygous familial hypercholesterolemia (FH). NCT00730236. In: WHO 
International Clinical Trials Registry Platform (ICTRP) [Internet]. Geneva: World 
Health Organization (WHO). 2008 [accessed 17.7.14]. Available from: 
http://clinicaltrials.gov/show/NCT00730236 
Not relevant trial design 
(not RCT) 
Aegerion Pharmaceuticals. A phase III study of microsomal triglyceride transfer 
protein (MTP) inhibitor AEGR-733 in patients with homozygous familial 
hypercholesterolemia on current lipid-lowering therapy. EUCTR2008-007058-36. In: 
EU Clinical Trials Register (EUCTR) [Internet]. London: European Medicines Agency 
(EMA). 2009 [accessed 2.6.14]. Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-
007058-36 
Not relevant trial design 
(not RCT) 
Aegerion Pharmaceuticals. A phase III, long term, open label, follow on study of 
microsomal triglyceride transfer protein (MTP) inhibitor ‘lomitapide’ (AEGR-733) in 
patients with homozygous familial hypercholesterolemia. EUCTR2010-023742-79. In: 
EU Clinical Trials Register (EUCTR) [Internet]. London: European Medicines Agency 
(EMA). 2011 [accessed 30.5.14]. Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-
023742-79 
Not relevant trial design 
(not RCT) 
Aggarwal RK, Showkathali R. Rosuvastatin calcium in acute coronary syndromes. 
Expert Opin Pharmacother 2013;14(9):1215-1227. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Agouridis AP, Kostapanos MS, Tsimihodimos V, Kostara C, Mikhailidis DP, Bairaktari 
ET, et al. Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 
fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and 
metabolic syndrome. Int J Clin Pract 2012;66(9):843-53. 
Not relevant population 
(statin status unclear) 
Aguilar-Salinas CA, Gomez-Perez FJ, Posadas-Romero C, Vazquez-Chavez C, 
Meaney E, Gulias-Herrero A, et al. Efficacy and safety of atorvastatin in 
hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study. 
Atherosclerosis 2000;152(2):489-96. 
Not relevant population; 
compares different doses 
of statin 
Al Badarin F, O'Keefe J. Fibrates lower the risk of myocardial infarction but not stroke 
or mortality in patients with cardiovascular disease: a meta-analysis and systematic 
review. Presented at Annual Scientific Sessions of the National Lipid Association, 
NLA; 13-16 May 2010; Chicago, IL: United States. J Clin Lipidol 2010;4(3):222-223. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Amarenco P, Labreuche J, Bruckert E. Meta-analysis of the effect of nicotinic acid 
alone or in combination on cardiovascular events and atherosclerosis. Presented at 
19th European Stroke Conference; 25-28 May 2010; Barcelona: Spain. Cerebrovasc 
Dis 2010;29:166. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
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Publication citation Reason(s) for exclusion 
Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM. Achieving 
goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with 
doubling the statin dose. A pooled analysis. Atherosclerosis. [Journal Article Research 
Support, Non-U.S. Gov't]. 2014 Dec;237(2):829-37. 
Not relevant study design 
(Meta-analysis) 
Amgen Inc. A multicenter, open-label extension (OLE) study to assess the long-term 
safety and efficacy of evolocumab. EUCTR2014-001524-30.  In: EU Clinical Trials 
Register (EUCTR) [Internet]. London: European Medicines Agency (EMA).  2014 
[accessed 19.3.15]; Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2014-001524-30. 
Not relevant study design 
(not RCT, open label 
extension) 
Amgen Inc. Study designed to evaluate the safety and efficacy of AMG 145, in people 
with elevated LDL-C and not treated with any other lipid-lowering medications.To do 
this, AMG 145 will be compared with placebo and with ezetimibe. EUCTR2012-
001362-15-BE.  In: EU Clinical Trials Register (EUCTR) [Internet]. London: European 
Medicines Agency (EMA). 2012 [accessed 27.10.14]. 
Not relevant population 
(not intolerant or resistant 
to statin treatment) 
Amgen Inc. Study to assess the long term safety and efficacy of AMG 145 in patients 
with high concentrations of lipids in the blood. EUCTR2012-004357-83-IT.  In: EU 
Clinical Trials Register (EUCTR) [Internet]. London: European Medicines Agency 
(EMA). 2013 [accessed 3.6.14]. Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-
004357-83 
Not relevant population; 
mixed refractory and naive 
population with no 
separate results or 
indication of numbers in 
each category at baseline 
Amgen. Ascending multiple dose study to evaluate the safety, tolerability, 
pharmacokinetics and pharmacodynamics of AMG 145 in subjects with hyperlipidemia 
on stable doses of a statin. NCT01133522. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US). 2012 [accessed 14.7.14]. Available from: 
http://ClinicalTrials.gov/show/NCT01133522 
Not relevant trial design 
(<12 wks) 
Amgen. Global assessment of plaque regression with a PCSK9 antibody as measured 
by intravascular ultrasound. NCT01813422. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US). 2014 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT01813422 
Not relevant outcomes 
Amgen. Open label study of long term evaluation against LDL-C trial. NCT01439880. 
In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
2014 [accessed 29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT01439880 
Not relevant population; 
mixed refractory and naive 
population with no 
separate results or 
indication of numbers in 
each category at baseline 
Amgen. Trial assessing long term use of PCSK9 inhibition in subjects with genetic 
LDL disorders. NCT01624142. In: ClinicalTrials.gov [Internet]. Bethesda (MD): 
National Library of Medicine (US). 2014 [accessed 15.7.14]. Available from: 
http://ClinicalTrials.gov/show/NCT01624142 
Not relevant trial design 
(Not RCT) 
Amgen. Trial assessing long term use of PCSK9 inhibition in subjects with genetic 
LDL disorders (TAUSSIG). NCT01624142. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US). 2012 [accessed 15.7.14]. Available from: 
http://clinicaltrials.gov/show/NCT01624142 
Not relevant trial design 
(not RCT) 
Amgen. Trial evaluating PCSK9 antibody in subjects with LDL receptor abnormalities. 
NCT01588496. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2014 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT01588496 
Duplicate of  
Ansquer J-C, Corda C, Le Malicot K, Jessent V. Effects of atorvastatin 10 mg and 
fenofibrate 200 mg on the low-density lipoprotein profile in dyslipidemic patients: a 12-
week, multicenter, randomized, open-label, parallel-group study. Current Therapeutic 
Research, Clinical & Experimental 2009;70(2):71-93. 
Not relevant population 
(mixed dyslipidemic and 
mixed statin history, 
numbers and separate 
data NR) 
Armitage J. HPS2-THRIVE: treatment of HDL to reduce the incidence of vascular 
events: a randomised trial of the long term clinical effects of raising HDL cholesterol 
with extended release niacin/laropiprant [Internet]. 2010 [accessed 27.10.14]. 
Not relevant population 
(around 38% of patients 
were at lipid target at 
baseline) 
Arntz HR, Bonner G, Kikis D, Kirch W, Klor HU, Lederle RM, et al. [Effectiveness of 
pravastatin and bezafibrate in primary hypercholesterolemia]. Dtsch Med Wochenschr 
1991;116(1):7-12. 
Not relevant population 
 by guest on O
ctober 20, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Toth et al | Network Meta-Analysis Lipid-Lowering Therapies | Supplemental Appendix 
S36 
Publication citation Reason(s) for exclusion 
Arshad AR. Comparison of low-dose rosuvastatin with atorvastatin in lipid-lowering 
efficacy and safety in a high-risk pakistani cohort: an open-label randomized trial. 
Journal of Lipids 2014;2014:875907. 
Not relevant population 
(mixed statin history; 
separate data and 
numbers of participants 
NR) 
Assmann G, Huwel D, Schussman KM, Smilde JG, Kosling M, Withagen AJAM, et al. 
Efficacy and safety of atorvastatin and pravastatin in patients with 
hypercholesterolemia. Eur J Intern Med 1999;10(1):33-39. 
Not relevant population 
(mixed) 
AstraZeneca A. B. A study to evluate the safety of rosuvastatin in children and 
adolescents with homozygous familial hypercholesterolemia. EUCTR2014-004746-
99-BE. In: WHO International Clinical Trials Registry Platform (ICTRP) [Internet]. 
Geneva: World Health Organization (WHO).  2014 [accessed 19.3.15] [updated 
23/02/2015]; Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2014-004746-99. 
Not relevant population 
(statin status unclear) 
AstraZeneca AB. A 12-week open-label, randomised, parallel-group, multicentre, 
phase IIIb study to compare the efficacy and safety of rosuvastatin (CRESTOR) 10 
mg and 20 mg in combination with ezetimibe 10 mg and sivastatin 40 mg and 80 mg 
in combination with ezetimibe 10 mg (fixed dose combination) in patients with 
hypercholesterolaemia and coronary heart disease (CHD) or a CHD risk equivalent, 
atherosclerosis or a 10-year CHD Risk of >20% (GRAVITY). EUCTR2007-002810-20.  
In: EU Clinical Trials Register (EUCTR) [Internet]. London: European Medicines 
Agency (EMA). 2007 [accessed 30.5.14]. Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-
002810-20 
Not relevant population 
(numbers of refractory pts 
unclear); not relevant trial 
design (treatment periods 
only 6wks) 
AstraZeneca AB. A randomized, double blind, placebo controlled, multi center, cross 
over study of rosuvastatin in children and adolescents (aged 6 to <18 years) with 
homozygous familial hypercholesterolemia (HoFH). EUCTR2014-000972-24. In: 
PharmNet.Bund [Internet]. Cologne: German Institute of Medical Documentation and 
Information (DIMDI).  2014 [accessed 19.3.15]; Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-000972-24/DE. 
Not relevant population 
(statin status unclear) 
AstraZeneca. An open-label randomised, multicentre, phase-IIIb, parallel-group 
switching study to compare the efficacy and safety of lipid-lowering agents 
atorvastatin, pravastatin, simvastatin and rosuvastatin in subjects with Type IIa and IIb 
hypercholesterolaemia (MERCURY I) [Internet]. 2002 [accessed 6.6.14]. Available 
from: http://www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-
trials/resources/pdf/8610186 
Not relevant population 
(statin status unclear); not 
relevant trial design (8wk 
treatment period) 
AstraZeneca. Compare the efficacy of rosuvastatin to atorvastatin in high risk patients 
with hypercholesterolemia. NCT00683618. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US). 2012 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00683618 
Not relevant population 
(unclear population); not 
relevant trial design (6wks 
treatment period) 
AstraZeneca. Evaluation of the efficacy and safety of rosuvastatin 5 mg versus 
pravastatin 40 mg and atorvastatin 10 mg in type IIa and IIb hypercholesterolaemic 
patients. NCT00631189. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National 
Library of Medicine (US). 2013 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00631189 
Not relevant trial design 
AstraZeneca. Rosuvastatin ORBITAL Germany. NCT00379249. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2009 [accessed 
29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00379249 
Not relevant intervention/ 
comparator 
NCT02226198. A Study to Evaluate the Efficacy and Safety of Rosuvastatin in 
Children and Adolescents With Homozygous Familial Hypercholesterolemia. 2014. 
Not relevant trial design 
(crossover with only 6wks 
treatment period) 
Athyros VG, Kakafika AI, Papageorgiou AA, Paraskevas KI, Tziomalos K, Anagnostis 
P, et al. Effects of statin treatment in men and women with stable coronary heart 
disease: a subgroup analysis of the GREACE Study. Curr Med Res Opin 
2008;24(6):1593-9. 
Not relevant population; 
not relevant trial design 
Athyros VG, Kakafika AI, Papageorgiou AA, Tziomalos K, Skaperdas A, Pagourelias 
E, et al. Atorvastatin decreases triacylglycerol-associated risk of vascular events in 
coronary heart disease patients. Lipids 2007;42(11):999-1009. 
Not relevant population 
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Publication citation Reason(s) for exclusion 
Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, 
Kranitsas DF, et al. Safety and efficacy of long-term statin-fibrate combinations in 
patients with refractory familial combined hyperlipidemia. Am J Cardiol 
1997;80(5):608-13. 
Not relevant population 
(statin status unclear) 
Bach LA, Wirth A, O'Brien RC, Jerums G, Cooper ME. Cholesterol lowering effects of 
simvastatin in patients with non-insulin dependent diabetes mellitus. Diabetes, 
Nutrition and Metabolism - Clinical and Experimental 1991;4(2):123-128. 
Not relevant population; 
not relevant trial design 
(dose doubled for non-
responders but outcomes 
only for 6wks) 
Bach RG, Cannon C, Giugliano R, White J, Lokhnygina Y, Tershakovec A, et al. 
Increasing Age and the Benefit From Higher-intensity Lipid Lowering With 
Ezetimibe/Simvastatin vs. Simvastatin Alone: Results From the IMPROVE-IT Trial. 
Circulation. 2015 November 10, 2015;132(Suppl 3):A16708. 
Not relevant population 
(statin status mixed) 
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and 
safety of cholesterol-lowering treatment: prospective meta-analysis of data from 
90,056 participants in 14 randomised trials of statins.[Erratum appears in Lancet. 
2005 Oct 15-21;366(9494):1358], [Erratum appears in Lancet. 2008 Jun 
21;371(9630):2084]. Lancet 2005;366(9493):1267-78. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Ballantyne CM, Bays HE, Shah AK, Sisk C, Dong Q, Maccubbin D. Extended release 
niacin/laropiprant lowers atherogenic lipids across patient subgroups. Presented at 
79th European Atherosclerosis Society Congress, EAS; 26-29 Jun 2011; Gothenburg: 
Sweden. Atheroscler Suppl 2011;12(1):25. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of 
ezetimibe co-administered with simvastatin compared with atorvastatin in adults with 
hypercholesterolemia. Am J Cardiol 2004;93(12):1487-94. 
Not relevant population 
(mixed) 
Ballantyne CM, Houri J, Notarbartolo A, Melani L, Lipka LJ, Suresh R, et al. Effect of 
ezetimibe coadministered with atorvastatin in 628 patients with primary 
hypercholesterolemia: A prospective, randomized, double-blind trial. Circulation 
2003;107(19):2409-2415. 
Not relevant population 
(mixed) 
Ballantyne CM, Lipka LJ, Sager PT, Strony J, Alizadeh J, Suresh R, et al. Long-term 
safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in 
patients with primary hypercholesterolaemia. Int J Clin Pract 2004;58(7):653-8. 
Not relevant population 
(mixed) 
Ballantyne CM, Miller M, Niesor EJ, Burgess T, Kallend D, Stein EA. Effect of 
dalcetrapib plus pravastatin on lipoprotein metabolism in dyslipidemic patients: results 
of a phase 2B dose-ranging study. Presented at American College of Cardiology's 
59th Annual Scientific Session and i2 Summit: Innovation in Intervention; 14-16 Mar 
2010; Atlanta, GA: United States. J Am Coll Cardiol 2010;55(10 suppl 1):A47.E444. 
Not relevant comparator 
(different doses of 
Dalceptrapib plus 
pravastatin vs. placebo); 
not relevant outcomes 
(lipid size) 
Ballantyne CM, Schiebinger R, Cain V. Randomized comparison of rosuvastatin plus 
ezetimibe versus simvastatin plus ezetimibe: results of the gravity study. Presented at 
American College of Cardiology's 59th Annual Scientific Session and i2 Summit: 
Innovation in Intervention; 14-16 Mar 2010; Atlanta, GA: United States. J Am Coll 
Cardiol 2010;55(10 suppl 1):A49.E463. 
Not relevant population 
(numbers of refractory pts 
unclear); not relevant trial 
design (treatment periods 
only 6wks) 
Ballantyne CM, McKenney JM, MacDougall DE, Margulies JR, 
Robinson PL, Hanselman JC, et al. Effect of ETC-1002 on Serum 
Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients 
Receiving Statin Therapy. Am J Cardiol. 2016 Jun 15;117(12):1928-
33. 
 
Not relevant intervention/ 
comparator - ETC-1002, 
new potential lipid lowering 
therapy but unlicensed and 
still in development 
Ballantyne CM, MacDougall DE, Margulies JR, Robinson PL, 
Hanselman JC, Lalwani ND. ETC-1002 Incrementally Lowers Low 
Density Lipoprotein-cholesterol in Patients With Hypercholesterolemia 
Receiving Stable Statin Therapy. Circulation. 2015 November 10, 
2015;132(Suppl 3):A17499. 
 
Not relevant intervention/ 
comparator - ETC-1002, 
new potential lipid lowering 
therapy but unlicensed and 
still in development 
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Publication citation Reason(s) for exclusion 
Banga JD, Jacotot B, Pfister P, Mehra M. Long-term treatment of 
hypercholesterolemia with fluvastatin: a 52-week multicenter safety and efficacy 
study. Am J Med 1994;96(6A):6A87S-6A93S. 
Not relevant population 
Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM. Ezetimibe + simvastatin 
versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a 
multicenter, randomized trial (the LEAD study). Cardiovasc Diabetol 2010;9(20). 
Not relevant trial design 
(6wk treatment period) 
Barrett PHR, Pang J, Chan DC, Hamilton SJ, Tenneti VS, Watts GF. Effect of niacin 
on triglyceride-rich lipoprotein apolipoprotein b-48 kinetics in type 2 diabetic subjects 
on a statin. Atherosclerosis. 2014;235(2):e167-e8. 
Not relevant study design 
(less than 10 participants 
per arm) 
Barrios V, Amabile N, Paganelli F, Chen JW, Allen C, Johnson-Levonas AO, et al. 
Lipid-altering efficacy of switching from atorvastatin 10 mg/day to 
ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in 
hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J 
Clin Pract 2005;59(12):1377-86. 
Not relevant trial design 
(<12 wks) 
Barter PJ, O'Brien RC. Achievement of target plasma cholesterol levels in 
hypercholesterolaemic patients being treated in general practice. Atherosclerosis 
2000;149(1):199-205. 
Not relevant population; 
mixed refractory and naive 
population with no 
separate results or 
indication of numbers in 
each category at baseline 
Bays HE, Averna M, Majul C, Muller-Wieland D, De Pellegrin A, Giezek H, et al. 
Ezetimibe & atorvastatin coadministration vs atorvastatin uptitration or switching to 
rosuvastatin in primary hypercholesterolemic patients at high cardiovascular risk. 
Presented at Annual Scientific Sessions of the National Lipid Association, NLA; 30 
May - 2 Jun 2013; Las Vegas, NV: United States. J Clin Lipidol 2013;7(3):280. 
Not relevant trial design 
(<12 wks) 
Bays HE, Averna M, Majul C, Muller-Wieland D, Pellegrin A, Giezek H, et al. Efficacy 
and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or 
switching to rosuvastatin in patients with primary hypercholesterolemia. Am J Cardiol 
2013;112(12):1885-1895. 
Not relevant trial design 
(6wk treatment period) 
Bays HE, Ballantyne C, Shah A, Sisk CM, Dong Q, Maccubbin D. Extended release 
niacin/laropiprant lowers atherogenic lipids across patient subgroups. Presented at 
Annual Scientific Sessions of the National Lipid Association, NLA; 19-22 May 2011; 
New York, NY: United States. J Clin Lipidol 2011;5(3):239. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Bays HE, Brinton EA, Triscari J, Chen E, Maccubbin D, MacLean A, et al. Extended-
release niacin/laropiprant significantly improves lipid levels in type 2 diabetes patients 
irrespective of baseline glycemic control. Presented at Annual Scientific Sessions of 
the National Lipid Association, NLA; 31 May - 3 Jun 2012; Scottsdale, AZ: United 
States. J Clin Lipidol 2012;6(3):270-271. 
Not relevant comparator 
(niacin/laropiprant) 
Bays HE, Jones PH, Mohiuddin SM, Kelly MT, Sun H, Setze CM, et al. Long-term 
safety and efficacy of fenofibric acid in combination with statin therapy for the 
treatment of patients with mixed dyslipidemia. J Clin Lipidol 2008;2(6):426-435. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Bays HE, Ose L, Fraser N, Tribble DL, Quinto K, Reyes R, et al. A multicenter, 
randomized, double-blind, placebo-controlled, factorial design study to evaluate the 
lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared 
with ezetimibe and simvastatin monotherapy in patients with primary 
hypercholesterolemia. Clin Ther 2004;26(11):1758-73. 
Not relevant population 
(mixed) 
Bays HE, Shah A, Lin J, McCrary Sisk C, Paolini JF, Maccubbin D. Efficacy and 
tolerability of extended-release niacin/laropiprant in dyslipidemic patients with 
metabolic syndrome. J Clin Lipidol 2010;4(6):515-21. 
Not relevant population; 
not relevant 
intervention/comparator 
Bays HE, Shah A, Macdonell G, Taggart WV, Gumbiner B. Effects of coadministered 
ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome. 
Metab Syndr Relat D 2011;9(2):135-42. 
Not relevant population 
Bays H. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 
randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol 
2014;63(23):2531-2540. 
Not relevant population 
(not previously received 
statins) 
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Publication citation Reason(s) for exclusion 
Behounek BD, McGovern ME, Kassler-Taub KB, Markowitz JS, Bergman M, Colman 
P, et al. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 
7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J 
Cardiol 1993;72(14):1031-1037. 
Not relevant outcome data 
(some patients received 
increased dose of statin if 
did not respond but data 
are not reported 
separately) 
Behounek BD, McGovern ME, Kassler-Taub KB, Markowitz JS, Bergman M. A 
multinational study of the effects of low-dose pravastatin in patients with non-insulin-
dependent diabetes mellitus and hypercholesterolemia. Pravastatin Multinational 
Study Group for Diabetes. Clin Cardiol 1994;17(10):558-62. 
Not relevant population 
Berberoglu Z, Guvener N, Asik M, Yazici AC, Bayraktar N. Effects of achieving LDL-
cholesterol levels <70 mg/dL with simvastatin or atorvastatin on steroidogenesis in 
high-risk diabetic patients. Endocrinologist 2009;19(3):102-107. 
Not relevant population 
Bertolini S, Bon GB, Campbell LM, Farnier M, Langan J, Mahla G, et al. Efficacy and 
safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. 
Atherosclerosis 1997;130(1-2):191-7. 
Not relevant population; 
mixed refractory and naive 
population with no 
separate results or 
indication of numbers in 
each category at baseline 
Betteridge J, Guyton JR, Farnier M, Leiter LA, Lin J, Shah A, et al. Greater 
dissociation of apolipoprotein B and LDL cholesterol targets in diabetes versus non-
diabetes patients receiving lipid-lowering therapy. Presented at 47th Annual Meeting 
of the European Association for the Study of Diabetes, EASD; 12-16 Sept 2011; 
Lisbon: Portugal. Diabetologia 2011;54:S278. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Binbrek AS, Elis A, Al-Zaibag M, Eha J, Keber I, Cuevas AM, et al. Rosuvastatin 
versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular 
disease in clinical practice: a randomized, open-label, parallel-group, multicenter 
study (DISCOVERY Alpha study). Curr Ther Res Clin Exp 2006;67(1):21-43. 
Not relevant population 
(mixed statin naïve and 
statin treated but only 
around 30% were statin 
treated and data not 
reported separately) 
Binbrek AS, Elis A, Al-Zaibag M, Eha J, Keber I, Cuevas AM, Mukherjee S, Miller TR, 
Discovery Alpha Study G. Rosuvastatin versus atorvastatin in achieving lipid goals in 
patients at high risk for cardiovascular disease in clinical practice: A randomized, 
open-label, parallel-group, multicenter study (DISCOVERY Alpha study). Current 
Therapeutic Research, Clinical & Experimental 2006;67(1):21-43. 
Not relevant population 
(mixed statin history; 
separate data NR; only 
40% had previously been 
treated with statin) 
Blazing MA, Giugliano RP, DeLemos J, Cannon CP, Musliner T, Tershakovec AM, et 
al. On-treatment analysis of the IMProved Reduction of Outcomes: Vytorin Efficacy 
International Trial (IMPROVE-IT). Circulation. 2014 December 2, 2014;130(23):2112. 
Not relevant population 
(mixed statin history, 
numbers and separate 
data NR) 
Blom D, Monsalvo ML, Tsirtsonis K, Wasserman S, Roth E. Effects of evolocumab 
(AMG 145) treatment on vitamin e levels: results from the 52-Week phase 3 double-
blind, randomized, placebo-controlled DESCARTES study (1107-102). Abstract 
presented at American College of Cardiology (ACC); 14-16 March 2015; San Diego, 
US. [Internet]2015 [accessed 30.4.15]. 
Not relevant outcomes 
(DESCARTES; Sub group 
analysis of patients having 
vitamin E) 
Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, et al. 
Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of 
cardiovascular events among statin-treated patients: a meta-analysis. Circulation 
2013;128(14):1504-12. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, et al. 
Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with 
risk of cardiovascular events among patients treated with statins: a meta-
analysis.[Erratum appears in JAMA. 2012 Apr 25;307(16):1694], [Erratum appears in 
JAMA. 2012 May 9;307(18):1915]. JAMA 2012;307(12):1302-9. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, 
LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman 
GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM, Jr., Ridker PM, 
Grundy SM, Kastelein JJP. Very low levels of atherogenic lipoproteins and the risk for 
cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol 
2014;64(5):485-94. 
Not relevant study design 
(meta-analysis; used for 
reference checking) 
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Publication citation Reason(s) for exclusion 
Boh M, Opolski G, Poredos P, Ceska R, Jezovnik M. Therapeutic equivalence of the 
generic and the reference atorvastatin in patients with increased coronary risk. Int 
Angiol 2011;30(4):366-74. 
Not relevant population 
Briasoulis A, Agarwal V, Valachis A, Messerli FH. Antihypertensive effects of statins: a 
meta-analysis of prospective controlled studies. J Clin Hypertens 2013;15(5):310-320. 
Not relevant trial design 
Bronx V. A. Medical Center. Tolerability and lipid lowering effect of weekly/biweekly 
crestor in statin intolerant patients treated with Zetia. NCT00972829. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009 
[accessed 27.6.14]. Available from: http://ClinicalTrials.gov/show/NCT00972829 
Not relevant outcome 
(early termination) 
Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson H, et al. 
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in 
patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am 
Heart J 2002;144(6):1036-1043. 
Not relevant population 
(Mixed statin naïve and 
statin treated) 
Bruckert E, De Gennes JL, Malbecq W, Baigts F. Comparison of the efficacy of 
simvastatin and standard fibrate therapy in the treatment of primary 
hypercholesterolemia and combined hyperlipidemia. Clin Cardiol 1995;18(11):621-9. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid 
alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 
2010;210(2):353-61. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Brudi P, Guyton JR, Betteridge J, Farnier M, Leiter LA, Lin J, et al. Meta-analysis 
evaluating the proportions of patients with and without diabetes achieving 
lipid/lipoprotein goals with ezetimibe/statin combination therapy versus statin alone. 
Presented at 46th Annual Meeting of the European Association for the Study of 
Diabetes, EASD; 20-24 Sept 2010; Stockholm: Sweden. Diabetologia 2010;53:S512. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Brudi PDP, Betteridge J, Guyton J, Farnier M, Leiter L, Lin J, et al. Greater 
dissociation of apolipoprotein B and LDL cholesterol targets in diabetes versus 
nondiabetes patients receiving lipid-lowering therapy. Presented at Annual Scientific 
Sessions of the National Lipid Association, NLA; 19-22 May 2011; New York, NY: 
United States. J Clin Lipidol 2011;5(3):198-199. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Brunetti L, Hermes-Desantis ER. The role of colesevelam hydrochloride in 
hypercholesterolemia and type 2 diabetes mellitus. Ann Pharmacother 2010;44(7-
8):1196-206. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al. Reduction 
in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events 
of the Pravastatin Atherosclerosis Intervention Program. Circulation 1995;92(9):2419-
25. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Cannon CP. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus 
simvastatin monotherapy on cardiovascular outcomes after acute coronary 
syndromes. Circulation. 2014 December 2, 2014;130(23):2109. 
Not relevant population 
(mixed statin history, 
numbers and separate 
data NR) 
Cannon CP. IMPROVE-IT: where is the ground in aggressive LDL lowering after 
ACS? Presented at ESC Congress 2015; 29 Aug-2 Sep 2015; London: United 
Kingdom. 2015. 
Not relevant population 
(mixed statin naïve and 
statin treated) 
Carr-Lopez S, Exstrum T, Morse T, Shepherd M, Bush AC. Efficacy of three statins at 
lower maintenance doses. Clin Ther 1999;21(2):331-339. 
Not relevant population 
Carter NJ. Rosuvastatin: a review of its use in the prevention of cardiovascular 
disease in apparently healthy women or men with normal LDL-C levels and elevated 
hsCRP levels. Am J Cardiovasc Drugs 2010;10(6):383-400. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Catapano AL, Reiner T, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. 
ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the 
management of dyslipidaemias of the European Society of Cardiology (ESC) and the 
European Atherosclerosis Society (EAS). Atherosclerosis 2011;217(1):3-46. 
Not relevant trial design 
(guidelines/guidance) 
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Publication citation Reason(s) for exclusion 
Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. 
ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the 
management of dyslipidaemias of the European Society of Cardiology (ESC) and the 
European Atherosclerosis Society (EAS). Atherosclerosis 2011;217(SUPPL. 1):S1-
S44. 
Not relevant trial design 
(guidelines/guidance) 
Chan DC, Hamilton SJ, Rye KA, Chew GT, Jenkins AJ, Lambert G, et al. Fenofibrate 
concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and 
very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic 
patients. Diabetes, Obesity & Metabolism 2010;12(9):752-6. 
Not relevant trial design 
(too few pts) 
Choi HD, Shin WG. Safety and efficacy of statin treatment alone and in combination 
with fibrates in patients with dyslipidemia: a meta-analysis. Curr Med Res Opin 
2014;30(1):1-10. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Clement Atlee W, Vasudevan M. Comparing the effect of monotherapies of 
hyperlipidemia over placebo treatment. Int J Drug Dev Res. 2014;6(3):68-76. 
Not relevant population 
(statin status unclear) 
Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M. Safety and efficacy of 
mipomersen administered as add-on therapy in patients with hypercholesterolemia 
and high cardiovascular risk. Presented at 60th Annual Scientific Session of the 
American College of Cardiology and i2 Summit: Innovation in Intervention, ACC; 2-5 
April 2011; New Orleans, LA: United States. J Am Coll Cardiol 2011;57(14 suppl 
1):E504. 
Not relevant population - 
mipomersen trial not in 
HoFH 
Cromwell WC, Thomas GS, Boltje I, Chin W, Davidson M. Safety and efficacy of 
mipomersen administered as addon therapy in patients with hypercholesterolemia and 
high cardiovascular risk. Presented at Annual Scientific Sessions of the National Lipid 
Association, NLA; 31 May - 3 Jun 2012; Scottsdale, AZ: United States. J Clin Lipidol 
2012;6(3):291-292. 
Not relevant population - 
mipomersen trial not in 
HoFH 
CymaBay Therapeutics I. A 12-week, open-label, dose-escalating, phase 2 study to 
evaluate the effects of MBX-8025 in patients with Homozygous Familial 
Hypercholesterolemia (HoFH). 2015. Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-
004856-68 
Not relevant intervention 
Daiichi Sankyo Inc. A study to determine the effect of WelChol tablets on cholesterol 
in patients who have been taking simvastatin for at least 4 weeks. NCT00753779. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2008 
[accessed 29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00753779 
Not relevant trial design 
(6wk treatment period) 
Daniel AS, Merck Sharp Dohme Corp, Hospital Italiano de Buenos Aires. Lipid 
efficacy of the extended release niacin/laropiprant combination in patients with 
cardiovascular disease. NCT01308203. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US). 2013 [accessed 27.10.14]. Available from: 
http://ClinicalTrials.gov/show/NCT01308203 
Not relevant outcome 
(early termination) 
Dargush A, Shah S, O'Dell K, Bhattacharyya M. Magnitude of benefit when ezetimibe 
is added to statin therapy: a meta-analysis. Presented at Joint Forces Pharmacy 
Seminar, JFPS; 28 Oct - 1 Nov 2012; San Diego, CA: United States. J Am Pharm 
Assoc 2012;52(5):679. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Davidson M, McKenney J, Stein E, Schrott H, Bakker-Arkema R, Fayyad R, et al. 
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in 
primary hypercholesterolemia. Atorvastatin Study Group I. Am J Cardiol 
1997;79(11):1475-81. 
Not relevant population; 
mixed refractory and naive 
population with no 
separate results or 
indication of numbers in 
each category at baseline 
Davidson M. The efficacy of colesevelam HCL in the treatment of heterozygous 
familial hypercholesterolemia in pediatric and adult patients. Clin Ther 
2013;35(8):1247-1252. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, et al. Ezetimibe 
coadministered with simvastatin in patients with primary hypercholesterolemia. J Am 
Coll Cardiol 2002;40(12):2125-34. 
Not relevant population 
(mixed) 
 by guest on O
ctober 20, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Toth et al | Network Meta-Analysis Lipid-Lowering Therapies | Supplemental Appendix 
S42 
Publication citation Reason(s) for exclusion 
Davidson MH, Rooney M, Pollock E, Drucker J, Choy Y. Effect of colesevelam and 
niacin on low-density lipoprotein cholesterol and glycemic control in subjects with 
dyslipidemia and impaired fasting glucose. J Clin Lipidol. 2013 Sep-Oct;7(5):423-32. 
Not relevant population 
(mixed statin history, 
numbers and separate 
data NR) 
Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M. 
Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet 
compared with atorvastatin and fenofibrate monotherapies in patients with 
dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. 
Clin Ther 2009;31(12):2824-2838. 
Not relevant population 
De Caterina R, Scarano M, Marfisi R, Lucisano G, Palma F, Tatasciore A, et al. 
Cholesterol-lowering interventions and stroke: insights from a meta-analysis of 
randomized controlled trials. J Am Coll Cardiol 2010;55(3):198-211. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Dias C, Shaywitz A, Cooke B, Uy S, Emery M, Gibbs J, et al. Effects of amg 145, a 
fully human monoclonal antibody against pcsk9, on low-density lipoprotein cholesterol 
in subjects taking statins: a phase 1, randomized, doubleblind, placebo-controlled, 
ascending multiple-dose study. Presented at 61st Annual Scientific Session of the 
American College of Cardiology and i2 Summit: Innovation in Intervention, ACC; 24-
27 Mar 2012; Chicago, IL: United States. J Am Coll Cardiol 2012;59(13 Suppl 
1):E1379. 
Not relevant trial design 
(<12 wks) 
Dias C, Shaywitz A, Smith B, Gao B, Gibbs J, Emery M, et al. AMG 145 a fully human 
monoclonal antibody against PCSK9, reduces LDL-C in healthy volunteers and 
patients on stable doses of statins. Presented at 65th Annual Meeting of the Canadian 
Cardiovascular Society; 27-31 Oct 2012; Toronto, ON: Canada. Can J Cardiol 
2012;28(5 suppl 1):S148. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Dias C, Shaywitz A, Smith B, Gao B, Gibbs J, Emery M, et al. AMG 145-a fully human 
monoclonal antibody against PCSK9, REDUCES LDL-C in healthy volunteers and 
patients on stable doses of statins. Can J Cardiol. 2012;28(5 SUPPL. 1):S148. 
Not relevant study design 
(pooled analysis) 
Dias CS, Shaywitz AJ, Wasserman SM, Smith BP, Gao B, Stolman DS, et al. Effects 
of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, 
double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy 
volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 
2012;60(19):1888-98. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Ditschuneit HH, Dreyer M, Dammann HG, Ditschuneit H. [Pravastatin, cholestyramine 
and gemfibrozil in long-term therapy of primary hypercholesterolemia. An open 
randomized comparative study]. Med Klin 1991;86(3):142-8. 
Not relevant population 
Ducobu J, Van Haelst L, Salomon H. Efficacy of micronised fenofibrate in patients 
with primary hyperlipidaemia: a comparison with pravastatin. Br J Cardiol 
2002;9(6):343-350. 
Not relevant population 
(mixed); Not relevant trial 
design 
Duell PB, Santos RD, East C, Guyton JR, Moriarty PM, Donovan JM, et al. Long-term 
safety and efficacy of mipomersen in patients with familial hypercholesterolemia 
uncontrolled by maximally tolerated lipid lowering therapy. Presented at Annual 
Scientific Sessions of the National Lipid Association, NLA; 31 May - 3 Jun 2012; 
Scottsdale, AZ: United States. J Clin Lipidol 2012;6(3):291. 
Not relevant population 
(mipomersen trial in FH); 
not relevant trial design 
Dufour R, Moriarty PM, Genestin E, Sasiela WJ, Du Y, Ferrand AC, et al. Effect of 
REGN727/SAR236553 anti-proprotein convertase subtilisin/kexin type 9 fully human 
monoclonal antibody in patients with elevated triglycerides/low high-density lipoprotein 
cholesterol: data from three phase 2 studies (NCT:01266876; 01288469; 01288443). 
Presented at American Heart Association 2012 Scientific Sessions and Resuscitation 
Science Symposium; 3-6 Nov 2012; Los Angeles, CA: United States. Circulation 
2012;126(21 suppl 1). 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al. Efficacy 
and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in 
patients with primary hypercholesterolemia. [Erratum appears in Am J Cardiol. 2003 
Jun 1;91(11):1399]. Am J Cardiol 2002;90(10):1092-7. 
Not relevant population 
(mixed) 
Dujovne CA, Le Beaut A, Lipka LJ, Suresh R, Veltri EP, Alderman J, et al. Evaluation 
of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: 
a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 
2003;57(5):363-368. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
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Eli Lilly and Company. A phase 2 efficacy and safety study of LY2484595 alone and 
in combination with atorvastatin, simvastatin, and rosuvastatin in patients with 
hypercholesterolemia or low HDL-C. EUCTR2009-017479-29-DE. In: EU Clinical 
Trials Register (EUCTR) [Internet]. London: European Medicines Agency (EMA). 2010 
[accessed 27.10.14]. Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2009-017479-29 
Not relevant population 
(mixed statin history; 
separate data and 
numbers of participants 
NR) 
Eriksson M, Budinski D, Hounslow N. Comparative efficacy of pitavastatin and 
simvastatin in high-risk patients: a randomized controlled trial. Adv Ther 
2011;28(9):811-23. 
Not relevant population 
(statin naive) 
Eriksson M, Budinski D, Hounslow N. Long-term efficacy of pitavastatin versus 
simvastatin. Adv Ther 2011;28(9):799-810. 
Not relevant population 
(statin naive) 
Esperion Therapeutics I. A randomized, double-blind, placebo-controlled, multi-center 
long-term safety and tolerability study of etc-1002 in patients with hyperlipidemia at 
high cardiovascular risk who are not adequately.  2016; Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-
004136-36. 
Not relevant intervention/ 
comparator - ETC-1002, 
new potential lipid lowering 
therapy but unlicensed and 
still in development 
Farnier M, Chen E, Johnson-Levonas AO, McCrary Sisk C, Mitchel YB. Effects of 
extended-release niacin/laropiprant, simvastatin, and the combination on correlations 
between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with 
dyslipidemia. Vasc Health Risk Manag 2014;10:279-90. 
Not relevant population 
(mixed dyslipidemic, 
separate data for 
subgroups but based on 
TG levels and not LDL-C) 
Farnier M, Guyton JR, Jensen E, Polis A, Johnson- Levonas AO, Brudi P. Effects of 
ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between 
apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary 
hypercholesterolemia. Presented at ESC Congress; 25-29 Aug 2012; Munich: 
Germany. Eur Heart J 2012;33:281-282. 
Not relevant population; 
not relevant trial design 
Farnier M, Taggart W, Dong Q, Shah A, Brudi P. Influence of fenofibrate, simvastatin 
and/or ezetimibe on correlation of LDL and non-HDL cholesterol with apolipoprotein B 
in mixed dyslipidemic patients. Presented at 78th EAS Congress; 20-23 Jun 2010; 
Hamburg: Germany. Atheroscler Suppl 2010;11(2):68. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Farnier M. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. 
Am J Cardiol 1998;82(4B):47J-51J. 
Not relevant intervention 
Fazio S, Guyton JR, Lin J, Tomassini JE, Shah A, Tershakovec AM. Long-term 
efficacy and safety of ezetimibe/simvastatin coadministered with extended-release 
niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes, 
Obesity & Metabolism 2010;12(11):983-93. 
Not relevant population 
Feldman T, Ose L, Shah A, Zakson M, Meehan A, Johnson-Levonas AO, et al. 
Efficacy and safety of ezetimibe/simvastatin versus simvastatin monotherapy in 
hypercholesterolemic patients with metabolic syndrome. Metab Syndr Relat D 
2007;5(1):13-21. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Ferdinand KC, Davidson MH, Kelly MT, Setze CM. One-year efficacy and safety of 
rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: 
evaluation of dose response. Am J Cardiovasc Drugs 2012;12(2):117-25. 
Not relevant trial design; 
not relevant populaton 
Ferrari P, Weidmann P, Riesen WF, Martius F, Luban S, Pasotti E, et al. [Pravastatin 
in the treatment of primary hypercholesterolemia: a Swiss multicenter study]. Schweiz 
Med Wochenschr 1993;123(37):1736-41. 
Not relevant population; 
not relevant trial design 
Fichtenbaum CJ, Yeh TM, Evans SR, Aberg JA. Treatment with pravastatin and 
fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 
5087. J Clin Lipidol 2010;4(4):279-287. 
Not relevant population 
(HIV infected individuals) 
Furiex Pharmaceuticals Inc. Study of the safety and tolerability associated with 
PPD10558 versus atorvastatin in patients previously intolerant to statins due to statin-
associated myalgia (SAM). NCT01279590. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US). 2011 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT01279590 
Not relevant comparator 
(PPD10558 versus 
atorvastatin) 
Gagné C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, et al. Efficacy and safety 
of ezetimibe added to ongoing statin therapy for treatment of patients with primary 
hypercholesterolemia. Am J Cardiol 2002;90(10):1084-91. 
Not relevant trial design 
(only 8wk treatment 
period) 
Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with 
atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. 
Circulation 2002;105(21):2469-2475. 
Not relevant trial design 
(only 8wk treatment 
period) 
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Garvey WT, Goldberg RB, Handelsman Y, Fonseca VA, Hernandez-Triana E, Jones 
MR, et al. Colesevelam significantly reduces low-density lipoprotein particle 
concentration in patients with prediabetes and hypercholesterolemia. Presented at 8th 
Annual World Congress on Insulin Resistance Diabetes and Cardiovascular Disease, 
WCIRDC; 4-6 Nov 2011; Los Angeles, CA: United States. Diab Vasc Dis Res 
2011;8(1):85-86. 
Not relevant population 
Gaudet D, Kereiakes D, McKenney J, Roth E, Hanotin C, Gipe D, et al. Alirocumab, a 
fully human monoclonal antibody to pcsk9, reduces high plasma lp(a) concentration: 
pooled analysis of 352 patients from phase 2. Presented at Annual Scientific Sessions 
of the National Lipid Association, NLA; 30 May - 2 Jun 2013; Las Vegas, NV: United 
States. J Clin Lipidol 2013;7(3):283-284. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Gaudet D, Kereiakes D, McKenney J, Roth E, Hanotin C, Gipe D, et al. Effect of 
SAR236553/REGN727 fully human monoclonal anti-proprotein convertase 
subtilisin/kexin type 9 antibody on plasma lipoprotein(a) concentrations: pooled 
analysis from three phase 2 studies (NCT:01266876; 01288469; 01288443). 
Presented at American Heart Association 2012 Scientific Sessions and Resuscitation 
Science Symposium; 3-6 Nov 2012; Los Angeles, CA: United States. Circulation 
2012;126(21 Suppl 1). 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand 
A-C, Ginsberg HN, Stein EA. Effect of alirocumab, a monoclonal proprotein 
convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled 
analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 
2014;114(5):711-5. 
Not relevant study design 
(pooled analysis of three 
trials; two have been 
reported as individual 
studies and one is not 
relevant as only 8wks 
duration) 
Gaudet D, Watts GF, Robinson J, Thompson D, Sasiela W, Edelberg J, et al. 
Sustained treatment effect of alirocumab on Lp(a): pooled analyses from 4,915 
patients in ten phase 3 trials in the ODYSSEY program. Presented at ESC Congress 
2015; 29 Aug-2 Sep 2015; London: United Kingdom. 2015. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Gavin IJR, Jones MR, Ford DM, Truitt KE. Safety and efficacy of colesevelam HCl in 
the treatment of elderly patients. Drugs Aging 2014;31(6):461-470. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Geiss HC, Otto C, Hund-Wissner E, Parhofer KG. Effects of ezetimibe on plasma 
lipoproteins in severely hypercholesterolemic patients treated with regular LDL-
apheresis and statins. Atherosclerosis 2005;180(1):107-12. 
Not relevant trial design 
(<12 wks) 
Geng Q, Ren J, Chen H, Lee C, Liang W. Adverse events of statin-fenofibric acid 
versus statin monotherapy: a meta-analysis of randomized controlled trials. Curr Med 
Res Opin 2013;29(3):181-188. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Genzyme Europe B.V. A prospective randomized, double-blind, placebo-controlled 
study to assess the safety and efficacy of mipomersen in patients with severe 
hypercholesterolemia on a maximally tolerated lipid-lowering regimen and who are not 
on apheresis. EUCTR2008-006020-53. In: PharmNet.Bund [Internet]. Cologne: 
German Institute of Medical Documentation and Information (DIMDI). 2008 [accessed 
30.5.14]. Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2008-006020-53   
Not relevant population 
(HeFH and HoFH 
population for 
mipomersen. No evidence 
for HoFH only) 
Genzyme, Isis Pharmaceuticals, Sanofi. Open label extension of ISIS 301012 
(Mipomersen) to treat familial hypercholesterolemia. NCT00477594. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 
[accessed 27.10.14]. Available from: http://ClinicalTrials.gov/show/NCT00477594 
Not relevant population 
(mipomersen trial not 
solely in HoFH patients) 
Genzyme, Isis Pharmaceuticals. Dose-escalating safety study of ISIS 301012 in 
homozygous familial hypercholesterolemia subjects on lipid lowering therapy. 
NCT00280995. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2013 [accessed 14.7.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00280995 
Not relevant trial design 
(<12 wks) 
Genzyme, Isis Pharmaceuticals. Safety and efficacy of mipomersen (ISIS 301012) as 
add-on therapy in high risk hypercholesterolemic patients. NCT00770146. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 
[accessed 29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00770146 
Not relevant population - 
mipomersen trial not in 
HoFH 
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Genzyme, Isis Pharmaceuticals. Safety and efficacy of mipomersen in patients with 
severe hypercholesterolemia on a maximally tolerated lipid-lowering regimen and who 
are not on apheresis. NCT00794664. In: ClinicalTrials.gov [Internet]. Bethesda (MD): 
National Library of Medicine (US). 2013 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00794664 
Not relevant population 
Genzyme, Isis Pharmaceuticals. Safety and efficacy study of ISIS 301012 
(mipomersen) administration in high risk statin intolerant subjects. NCT00707746. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 
[accessed 30.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00707746 
Not relevant population - 
mipomersen trial not in 
HoFH 
Genzyme, Sanofi. A study of the safety and efficacy of two different regimens of 
mipomersen in patients with familial hypercholesterolemia and inadequately controlled 
low-density lipoprotein cholesterol. NCT01475825. In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2014 [accessed 27.10.14]. 
Available from: http://ClinicalTrials.gov/show/NCT01475825 
Not relevant population 
(mipomersen trial in HeFH) 
Giannini SD. [Comparison of lipid-lowering effects of lovastatin and bezafibrate in 
patients with primary hypercholesterolemia. The Brazilian multicenter study]. Rev Bras 
Med 1990;47(5):177-184. 
Not relevant population 
Giugliano RP, Wiviott SD, Blazing MA, Murphy SA, Zhou J, White JA, et al. Safety 
and efficacy of long-term very low achieved LDL-C in the IMPROVE IT trial. Presented 
at ESC Congress 2015; 29 Aug-2 Sep 2015; London: United Kingdom. 2015. 
Not relevant population 
(mixed statin status) 
Giugliano RP. Achievement of dual LDL-C (<70 mg/dL) and hs-CRP (<2 mg/L) goals 
more frequent with addition of ezetimibe and associated with better outcomes in 
IMPROVE-IT. Presented at ESC Congress 2015; 29 Aug-2 Sep 2015; London: United 
Kingdom. 2015. 
Not relevant population 
(mixed statin status) 
Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB, Ezetimibe Study G. Efficacy and 
safety of ezetimibe coadministered with simvastatin in patients with primary 
hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin 
Proc 2004;79(5):620-9. 
Not relevant population 
Gray J, Edwards SJ, Lip GYH. Comparison of sequential rosuvastatin doses in 
hypercholesterolaemia: a meta-analysis of randomised controlled trials. Curr Med Res 
Opin 2010;26(3):537-47. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, et al. 
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia 
associated with type 2 diabetes: results of the assessment of diabetes control and 
evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162(14):1568-76. 
Not relevant population 
(mixed) 
Gudzune KA, Monroe AK, Sharma R, Ranasinghe PD, Chelladurai Y, Robinson KA. 
Effectiveness of combination therapy with statin and another lipid-modifying agent 
compared with intensified statin monotherapy: a systematic review. Ann Intern Med 
2014;160(7):468-76. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Gumbiner B, Joh T, Udata C, Forgues P, Baum CM, Garzone PD. Effects of 12 weeks 
of treatment with RN316 (PF-04950615), a humanized IgG2a monoclonal antibody 
binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic subjects 
on high and maximal dose statins. Presented at American Heart Association 2012 
Scientific Sessions and Resuscitation Science Symposium; 3-6 Nov 2012; Los 
Angeles, CA: United States. Circulation 2012;126(23):2782. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Gumbiner B, Udata C, Joh T, Liang H, Wan H, Shelton D, et al. The effects of single 
dose administration of RN316 (PF-04950615), a humanized IGG2A monoclonal 
antibody binding proprotein convertase subtilisin kexin type 9, in hypercholesterolemic 
subjects treated with and without atorvastatin. Presented at American Heart 
Association 2012 Scientific Sessions and Resuscitation Science Symposium; 3-6 Nov 
2012; Los Angeles, CA: Unites States. Circulation 2012;126(21 suppl 1). 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Gumprecht J, Gosho M, Budinski D, Hounslow N. Comparative long-term efficacy and 
tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 
diabetes mellitus and combined (mixed) dyslipidaemia. Diabetes, Obesity & 
Metabolism 2011;13(11):1047-55. 
Not relevant population 
(statin status unclear) 
Guo J, Meng F, Ma N, Li C, Ding Z, Wang H, et al. Meta-analysis of safety of the 
coadministration of statin with fenofibrate in patients with combined hyperlipidemia. 
Am J Cardiol 2012;110(9):1296-301. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
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Guyton JR, Betteridge DJ, Farnier M, Leiter LA, Lin J, Shah A, et al. Achievement of 
recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy 
versus statin alone in patients with and without diabetes. Diab Vasc Dis Res 
2011;8(2):160-72. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Guyton JR, Farnier M, Jensen EH, Polis AB, Johnson-Levonas AO, Brudi P. Effects of 
ezetimibe, simvastatin, and ezetimibe/ simvastatin on apolipoprotein B, low-density 
lipoprotein cholesterol, and non-high-density lipoprotein cholesterol targets in patients 
with primary hypercholesterolemia. Presented at Annual Scientific Sessions of the 
National Lipid Association, NLA; 31 May - 3 Jun 2012; Scottsdale, AZ: United States. 
J Clin Lipidol 2012;6(3):289-290. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Habib G, Paillard F, Charpentier G, Angellier JF, Roux T, Portal JJ, et al. A 
multicenter, open-label, randomized study comparing the efficacy of atorvastatin 
versus usual care in reducing refractory hypercholesterolemia in high-risk patients to 
target levels. Curr Ther Res Clin Exp 2000;61(4):175-190. 
Not relevant population 
(statin status unclear) 
Hamilton SJ, Chew GT, Davis TME, Watts GF. Fenofibrate improves endothelial 
function in the brachial artery and forearm resistance arterioles of statin-treated Type 
2 diabetic patients. Clin Sci 2010;118(10):607-15. 
Not relevant trial design 
(too few pts) 
Handelsman Y, Goldberg RB, Rosenstock J, Garvey WT, Fonseca VA, Hernandez-
Triana E, et al. Colesevelam for hispanic patients with hypercholesterolemia and 
prediabetes. Pharmacotherapy. 2010;30(10):390e-1e. 
Not relevant population 
(statin status unclear) 
Hao Y, Zhang H, Yang X, Wang L, Gu D. Effects of fibrates on C-reactive protein 
concentrations: a meta-analysis of randomized controlled trials. Clin Chem Lab Med 
2012;50(2):391-7. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Harivenkatesh N, David DC, Haribalaji N, Sudhakar MK. Efficacy and safety of 
alternate day therapy with atorvastatin and fenofibrate combination in mixed 
dyslipidemia: a randomized controlled trial. J Cardiovasc Pharmacol Ther 
2014;19(3):296-303. 
Not relevant population 
(mixed dyslipidemic and 
mixed statin history, 
numbers and separate 
data NR) 
Hoogerbrugge N, Jansen H, De Heide L, Zillikens MC, Deckers JW, Birkenhager JC. 
The additional effects of acipimox to simvastatin in the treatment of combined 
hyperlipidaemia.[Republished from J Intern Med. 1997 Feb;241(2):151-5; PMID: 
9077372]. J Intern Med 1998;243(5):151-6. 
Not relevant trial design 
Hopkins PN, Swergold GD, Mellis S, Bruckert E, Luc G, Mendoza J, et al. A 
randomized placebo-phase clinical trial with the monoclonal antibody alirocumab 
demonstrates reductions in low-density lipoprotein cholesterol in patients with 
proprotein convertase subtilisin/kexin type 9 gain-of-function mutations. Presented at 
American Heart Association 2013 Scientific Sessions and Resuscitation Science 
Symposium; 16-20 Nov 2013; Dallas, TX: United States. Circulation 2013;128(22 
suppl 1). 
Not relevant trial design; 
<10 pts per arm 
Hospital of the University of Munich. Effect of mipomersen on LDL-cholesterol levels 
in patients with severe LDL-hypercholesterolemia and atherosclerosis treated by 
regular LDL-apheresis. EUCTR2011-002539-24. In: EU Clinical Trials Register 
(EUCTR) [Internet]. London: European Medicines Agency (EMA). 2012 [accessed 
27.10.14]. Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2011-002539-24 
Not relevant population 
(statin history unclear) 
Hounslow N, Budinski D, Eriksson M. Pitavastatin 4 mg shows comparable LDL-
cholesterol and superior triglyceride reduction to simvastatin 40 mg in high-risk 
primary hypercholesterolemia or combined dyslipidemia. Presented at 78th EAS 
Congress; 20-23 Jun 2010; Hamburg: Germany. Atheroscler Suppl 2010;11(2):188. 
Not relevant population; 
Not relevant trial design 
(not RCT) 
Hounslow N. Pitavastatin LDL-C target attainment in elderly and CHD risk populations 
in a Phase 3 programme. Presented at European Society of Cardiology, ESC 
Congress; 28 Aug - 1 Sept 2010; Stockholm: Sweden. Eur Heart J 2010;31:256-257. 
Not relevant trial design - 
summary of phase 3 trial 
programme 
Hovingh GK, Kastelein JJ, van Deventer SJ, Round P, Ford J, Saleheen D, et al. 
Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild 
dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. 
Lancet. 2015 Aug 1;386(9992):452-60. 
Not relevant population 
(statin status unclear) 
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Publication citation Reason(s) for exclusion 
HPS Thrive Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, 
Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of 
extended-release niacin with laropiprant in high-risk patients. N Engl J Med 
2014;371(3):203-12. 
Not relevant population 
(around 38% of patients 
were at lipid targets at 
baseline) 
Hu M, Yang Y, Yamashita S, Masuda D, Tomlinson B. Effect of niacin on oxidized 
low-density lipoprotein levels in Chinese patients with dyslipidaemia. Atherosclerosis 
2014;235(2):e256. 
Not relevant population 
(statin history unclear); not 
relevant outcome (ox-LDL 
and correlation study) 
Illingworth DR, Crouse JR, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef 
AFH, et al. A comparison of simvastatin and atorvastatin up to maximal recommended 
doses in a large multicenter randomized clinical trial. Curr Med Res Opin 
2001;17(1):43-50. 
Not relevant population 
(mixed) 
Inazawa T, Sakamoto K, Kohro T, Iijima R, Kitazawa T, Hirano T, et al. RESEARCH 
(Recognized effect of Statin and ezetimibe therapy for achieving LDL-C Goal), a 
randomized, doctor-oriented, multicenter trial to compare the effects of higher-dose 
statin versus ezetimibe-plus-statin on the serum LDL-C concentration of Japanese 
type-2 diabetes patients design and rationale. Lipids Health Dis 2013;12:142. 
Duplicate of  
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen. Ezetimibe for 
hypercholesterolaemia. Köln: IQWiG, 2011. 134p. Available from: 
https://www.iqwig.de/download/A10-
02_Abschlussbericht_Ezetimib_bei_Hypercholesterinaemie.pdf 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Merck Sharp 
Dohme Corp. Efficacy of ezetimibe/simvastatin 10/20 mg and MK0524A (1-2 g/Day) in 
mixed hyperlipidemia and two or more risk factors. NCT00738985. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011 
[accessed 27.6.14]. Available from: http://ClinicalTrials.gov/show/NCT00738985 
Not relevant outcome 
(early termination) 
Insull Jr W, Toth PP, Superko HR, Thakkar RB, Krause S, Jiang P, et al. Combination 
of niacin extended-release and simvastatin results in a less atherogenic lipid profile 
than atorvastatin monotherapy. Vasc Health Risk Manag 2010;6(1):1065-1075. 
Not relevant population 
(statin status unclear) 
Isaacsohn J, Insull Jr W, Stein E, Kwiterovich P, Ma P, Brazg R, et al. Long-term 
efficacy and safety of cerivastatin 0.8 mg in patients with primary 
hypercholesterolemia. Clin Cardiol 2001;24(10 SUPPL.):IV1-IV9. 
Not relevant population 
(mixed statin naïve and 
statin treated but numbers 
not reported and data not 
reported separately); not 
relevant comparator 
(different doses of 
cerivastatin vs. placebo) 
Isis Pharmaceuticals Inc. A randomized, double-blind, placebo-controlled phase 3 
study of ISIS 304801 administered subcutaneously to patients with 
hypertriglyceridemia. EUCTR2014-003434-93. In: PharmNet.Bund [Internet]. Cologne: 
German Institute of Medical Documentation and Information (DIMDI).  2014 [accessed 
19.3.15]; Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=2014-003434-93. 
Not relevant population 
(mixed statin history; 
separate data and 
numbers of participants 
NR) 
Ito MK. Dyslipidemia: management using optimal lipid-lowering therapy. Ann 
Pharmacother 2012;46(10):1368-81. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Itoh M, Kato T, Sawai Y, Inagaki K, Kanayama H, Katada N. Comparison of efficacy of 
pitavastatin and colestimide in Japanese patients with diabetes mellitus complicated 
by hyperlipidaemia and metabolic syndrome. Presented at 45th EASD Annual 
Meeting of the European Association for the Study of Diabetes; 30 Sept - 2 Oct 2009; 
Vienna: Austria. Diabetologia 2009;52(S1):S491-492. 
Not relevant population 
Izawa A, Kashima Y, Miura T, Ebisawa S, Kitabayashi H, Yamamoto H, et al. 
Assessment of lipophilic vs. hydrophilic statin therapy in acute myocardial infarction - 
ALPS-AMI study. Circ J. 2015;79(1):161-8. 
Not relevant population 
(statin history unclear)  
Jiang Z, Gong RR, Qiu L, Wang Q, Su M, Liu XJ, Hu MS, Lin J, Fang DZ. Efficacy and 
safety of pitavastatin versus simvastatin: a meta-analysis of randomized controlled 
trials. Clin Drug Investig 2014;34(9):599-608. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
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Publication citation Reason(s) for exclusion 
Jones PH, Bays H, Chaudhari U, Pordy R, Lorenzato C, Miller K, et al. Pooled safety 
and adverse events in nine randomized, placebo-controlled, phase 2 and 3 clinical 
trials of alirocumab (914-08). Abstract presented at American College of Cardiology 
(ACC); 14-16 March 2015; San Diego, US. [Internet].  2015 [accessed 30.4.15]; 
Available from: http://www.abstractsonline.com/pp8/#!/3658/presentation/28389. 
Not relevant study design 
(Pooled data) 
Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, et al. Efficacy and 
safety of fenofibric acid co-administered with low- or moderate-dose statin in patients 
with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup 
analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc 
Drugs 2010;10(2):73-84. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Jones PH, Davidson MH, Goldberg AC, Pepine CJ, Kelly MT, Buttler SM, et al. 
Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed 
dyslipidemia: pooled analysis of three phase 3, 12-week randomized, controlled 
studies. J Clin Lipidol 2009;3(2):125-137. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ. Statin 
Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin Study 
Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on 
non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients 
with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 
2004;26(9):1388-99. 
Not relevant population 
(mixed) 
Jover E, Aranda JL, Nogués X, Palacio A, Rubiés-Prat J. [Multicenter comparative 
study on safety, tolerance, and effectiveness of lovastatin combined or not with 
cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment 
of primary hypercholesterolemia]. Med Clin 1996;106(20):776-9. 
Not relevant population 
(mixed) 
Jukema JW, Liem AH, Dunselman PHJM, Van Der Sloot JAP, Lok DJA, Zwinderman 
AH. LDL-C/HDL-C ratio in subjects with cardiovascular disease and a low HDL-C: 
results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages and 
Reverse cholesterol transport) study. Curr Med Res Opin 2005;21(11):1865-1874. 
Not relevant population 
Kadikoylu G, Yukselen V, Yavasoglu I, Bolaman Z. Hemostatic effects of atorvastatin 
versus simvastatin. Ann Pharmacother 2003;37(4):478-84. 
Not relevant population 
Kang S, Liu Y, Liu XB. Effects of aggressive statin therapy on patients with coronary 
saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, 
controlled trials. Clin Ther 2013;35(8):1125-1136. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Karalis I, Bergheanu SC, Van Tol A, Dallinga-Thie GM, Liem AH, Jukema JW. Effect 
of increasing doses of rosuvastatin and atorvastatin on apolipoproteins, enzymes 
involved in lipoprotein metabolism and inflammatory parameters. Presented at 
European Society of Cardiology, ESC Congress; 28 Aug - 1 Sept 2010; Stockholm: 
Sweden. Eur Heart J 2010;31:104-105. 
Not relevant population 
Karlson BW, Barter PJ, Lundman P, Palmer M, Nicholls SJ. Impact of increasing 
statin dose on the non-high-density lipoprotein cholesterol to high-density lipoprotein 
cholesterol ratio: results from VOYAGER. Presented at 15th Svenska Kardiovaskulara 
Varmotet; 17-19 Apr 2013; Goteborg: Sweden. Scand Cardiovasc J 2013;47:38. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Doses of rosuvastatin, 
atorvastatin and simvastatin inducing an equipotent effect on LDL-C: results from the 
voyager meta-analysis. Atherosclerosis 2014;235(2):e35. 
Not relevant population 
(statin history unclear); not 
relevant study design (IPD 
from VOYAGER database) 
Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Doses of rosuvastatin, 
atorvastatin and simvastatin inducing an equipotent effect on LDL-C: results from the 
voyager meta-analysis. Atherosclerosis. 2014;235(2):e35. 
Not relevant study design 
(Meta-analysis of IPD 
data) 
Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Impact of statin therapy 
on low-density lipoprotein cholesterol and triglyceride levels in patients with 
hypertriglyceridaemia: a VOYAGER meta-analysis. Eur Heart J. 2014;35:217. 
Not relevant study design 
(Meta-analysis of IPD 
data) 
Karlson BW, Toth PP, Palmer MK, Barter PJ, Nicholls SJ. Achievement of combined 
goals of low-density lipoprotein cholesterol and non-high-density lipoprotein 
cholesterol with three different statins: results from VOYAGER. IJC Metabolic and 
Endocrine. 2014;5:61-6. 
Not relevant study design 
(Meta-analysis of IPD 
data) 
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Publication citation Reason(s) for exclusion 
Kastelein JJ, Kereiakes DJ, Cannon CP, Bays HE, Minini P, Lee LV, et al. Additional 
LDL-C Reduction Achieved With Alirocumab Dose Increase on Background Statin. 
Circulation. 2015 November 10, 2015;132(Suppl 3):A17099. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Kastelein JJP. Efficacy and safety of the PCSK9 monoclonal antibody alirocumab vs 
placebo in 1254 patients with heterozygous familial hypercholesterolaemia (HeFH): 
analyses up to 78 weeks from four ODYSSEY trials. Presented at ESC Congress 
2015; 29 Aug-2 Sep 2015; London: United Kingdom. 2015. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Kato T, Inagaki K, Sawai Y, Kanayama H, Katada N, Itoh M. Comparison of efficacy of 
pitavastatin and colestimide in Japanese patients with diabetes mellitus complicated 
by hyperlipidemia and metabolic syndrome. Experimental & Clinical Endocrinology & 
Diabetes 2011;119(9):554-8. 
Not relevant population; 
not relevant 
intervention/comparator 
Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high 
density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: 
meta-analysis of randomised controlled trials including 117,411 patients. Br Med J 
2014;349:g4379. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Khera AV, Patel PJ, Reilly MP, Rader DJ. The addition of niacin to statin therapy 
improves high-density lipoprotein cholesterol levels but not metrics of functionality. 
Presented at 62nd Annual Scientific Session of the American College of Cardiology 
and i2 Summit: Innovation in Intervention, ACC; 9-11 Mar 2013; San Francisco: 
United States. J Am Coll Cardiol 2013;61(10 suppl 1):E1390. 
Not relevant population 
Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, et al. Year two 
assessment of fenofibric acid and moderate-dose statin combination: a phase 3, 
open-label, extension study. Clin Drug Investig 2010;30(1):51-61. 
Not relevant trial design; 
not relevant comparator 
Knopp RH, Brown WV, Dujovne CA, Farquhar JW, Feldman EB, Goldberg AC, et al. 
Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined 
hyperlipidemia. Am J Med 1987;83(5B):50-9. 
Not relevant population 
Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, et al. Effects of ezetimibe, 
a new cholesterol absorption inhibitor, on plasma lipids in patients with primary 
hypercholesterolemia. Eur Heart J 2003;24(8):729-741. 
Not relevant population 
(mixed) 
Koren M, Giugliano RP, Raal F, Sullivan D, Bolognese M, Langslet G, et al. Safety, 
tolerability, and efficacy of long-term administration of AMG 145: preliminary results 
from the OSLER study. Presented at European Society of Cardiology, ESC Congress; 
31 Aug - 4 Sept 2013; Amsterdam: Netherlands. Eur Heart J 2013;34:767. 
Not relevant population; 
mixed refractory and naive 
population with no 
separate results or 
indication of numbers in 
each category at baseline 
Koren M, Rosenson R, Khan B, Honarpour N, Elliot M, Somaratne R, et al. LDL 
cholesterol reduction in elderly patients with the PCSK9 monoclonal antibody 
evolocumab (AMG 145): a pooled analysis of 1779 patients in phase 2, 3 and open 
label extension studies (1107-101). Abstract presented at American College of 
Cardiology (ACC); 14-16 March 2015; San Diego, US. [Internet].  2015 [accessed 
30.4.15]; Available from: 
http://www.abstractsonline.com/pp8/#!/3658/presentation/33653. 
Not relevant study design 
(Pooled data) 
Koren M, Stein E, Roth E, McKenney JM, Gipe D, Hanotin C, et al. Efficacy, safety 
and tolerability of 150 mg Q2W dose of the anti-PCSK9 mAb, REGN727/SAR236553: 
data from 3 phase 2 studies. Presented at ESC Congress; 25-29 Aug 2012; Munich: 
Germany. Eur Heart J 2012;33:37. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Koren M, Stein E, Roth E, McKenney JM, Gipe D, Hanotin C, et al. Efficacy, safety 
and tolerability of 150 mg Q2W dose of the anti-PCSK9 mAb, REGN727/SAR236553: 
data from 3 phase 2 studies. Eur Heart J. 2012;33:37. 
Not relevant study design 
(pooled analysis) 
Koren MJ, Giugliano RP, Raal F, Sullivan D, Bolognese M, Langslet G, et al. Safety, 
tolerability, and efficacy of long-term administration of AMG 145: preliminary results 
from the osler study. Presented at 66th Annual Meeting of the Canadian 
Cardiovascular Society; 17-20 Oct 2013; Montreal, QC: Canada. Can J Cardiol 
2013;29(10 suppl 1):S332. 
Not relevant population; 
mixed refractory and naive 
population with no 
separate results or 
indication of numbers in 
each category at baseline 
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Publication citation Reason(s) for exclusion 
Koren MJ, Giugliano RP, Raal F, Sullivan D, Bolognese M, Langslet G, et al. 
Randomized comparison of the safety, tolerability, and efficacy of long-term 
administration of AMG 145 versus standard of care in 1104 patients: 52-week results 
from the OSLER study. Presented at American Heart Association's Scientific 
Sessions; 16-20 Nov 2013; Dallas, TX: United States. Circulation 2013;128(24):2717-
2718. 
Not relevant population; 
mixed refractory and naive 
population with no 
separate results or 
indication of numbers in 
each category at baseline 
Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, et al. Efficacy 
and safety of longer-term administration of evolocumab (AMG 145) in patients with 
hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term 
Evaluation Against LDL-C (OSLER) randomized trial. Circulation 2014;129(2):234-43. 
Not relevant population; 
mixed refractory and naive 
population with no 
separate results or 
indication of numbers in 
each category at baseline 
Koren MJ, Giugliano RP, Raal FJ, Sullivan D, Bolognese M, Langslet G, et al. Efficacy 
and safety of longer-term administration of evolocumab (AMG 145) in patients with 
hypercholesterolemia: 52-week results from the open-label study of long-term 
evaluation against LDL-C (OSLER) randomized trial. Circulation. 2014 January 14, 
2014;129(2):234-43. 
Not relevant population 
(mixed populations from 
other Amgen trials) 
Koren MJ, Guigliano R, Raal F, Sullivan D, Bolognese M, Langslet G, et al. Two year 
analysis of the safety and tolerability of evolocumab: the OSLER-1 Study (914-10). 
Abstract presented at American College of Cardiology (ACC); 14-16 March 2015; San 
Diego, US. [Internet].  2015 [accessed 30.4.15]; Available from: 
http://www.abstractsonline.com/pp8/#!/3658/presentation/36653. 
Not relevant population 
(mixed populations from 
other Amgen trials) 
Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, et al. Anti-
PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, 
controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531-
40. 
Not relevant population 
(not receiving statins) 
Koren MJ, Scott R, Kim JB, Knusel B, Liu T, Lei L, et al. Efficacy and safety of a fully 
human monoclonal antibody against PCSK9 as monotherapy for 
hypercholesterolemia: results from the MENDEL study, a global phase 2 trial of AMG 
145. Circulation. 2012;126(23):2791. 
Not relevant population 
(not receiving statins) 
Koren MJ, Stein E, Roth E, McKenney J, Gipe D, Hanotin C, et al. Efficacy, safety and 
tolerability of alirocumab 150 mg q2w, a fully human pcsk9 monoclonal antibody: a 
pooled analysis of 352 patients from phase 2. Presented at Annual Scientific Sessions 
of the National Lipid Association, NLA; 30 May - 2 Jun 2013; Las Vegas, NV: United 
States. J Clin Lipidol 2013;7(3):279-280. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Koren MJ, Doshi S, Castro R, Gibbs JP, Emery MG, Somaratne R, et al. Comparisons 
of Peak LDL-C Reduction and Duration of Effect With Lower or Higher Dosing 
Regimens of the PCSK9 Inhibitor Evolocumab. Circulation. 2015 November 10, 
2015;132(Suppl 3):A12729. 
No relevant outcomes 
Koshelskaya O, Sushkova A, Suslova T, Karpov R. Lipid and pleotropic effects of 
atorvastatin therapy and its combination with ezetimibe in patients with coronary 
artery disease and diabetes. Atherosclerosis 2014;235(2):e257. 
Not relevant population 
(statin history unclear) 
Kowa Research Europe Ltd. Double-blind follow-on study of pitavastatin (4 mg) 
versus simvastatin (40 mg and 80 mg), with a single-blind extension of treatment, in 
patients with primary hypercholesterolemia or combined dyslipidemia and 2 or more 
risk factors for coronary heart disease. EUCTR2005-005981-35-GB.  In: WHO 
International Clinical Trials Registry Platform (ICTRP) [Internet]. Geneva: World 
Health Organization (WHO). 2006 [accessed 2.6.14]. Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-
005981-35 
Not relevant trial design 
(extension of excluded 
study) 
Kowa Research Europe Ltd. Open-label, long-term (=1 year) extension study of 
pitavastatin 2 mg and 4 mg qd in elderly patients with primary hypercholesterolemia or 
combined dyslipidemia. EUCTR2005-005980-27-GB.  In: WHO International Clinical 
Trials Registry Platform (ICTRP) [Internet]. Geneva: World Health Organization 
(WHO). 2006 [accessed 2.6.14]. Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2005-
005980-27 
Not relevant population; 
not relevant trial design 
(follow-up to excluded trial) 
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Publication citation Reason(s) for exclusion 
Krempf M, Bergeron J, Elassal J, Minini P, Miller K, Kastelein JJP. Efficacy of 
alirocumab according to background statin intensity and other lipid-lowering therapy in 
heterozygous familial hypercholesterolemia or high cv risk populations: phase 3 sub-
group analyses. Atherosclerosis 2015;241(1):e21. 
Not relevant study design 
(subgroup analysis using 
data from six pooled 
alirocumab trials) 
Kumamoto University. Comparison of pitavastatin with atorvastatin in increasing high 
density lipoprotein - cholesterol (HDL-C) and adiponectin in patients with dyslipidemia 
and coronary artery disease (CAD). NCT00861861. In: WHO International Clinical 
Trials Registry Platform (ICTRP) [Internet]. Geneva: World Health Organization 
(WHO).  2009 [accessed 16.4.15] [updated September 2008]; Available from: 
http://clinicaltrials.gov/show/NCT00861861. 
Not relevant population 
(statin status unclear) 
Kurogi K, Sugiyama S, Sakamoto K, Tayama S, Nakamura S, Biwa T, Matsui K, 
Ogawa H, Investigators C-C. Comparison of pitavastatin with atorvastatin in 
increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary 
artery disease: the COMPACT-CAD study. J Cardiol 2013;62(2):87-94. 
Not relevant population 
(mixed population 62% 
had not previously 
received statin) 
Laboratoires Merck Sharp & Dohme. A multicenter, randomized, double-blind, 
placebo-controlled, 12-week study to evaluate the efficacy and safety of extended 
release (ER) niacin/laropiprant when added to ongoing lipid-modifying therapy in 
dyslipidemic patients. EUCTR2008-000465-37-FR.  In: WHO International Clinical 
Trials Registry Platform (ICTRP) [Internet]. Geneva: World Health Organization 
(WHO). 2008 [accessed 2.6.14]. Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-
000465-37 
Not relevant population; 
not relevant trial design 
(withdrawn prior to 
recruitment) 
Lecerf JM, Luc G, Baigts F, Devulder B. [Comparison of the efficacy between 
simvastatin and gemfibrozil in primary hypercholesterolemia]. Rev Med Interne 
1993;14(4):269-74. 
Not relevant population 
(mixed) 
Lee J-H, Kang H-J, Kim H-S, Sohn D-W, Oh B-H, Park Y-B. Effects of 
ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein 
B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a 
randomized controlled trial. Am J Cardiovasc Drugs 2013;13(5):343-51. 
Not relevant population 
Leiter LA, Bays H, Conard S, Lin J, Hanson ME, Shah A, et al. Attainment of 
Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. 
doubling the dose of atorvastatin. Int J Clin Pract 2010;64(13):1765-72. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Leiter LA, Betteridge DJ, Farnier M, Guyton JR, Lin J, Shah A, et al. Lipid-altering 
efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin 
monotherapy in patients with and without diabetes: an analysis of pooled data from 27 
clinical trials. Diabetes, Obesity & Metabolism 2011;13(7):615-28. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Li C, Zhang W, Zhou F, Chen C, Zhou L, Li Y, et al. Cholesteryl ester transfer protein 
inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis. 
PLoS One 2013;8(10). 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Li C, Lin L, Zhang W, Zhou L, Wang H, Luo X, et al. Efficiency and safety of 
proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: 
a meta-analysis of 20 randomized controlled trials. J Am Heart Assoc. 2015 
Jun;4(6):e001937. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Li N, Li Q, Tian X-Q, Qian H-Y, Yang Y-J. Mipomersen is a promising therapy in the 
management of hypercholesterolemia: a meta-analysis of randomized controlled 
trials. Am J Cardiovasc Drugs 2014;14(5):367-76. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Liang L, Qiqn JL, Xue HY, Lin P, Yang L. [Treatment with atorvastatin for unstable 
angina: a systematic review]. Chinese Pharmacological Bulletin 2012;28(11):1500-
1507. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC, 
et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease 
inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: 
a network meta-analysis. Eur Heart J 2016 Feb 7;37(6):536-45. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
 by guest on O
ctober 20, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Toth et al | Network Meta-Analysis Lipid-Lowering Therapies | Supplemental Appendix 
S52 
Publication citation Reason(s) for exclusion 
Lipinski MJ, Escarcega RO, Lhermusier T, Baker NC, Torguson R, Brewer HB, et al. 
The Impact of PCSK9 Inhibitors on Lipid Levels and Outcomes in Patients With 
Primary Hypercholesterolemia: A Network Meta-analysis. Circulation. 2015 November 
10, 2015;132(Suppl 3):A19342. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Loomba RS, Arora R. Prevention of cardiovascular disease utilizing fibrates: a pooled 
meta-analysis. Am J Ther 2010;17(6):e182-8. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Lundman P, Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Does gender 
impact on statin dose response? results from the VOYAGER individual patient data 
meta-analysis. Presented at 78th EAS Congress; 20-23 Jun 2010; Hamburg: 
Germany. Atheroscler Suppl 2010;11(2):75. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Mamata Medical College. A comparison of two drugs used in patients with high 
cholesterol levels. CTRI/2014/11/005169. In: WHO International Clinical Trials 
Registry Platform (ICTRP) [Internet]. Geneva: World Health Organization (WHO).  
2014 [accessed 16.4.15] [updated 15-01-2013]; Available from: 
http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=5897. 
Not relevant population 
(statin status unclear) 
Martineau P, Gaw A, de Teresa E, Farsang C, Gensini GF, Leiter LA, et al. Effect of 
individualizing starting doses of a statin according to baseline LDL-cholesterol levels 
on achieving cholesterol targets: the achieve cholesterol targets fast with atorvastatin 
stratified titration (ACTFAST) study. Atherosclerosis 2007;191(1):135-46. 
Not relevant trial design 
Martinez-Abundis E, Barrera-Duran C, Gonzalez-Ortiz M, Hernandez-Salazar E. 
Effect of simvastatin plus inulin vs. Simvastatin plus ezetimibe in mixed dyslipidemia. 
Presented at 70th Scientific Sessions of the American Diabetes Association; 25-29 
Jun 2010; Florida: United States. Diabetes 2010. 
Not relevant population 
(mixed statin history and 
no separate results; 
dyslipidemic population) 
Matalka MS, Ravnan MC, Deedwania PC. Is alternate daily dose of atorvastatin 
effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily 
Dosing of Atorvastatin Study (ADDAS). Am Heart J 2002;144(4):674-7. 
Not relevant population; 
compares daily vs. every 
other day treatment 
schedules 
McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P. Incremental 
cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK 
General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint 
British Societies (JBS-2) cholesterol targets. Int J Clin Pract 2010;64(8):1052-1061. 
Not relevant trial design 
(6wk treatment period) 
McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and 
adolescents with familial hypercholesterolemia or severe hyperlipidemia: a 
multicenter, randomized, placebo-controlled trial. J Pediatr 2003;143(1):74-80. 
Not relevant population 
McDonagh M, Peterson K, Holzhammer B, Fazio S. A Systematic Review of PCSK9 
Inhibitors Alirocumab and Evolocumab. J Manag Care Spec Pharm 2016 
Jun;22(6):641-53q. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
McGowan M, Parhofer K. Evaluation of mipomersen, an ApoB synthesis inhibitor, for 
potential to control LDL-C in patients with severe heterozygous familial 
hypercholesterolemia who may be eligible for apheresis. Presented at ESC Congress; 
25-29 Aug 2012; Munich: Germany. Eur Heart J 2012;33:1076. 
Not relevant population - 
mipomersen trial not in 
HoFH 
McGowan MP, Tardif J-C, Ceska R, Burgess LJ, Soran H, Gouni-Berthold I, et al. 
Randomized, placebo-controlled trial of mipomersen in patients with severe 
hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 
2012;7(11):e49006. 
Not relevant population - 
mipomersen trial not in 
HoFH 
Mearns BM. Dyslipidaemia: 1-Year results from OSLER trial of anti-PCSK9 
monoclonal antibody evolocumab. Nat Rev Cardiol 2014;11(2):63. 
Not relevant population; 
mixed refractory and naive 
population with no 
separate results or 
indication of numbers in 
each category at baseline 
Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A, et al. Efficacy and safety 
of ezetimibe coadministered with pravastatin in patients with primary 
hypercholesterolemia: A prospective, randomized, double-blind trial. Eur Heart J 
2003;24(8):717-728. 
Not relevant population 
(mixed) 
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Merck & Co Inc. A multicenter, randomized, double-blind, parallel arm, 12-week trial to 
evaluate the efficacy and safety of ezetimibe/simvastatin combination tablet versus 
atorvastatin in elderly patients with hypercholesterolemia at moderately high risk and 
high risk for CHD. EUCTR2007-004448-60-LT.  In: WHO International Clinical Trials 
Registry Platform (ICTRP) [Internet]. Geneva: World Health Organization (WHO). 
2007 [accessed 2.6.14]. Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2007-004448-60 
Not relevant population 
(therapy naïve) 
Merck Sharp & Dohme Corp, P. T. Schering-Plough Tbk Indonesia. Adding ezetimibe 
tablet to ongoing treatment with atorvastatin in subjects with high cholesterol and 
multiple coronary heart disease risk factors (Study P04060)(completed). In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
NCT00319449. . 2013 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00319449 
Not relevant trial design 
(6wk treatment period) 
Merck Sharp & Dohme Corp. A 12 week study of MK0653A in patients who have been 
hospitalized for a possible heart problem (0653A-808)(completed). NCT00132717. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 
[accessed 29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00132717 
Not relevant comparator 
(mixed statin treatment 
history with no separate 
data) 
Merck Sharp & Dohme Corp. A worldwide, multicenter, double-blind, randomized, 
placebo-controlled, 12-week study to assess the efficacy and tolerability of 
anacetrapib when added to ongoing lipid-lowering therapy in adult patients with 
homozygous familial hypercholesterolemia (HoFH). EUCTR2012-002434-37-GB.  In: 
EU Clinical Trials Register (EUCTR) [Internet]. London: European Medicines Agency 
(EMA).  2012 [accessed 11.7.14] [updated 23/05/2013]; Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-
002434-37. 
Not relevant outcome 
(early termination) 
Merck Sharp Dohme Corp, Merck Shering-Plough, J. V. Study. A study to assess the 
cholesterol lowering effect of ezetimibe/simvastatin combination tablet compared to 
another cholesterol lowering drug in elderly patients with high cholesterol at high or 
moderately high risk for coronary heart disease (0653A-128). NCT00535405. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US).  2015 
[accessed 19.3.15]; Available from: http://ClinicalTrials.gov/show/NCT00535405. 
Not relevant population 
(statin status unclear) 
Merck Sharp Dohme Corp, Schering Plough. Ezetimibe and simvastatin in primary 
hypercholesterolemia, diabetes mellitus Type 2, and coronary heart disease 
(completed). NCT00423488. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National 
Library of Medicine (US). 2013 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00423488 
Not relevant trial design 
(6wk treatment period) 
Merck Sharp Dohme Corp. A study comparing ezetimibe plus simvastatin versus 
simvastatin alone in patients at risk for heart disease (0653-023). NCT00551447. In: 
WHO International Clinical Trials Registry Platform (ICTRP) [Internet]. Geneva: World 
Health Organization (WHO).  2007 [accessed 16.4.15] [updated January 2002]; 
Available from: http://clinicaltrials.gov/show/NCT00551447. 
Not relevant population 
(statin status unclear) 
Merck Sharp Dohme Corp. A study of ezetimibe added on to rosuvastatin versus up 
titration of rosuvastatin in patients with hypercholesterolemia (MK0653-139). 
NCT00783263. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2014 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00783263 
Not relevant trial design 
(6wk treatment period) 
Merck Sharp Dohme Corp. A study of MK0653A (ezetimibe (+) simvastatin) in 
patients with hypercholesterolemia (0653A-038). NCT00092651. In: WHO 
International Clinical Trials Registry Platform (ICTRP) [Internet]. Geneva: World 
Health Organization (WHO).  2004 [accessed 16.4.15] [updated September 2002]; 
Available from: http://clinicaltrials.gov/show/NCT00092651. 
Not relevant population 
(statin status unclear) 
Merck Sharp Dohme Corp. A study of MK0653A (ezetimibe (+) simvastatin) in 
patients with hypercholesterolemia (0653A-038). NCT00092651. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US).  2014 [accessed 
19.3.15]; Available from: http://ClinicalTrials.gov/show/NCT00092651. 
Not relevant population 
(statin status unclear); Not 
relevant outcomes 
Merck Sharp Dohme Corp. A study of MK0859 in patients with primary 
hypercholesterolemia or mixed hyperlipidemia. NCT00565292. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2007 [accessed 
29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00565292 
Not relevant population 
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Merck Sharp Dohme Corp. A study to assess the cholesterol lowering effect of an 
ezetimibe/simvastatin combination tablet compared to another cholesterol lowering 
drug in patients with high cholesterol and with high cardiovascular risk (0653A-
809)(completed). NCT00479713. In: ClinicalTrials.gov [Internet]. Bethesda (MD): 
National Library of Medicine (US). 2013 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00479713 
Not relevant trial design 
(6wk treatment period) 
Merck Sharp Dohme Corp. A study to evaluate an investigational drug in patients with 
mixed hyperlipidemia (0653A-071). NCT00093899.  In: WHO International Clinical 
Trials Registry Platform (ICTRP) [Internet]. Geneva: World Health Organization 
(WHO).  2004 [accessed 19.3.15] [updated November 2004]; Available from: 
http://clinicaltrials.gov/show/NCT00093899. 
Not relevant population 
(statin status unclear) 
Merck Sharp Dohme Corp. A study to evaluate an investigational drug in patients with 
mixed hyperlipidemia (0653A-071). NCT00093899. In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US).  2015 [accessed 19.3.15]; 
Available from: http://ClinicalTrials.gov/show/NCT00093899. 
Not relevant population 
(statin status unclear); Not 
relevant outcomes 
Merck Sharp Dohme Corp. A study to evaluate ezetimibe in Korean patients with 
primary hypercholesterolemia (0653-042). NCT00157911. In: WHO International 
Clinical Trials Registry Platform (ICTRP) [Internet]. Geneva: World Health 
Organization (WHO).  2005 [accessed 19.3.15] [updated December 2002]; Available 
from: http://clinicaltrials.gov/show/NCT00157911. 
Not relevant population 
(statin status unclear) 
Merck Sharp Dohme Corp. A study to evaluate ezetimibe in Korean patients with 
primary hypercholesterolemia (0653-042). NCT00157911. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US).  2014 [accessed 
19.3.15]; Available from: http://ClinicalTrials.gov/show/NCT00157911. 
Not relevant population 
(statin status unclear) 
Merck Sharp Dohme Corp. A worldwide, multicenter, double-blind, randomized, 
parallel, placebo-controlled study to evaluate the long-term efficacy, safety and 
tolerability of extended-release (ER) niacin and laropiprant (ERN/LRPT) in patients 
with dyslipidemia. EUCTR2009-012772-27. In: EU Clinical Trials Register (EUCTR) 
[Internet]. London: European Medicines Agency (EMA). 2009 [accessed 2.6.14]. 
Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2009-012772-27 
Not relevant outcome 
(flushing AEs with statins) 
Merck Sharp Dohme Corp. An extension study of an investigational drug in patients 
with hypercholesterolemia (0653A-038). NCT00092664. In: WHO International Clinical 
Trials Registry Platform (ICTRP) [Internet]. Geneva: World Health Organization 
(WHO).  2004 [accessed 16.4.15] [updated January 2003]; Available from: 
http://clinicaltrials.gov/show/NCT00092664. 
Not relevant population 
(statin status unclear) 
Merck Sharp Dohme Corp. An extension study of an investigational drug in patients 
with hypercholesterolemia (0653A-038). NCT00092664. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US).  2015 [accessed 
19.3.15]; Available from: http://ClinicalTrials.gov/show/NCT00092664. 
Not relevant population 
(statin status unclear) 
Merck Sharp Dohme Corp. An investigational drug study in patients with elevated 
cholesterol and coronary heart disease (0653-804)(completed). NCT00092638. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 
[accessed 29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00092638 
Not relevant trial design 
(6wk treatment period) 
Merck Sharp Dohme Corp. Co-administration study in patients with elevated 
cholesterol and coronary heart disease (0653-802)(completed). NCT00092612. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 
[accessed 29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00092612 
Not relevant trial design 
(6wk treatment period) 
Merck Sharp Dohme Corp. Effectiveness of two approved drugs in lowering high 
cholesterol (0733-224). NCT00092157. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US).  2014 [accessed 19.3.15]; Available from: 
http://ClinicalTrials.gov/show/NCT00092157. 
Not relevant population 
(statin status unclear) 
Merck Sharp Dohme Corp. Efficacy and safety of extended release (ER) 
niacin/laropiprant when added to ongoing lipid-modifying therapy in patients with high 
cholesterol or abnormal lipid levels (MK-0524A-133). NCT01274559. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US).  2015 
[accessed 19.3.15]; Available from: http://ClinicalTrials.gov/show/NCT01274559. 
Not relevant outcome 
(early termination) 
 by guest on O
ctober 20, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Toth et al | Network Meta-Analysis Lipid-Lowering Therapies | Supplemental Appendix 
S55 
Publication citation Reason(s) for exclusion 
Merck Sharp Dohme Corp. Efficacy and tolerability of anacetrapib added to ongoing 
lipid-lowering therapy in adult participants with homozygous familial 
hypercholesterolemia (HoFH) (MK-0859-042). NCT01841684. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US).  2014 [accessed 
11.7.14]; Available from: http://ClinicalTrials.gov/show/NCT01841684. 
Not relevant outcome 
(early termination) 
Merck Sharp Dohme Corp. Ezetimibe (+) simvastatin vs. atorvastatin comparative 
study in DM or metabolic syndrome patients. NCT00157924. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2008 [accessed 
29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00157924 
Not relevant trial design 
(6wk treatment period) 
Merck Sharp Dohme Corp. Ezetimibe/simvastatin (MK-0653A) versus rosuvastatin 
versus doubling statin dose in participants with cardiovascular disease and diabetes 
mellitus (MK-0653A-133)(completed). NCT00862251. In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2012 [accessed 29.5.14]. Available 
from: http://ClinicalTrials.gov/show/NCT00862251 
Not relevant trial design 
(6wk treatment period) 
Merck Sharp Dohme Corp. IMPROVE-IT: examining outcomes in subjects with acute 
coronary syndrome: vytorin (ezetimibe/simvastatin) vs simvastatin (P04103 AM5). 
NCT00202878. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US).  2014 [accessed 11.7.14]; Available from: 
http://ClinicalTrials.gov/show/NCT00202878. 
Not relevant population 
(mixed statin history, 
numbers and separate 
data NR) 
Merck Sharp Dohme Corp. Investigational drug study in patients with elevated 
cholesterol and coronary heart disease (0653-801)(completed). NCT00092599. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 
[accessed 29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00092599 
Not relevant trial design 
(6wk treatment period) 
Merck Sharp Dohme Corp. Lipid efficacy and safety in patients with mixed 
hyperlipidemia (MK-0524B-024). NCT00289900. In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US).  2014 [accessed 19.3.15]; 
Available from: http://ClinicalTrials.gov/show/NCT00289900. 
Not relevant population 
(statin status unclear) 
Merck Sharp Dohme Corp. MK0524B lipid study (0524B-063). NCT00479882. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 
[accessed 29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00479882 
Not relevant population 
(mixed) 
Merck Sharp Dohme Corp. MK0859 dose-ranging study (0859-003). NCT00325455. 
In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US).  
2015 [accessed 19.3.15]; Available from: http://ClinicalTrials.gov/show/NCT00325455. 
Not relevant population 
(statin status unclear) 
Merck Sharp Dohme Corp. Randomized parallel group trial of the efficacy and safety 
of ezetimibe with a statin versus statin dose doubling in patients with persistent 
primary hypercholesterolemia. NCT00652847. In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2008 [accessed 29.5.14]. Available 
from: http://ClinicalTrials.gov/show/NCT00652847 
Not relevant trial design 
(6wk treatment period) 
Merck Sharp Dohme Corp. Study of an approved drug with a statin (a medication that 
lowers cholesterol levels) as compared to statin therapy alone in patients with high 
cholesterol (0653-040)(completed). NCT00092586. In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2013 [accessed 29.5.14]. Available 
from: http://ClinicalTrials.gov/show/NCT00092586 
Not relevant trial design 
(6wk treatment period) 
Merck Sharp Dohme Corp. Study of ezetimibe and fenofibrate in patients with mixed 
hyperlipidemia (0653-036). NCT00092573. In: WHO International Clinical Trials 
Registry Platform (ICTRP) [Internet]. Geneva: World Health Organization (WHO).  
2004 [accessed 16.4.15] [updated April 2003]; Available from: 
http://clinicaltrials.gov/show/NCT00092573. 
Not relevant study design 
(Not RCT); Not relevant 
population (statin status 
unclear); Not relevant 
outcomes 
Merck Sharp Dohme Corp. Study of ezetimibe and fenofibrate in patients with mixed 
hyperlipidemia (0653-036). NCT00092573. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US).  2015 [accessed 19.3.15]; Available from: 
http://ClinicalTrials.gov/show/NCT00092573. 
Not relevant population 
(statin status unclear); Not 
relevant outcomes 
Merck Sharp Dohme Corp. To evaluate ezetimibe plus atorvastatin versus 
atorvastatin in patients with high cholesterol not controlled on atorvastatin 20 mg 
(0653-079)(completed). NCT00276458. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US). 2013 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00276458 
Not relevant trial design 
(6wk treatment period) 
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Merck Sharp Dohme Corp. To Evaluate Ezetimibe Plus Atorvastatin Versus 
Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg 
(0653-090)(completed). NCT00276484. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US). 2013 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00276484 
Not relevant trial design 
(6wk treatment period) 
Merck Sharp Dohme Corp. To evaluate ezetimibe/simvastatin and niacin (extended 
release tablet) in patients with Type IIa or Type IIb hyperlipidemia (0653A-
091)(COMPLETED). NCT00271817.  In: ClinicalTrials.gov [Internet]. Bethesda (MD): 
National Library of Medicine (US). 2014 [27.10.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00271817 
Not relevant population 
(statin history unclear) 
Merck Sharp Dohme Corp. TWICE (ezetimibe together with any statin cholesterol 
enhancement) (0653-060). NCT00328523. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US).  2015 [accessed 19.3.15]; Available from: 
http://ClinicalTrials.gov/show/NCT00328523. 
Not relevant 
intervention/comparator 
Merck Sharp Dohme Corp. Two investigational drugs in patients with mixed 
hyperlipidemia (0653-036). NCT00092560. In: WHO International Clinical Trials 
Registry Platform (ICTRP) [Internet]. Geneva: World Health Organization (WHO). 
2004 [accessed 16.4.15]. 
Not relevant study design 
(Not RCT); Not relevant 
population (statin status 
unclear) 
Merck Sharp Dohme Corp. Vytorin (10/20 Or 10/40) compared to atorvastatin (10 mg 
or 20 mg) in patients with coronary artery disease (0653A-126)(completed). 
NCT00442897. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2013 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00442897 
Not relevant trial design 
(6wk treatment period) 
Merck S, Dohme C. A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in 
Japanese Participants With Hypercholesterolemia (MK-0653C-383).  2016; Available 
from: https://ClinicalTrials.gov/show/NCT02550288. 
Not relevant population 
(statin status unclear and 
stabilized on diet) 
Mikhailidis DP, Lawson RW, McCormick AL, Sibbring GC, Tershakovec AM, Davies 
GM, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration 
in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr 
Med Res Opin 2011;27(6):1191-1210. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Mikhailidis DP, Wierzbicki AS. The Greek atorvastatin and coronary-heart-disease 
evaluation (GREACE) study. Curr Med Res Opin 2002;18(4):215-219. 
Not relevant population; 
not relevant trial design 
Miller PE, Martin SS, Joshi PH, Jones SR, Massaro JM, D'Agostino 
RB, et al. Pitavastatin 4 mg Provides Significantly Greater Reduction 
in Remnant Lipoprotein Cholesterol Compared With Pravastatin 40 
mg: Results from the Short-term Phase IV PREVAIL US Trial in 
Patients With Primary Hyperlipidemia or Mixed Dyslipidemia. Clin 
Ther. [Journal Article 
Research Support, Non-U.S. Gov't]. 2016 Mar;38(3):603-9. 
Not relevant population 
(statin status unclear) 
Milionis H, Barkas F, Ntaios G, Papavasileiou V, Vemmos K, Michel P, et al. 
Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat 
hypercholesterolemia: Effect on stroke risk. Eur J Intern Med 2016 Jun 28;28:28. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Mita T, Nakayama S, Abe H, Gosho M, Iida H, Hirose T, et al. Comparison of effects 
of pitavastatin and atorvastatin on glucose metabolism in type 2 diabetic patients with 
hypercholesterolemia. Journal of Diabetes Investigation 2013;4(3):297-303. 
Not relevant trial design 
(quasi randomized) 
Moon KT. No added benefit of fenofibrate for cardiovascular risk in diabetes mellitus. 
Am Fam Physician 2011;83(5):612. 
Not relevant trial design 
(secondary publication for 
ACCORD trial) 
Morales DCV, Parker B, Lorson L, White CM, Polk D, Thompson P. Greater 
reductions in total and low density lipoprotein cholesterol are associated with 
concomitant development of statin myopathy. Presented at 60th Annual Scientific 
Session of the American College of Cardiology and i2 Summit: Innovation in 
Intervention, ACC; 2-5 Apr 2011; New Orleans, LA: United States. J Am Coll Cardiol 
2011;57(14 suppl 1):E574. 
Not relevant population; 
not relevant comparator - 
assessing incidence of 
statin myopathy in statin 
intolerant (previous statin-
associated muscle 
complaints) randomized to 
20mg simvastatin vs. 
placebo 
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Moriarty P, Lecorps G, Hanotin C, Pordy R, Roth EM. Homogeneity of treatment effect 
of REGN727/SAR236553, a fully human monoclonal antibody against PCSK9, in 
lowering LDL-C: data from three phase 2 studies. European Society of Cardiology, 
ESC Congress; 31 Aug - 4 Sept 2013; Amsterdam: Netherlands. Eur Heart J 
2013;34:18. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Morrone D, Weintraub W, Toth P, Hanson M, Lowe R, Lin J, et al. Efficacy of 
ezetimibe/statins and statin monotherapy and factors associated with treatment 
response: pooled analysis of >21,000 subjects from 27 trials. Presented at Annual 
Scientific Sessions of the National Lipid Association, NLA; 19-22 May 2011; New 
York, NY: United States. J Clin Lipidol 2011;5(3):236-237. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Naci H, Brugts JJ, Fleurence R, Ades AE. Dose-comparative effects of different 
statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 
randomized controlled trials. Eur J Prev Cardiolog 2013;20(4):658-670. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
National Heart Institute Mexico. Effect of fenofibrate on endothelial function and high-
density lipoproteins (HDL) in patients with coronary heart disease. NCT00552747. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011 
[accessed 29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00552747 
Not relevant outcomes; not 
relevant trial design (8wks 
treatment period) 
National Institute for Health and Clinical Excellence. Ezetimibe for the treatment of 
primary (heterozygous-familial and non-familial) hypercholesterolemia [Internet]. 
London, 2007 [accessed 30.5.14] Available from: 
http://www.nice.org.uk/nicemedia/live/11886/38799/38799.pdf 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
NCT02293538. FID# 114657 in Contact Lens Wearers. 2014. Not relevant population 
(statin status unclear);  Not 
relevant outcomes;  Not 
relevant intervention; Not 
relevant comparators 
NCT02458287. Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab 
And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia. 
2015. 
Not relevant study design 
(10wk treatment period) 
Newman TJ, Kassler-Taub KB, Gelarden RT, Korzin EG, DeVault AR, McGovern ME, 
et al. Safety of pravastatin in long-term clinical trials conducted in the United States. 
Journal of Drug Development, Supplement 1990;3(1):275-281. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Nicholls SJ, Lundman P, Brandrup-Wognsen G, Palmer M, Barter PJ. Effects of age 
and statin dose on lipid levels: results from the VOYAGER individual patient data 
meta-analysis. Presented at 78th EAS Congress; 20-23 Jun 2010; Hamburg: 
Germany. Atheroscler Suppl 2010;11(2):119-120. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Nicholls SJ, Ruotolo G, Brewer HB, Wang MD, Liu L, Willey MB, et al. Evacetrapib 
alone or in combination with statins lowers lipoprotein(a) and total and small LDL 
particle concentrations in mildly hypercholesterolemic patients. J Clin Lipidol. 2016 
May-Jun;10(3):519-27.e4. 
Not relevant population 
(statin status unclear and 
patients selected on low 
HDL as well as high LDL-
C) 
NIHR Horizon Scanning Centre. SAR236553/REGN727 for the reduction of elevated 
total cholesterol and low density lipoprotein cholesterol [Internet], 2012 [accessed 
6.6.14] Available from: http://www.hsc.nihr.ac.uk/topics/sar236553-regn727-for-the-
reduction-of-elevated-to/ 
Not relevant trial design 
Nissen SE, Nicholls SJ, Wolski K, Howey DC, McErlean E, Wang MD, et al. Effects of 
a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia 
or hypercholesterolemia: two randomized controlled trials. JAMA 2007;297(12):1362-
1373. 
Not relevant trial design 
Novartis Pharma Services A. G. A phase 2 12-week multi-center, randomized, double-
blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety 
and efficacy of LCQ908 for weight reduction and reduced LDL cholesterol in patients 
with obesity and mixed dyslipidemia. EUCTR2009-010198-19. In: EU Clinical Trials 
Register (EUCTR) [Internet]. London: European Medicines Agency (EMA). 2009 
[accessed 2.6.14]. Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2009-010198-19 
Not relevant population 
(mixed); not relevant 
comparator (weight 
reduction) 
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Publication citation Reason(s) for exclusion 
O'Brien RC, Simons LA, Clifton P, Cooper ME, Jennings GL, Jerums G, et al. 
Comparison of simvastatin and cholestyramine in the treatment of primary 
hypercholesterolaemia.[Erratum appears in Med J Aust 1991 Feb 18;154(4):296]. 
Med J Aust 1990;152(9):480-3. 
Not relevant population 
Ogawa H, Matsui K, Saito Y, Sugiyama S, Jinnouchi H, Sugawara M, et al. 
Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect 
on glucose metabolism in Japanese hypercholesterolemic patients with concurrent 
diabetes - lipid-lowering with highly potent statins in hyperlipidemia with type 2 
diabetes patients (LISTEN) study. Circ J. 2014;78(10):2512-5. 
Not relevant population 
(not receiving statins) 
Oida K, Taniguchi N, Kono M, Kutsumi Y. Direct comparison of hypolipidemic effects 
of pitavastatin and atorvastatin. Ther Res 2007;28(4):733-9. 
Not relevant trial design 
(no mention of 
randomization) 
Oikawa S, Yamashita S, Nakaya N, Sasaki J, Kono S, Effect of F, et al. Efficacy and 
Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with 
Combined Hyperlipidemia: Results of the EFECTL Study. Journal of Atherosclerosis & 
Thrombosis 2016; Jul 8;8:8. 
Not relevant population 
(statin status unclear) 
Olsson AG, Eriksson M, Johnson O, Kjellström T, Lanke J, Larsen ML, et al. A 52-
week, multicenter, randomized, parallel-group, double-blind, double-dummy study to 
assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein 
cholesterol and triglyceride targets: the treat-to-target (3T) study. Clin Ther 
2003;25(1):119-38. 
Not relevant population 
(statin naive) 
Paez Moreno JP, Gonzalez G. Comparative study of bezafibrate and probucol in 
hyperlipidaemia. Curr Med Res Opin 1989;11(8):523-32. 
Not relevant population 
Panta R, Dahal K. Efficacy and safety of mipomersen in treatment of 
dyslipidemia: A meta-analysis of randomized controlled trials. Endocr 
Rev. 2014. 
 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM. Effect of 
combination therapy with lipid-reducing drugs in patients with coronary heart disease 
and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard 
Atherosclerosis Reversibility Project (HARP) Study Group. Ann Intern Med 
1996;125(7):529-40. 
Not relevant population 
Patel N, Hegele RA. Mipomersen as a potential adjunctive therapy for 
hypercholesterolemia. Expert Opin Pharmacother 2010;11(15):2569-72. 
Not relevant trial design 
(not an original report of 
trial) 
Patel P, Barkate H. Comparison of efficacy and safety of choline fenofibrate (fenofibric 
acid) to micronized fenofibrate in patients of mixed dyslipidemia: A randomized, open-
label, multicenter clinical trial in Indian population. Indian J Endocrinol Metab 2016 
Jan-Feb;20(1):67-71. 
Not relevant population 
(statin status unclear and 
mixed dyslipidemia with 
patients selected on basis 
of TG 150 to 500 mg/dL) 
Pearson TA, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J. Effectiveness 
of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and 
attaining low-density lipoprotein cholesterol goals in older and elderly patients: 
subanalyses of data from a randomized, double-blind, placebo-controlled trial. Am J 
Geriatr Pharmacother 2005;3(4):218-228. 
Not relevant trial design 
(6wk treatment period) 
Pedersen TR, Faergeman O, Kastelein JJP, Olsson AG, Tikkanen MJ, Holme I, et al. 
Design and baseline characteristics of the Incremental Decrease in End Points 
through Aggressive Lipid Lowering study. Am J Cardiol 2004;94(6):720-724. 
Not relevant population 
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WMM, et al. 
European Guidelines on cardiovascular disease prevention in clinical practice (version 
2012): the Fifth Joint Task Force of the European Society of Cardiology and Other 
Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by 
representatives of nine societies and by invited experts). Eur J Prev Cardiolog 
2012;19(4):585-667. 
Not relevant trial design 
(guidelines/guidance) 
Philpott AC, Hubacek J, Sun YC, Hillard D, Anderson TJ. Niacin improves lipid profile 
but not endothelial function in patients with coronary artery disease on high dose 
statin therapy. Atherosclerosis 2013;226(2):453-458. 
Not relevant population 
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Publication citation Reason(s) for exclusion 
Pordy R, Lecorps G, Bessac L, Sasiela WJ, Ginsberg H. Alirocumab, a fully human 
monoclonal antibody to proprotein convertase subtilisin/kexin type 9: therapeutic 
dosing in phase 3 studies. Presented at Annual Scientific Sessions of the National 
Lipid Association, NLA; 30 May - 2 Jun 2013; Las Vegas, NV: United States. J Clin 
Lipidol 2013;7(3):279. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Positive Trial Group. Primary prevention of major adverse cardiac events (MACE) with 
standard and intensive statin treatment in patients with diabetes: survival and 
cardiovascular event assessments. NCT01173939. In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2011 [accessed 29.5.14]. Available 
from: http://ClinicalTrials.gov/show/NCT01173939 
Not relevant population; 
not relevant comparator 
Preiss D, Seshasai SRK, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of 
incident diabetes with intensive-dose compared with moderate-dose statin therapy: a 
meta-analysis. JAMA 2011;305(24):2556-2564. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, et al. Lipid-modifying 
therapies and risk of pancreatitis: a meta-analysis. JAMA 2012;308(8):804-811. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Qamar A, Usman H, Reilly M, Dunbar R, Rader D. Niacin reverses increased plasma 
PCSK9 induced by statin and fibrate therapy: a novel mechanism for further LDL 
reduction. Presented at American Heart Association Scientific Sessions and 
Resuscitation Science Symposium; 3-6 Nov 2012; Los Angeles. Circulation 
2012;126(21 suppl 1). 
Not relevant trial design 
Quaglini S, Stefanelli M, Boiocchi L, Campari F, Cavallini A, Micieli G. Cardiovascular 
risk calculators: understanding differences and realising economic implications. Int J 
Med Inf 2005;74(2-4):191-9. 
Not relevant population 
Raal FJ, Tuomilehto J, Lee LV, Louie M, Minini P, Ginsberg H. Efficacy and safety of 
alirocumab stratified by age in phase 3 trials. J Am Coll Cardiol. 2016;67(13, 
Supplement):2005. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Reckless JPD, Henry P, Pomykaj T, Lim ST, Massaad R, Vandormael K, et al. Lipid-
altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin 
dose in patients admitted to the hospital for a recent coronary event: the INFORCE 
study. Int J Clin Pract 2008;62(4):539-54. 
Not relevant comparator 
(mixed statin treatment 
status) 
Regeneron Pharmaceuticals. Study of REGN1500 in patients with homozygous 
familial hypercholesterolemia (HoFH). NCT02265952. In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US).  2015 [accessed 19.3.15]; 
Available from: http://ClinicalTrials.gov/show/NCT02265952. 
Not relevant population 
(statin status unclear); Not 
relevant study design (not 
RCT) 
Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. 
ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J 
2011;32(14):1769-1818. 
Not relevant trial design 
(guidelines/guidance) 
Rensing UFE, Roskamm H, Betz P, Benesch L, Blumchen G, Wieland H, et al. [Lipid 
intervention and coronary artery disease (CAD) in men below 56 years of age. The 
coronary intervention study: CIS]. Z Kardiol 1999;88(4):270-282. 
Not relevant population 
Robinson J, Abrams B, Hanson M, Lin J, Sha A, Tershakovec A. Achievement of 
specified lipid and high-sensitivity C-reactive protein levels with statin-ezetimibe 
versus statin in male and female patients using combined data from 22,913 patients. 
Presented at Annual Scientific Sessions of the National Lipid Association, NLA; 13-16 
May 2010; Chicago, IL: United States. J Clin Lipidol 2010;4(3):200-201. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Robinson JG, Ballantyne CM, Hsueh W, Rosen J, Lin J, Shah A, et al. Achievement of 
specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol 
apolipoprotein B, and high-sensitivity C-reactive protein levels with 
ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without 
atherosclerotic vascular disease (from the VYMET study). J Clin Lipidol 
2011;5(6):474-82. 
Not relevant population 
Rodney RA, Sugimoto D, Wagman B, Zieve F, Kerzner B, Strony J, et al. Efficacy and 
safety of coadministration of ezetimibe and simvastatin in African-American patients 
with primary hypercholesterolemia. J Natl Med Assoc 2006;98(5):772-8. 
Not relevant population 
(mixed) 
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Ros E, Olivan J, Mostaza JM, Vilardell M, Pinto X, Civeira F, et al. Atorvastin versus 
bezafibrate in mixed hyperlipidaemia: randomised clinical trial of efficacy and safety 
(the ATOMIX study). Clin Drug Investig 2003;23(3):153-65. 
Not relevant population 
Rosen JB, Jimenez JG, Pirags V, Vides H, Massaad R, Hanson ME, et al. 
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering 
treatment strategies in obese and non-obese diabetic subjects. Lipids Health Dis 
2013;12(1). 
Not relevant population 
(mixed) 
Rosenson RS, Jacobson TA, Priess D, Djedjos C, Dent R, Bridges I, et al. Efficacy 
and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia. 
Can J Cardiol. 2015;Conference Publication:(var.pagings). 31 (10 SUPPL. 1):S294-
S5. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Roth EM, Jones P, Kelly MT, Setze CM, Lele A, Sleep DJ. Effect of ABT-335 
(fenofibric acid) and rosuvastatin combination therapy on multiple lipid parameters in 
patients with hypercholesterolemia: subgroup analysis of a phase 3, 12-week, 
randomized, controlled study. Presented at Arteriosclerosis, Thrombosis, and 
Vascular Biology Annual Conference; 29 Apr - 1 May 2009; Washington, DC: United 
States. Arterioscler Thromb Vasc Biol 2010;29(7):e68-e69. 
Not relevant trial design 
(<12 wks) 
Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without 
an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 
2012;367(20):1891-900. 
Not relevant trial design 
(<12 wks) 
Roth EM, Taskinen MR, Ginsberg H, Kastelein J, Colhoun HM, Merlet L, Pordy R, 
Baccara-Dinet MT. A 24-week study of alirocumab as monotherapy versus ezetimibe: 
the first phase 3 data of a proprotein convertase subtilisin/kexin type 9 inhibitor. 
Presented at 63rd Annual Scientific Session of the American College of Cardiology 
and i2 Summit: Innovation in Intervention; 29-31 Mar 2014; Washington: United 
States. J Am Coll Cardiol 2014;63(12 SUPPL 1):A1370. 
Not relevant population 
(not required to have been 
previously treated with 
statin and no separate 
data reported) 
Roth EM, Taskinen MR, Ginsberg HN, Kastelein JJ, Colhoun HM, Robinson JG, et al. 
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with 
hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial. 
Int J Cardiol. 2014 Sep;176(1):55-61. 
Not relevant population 
(not receiving statins) 
Roth EM, Taskinen M-R, Ginsberg HN, Kastelein JJP, Colhoun HM, Robinson JG, 
Merlet L, Pordy R, Baccara-Dinet MT. Monotherapy with the PCSK9 inhibitor 
alirocumab versus ezetimibe in patients with hypercholesterolemia : results of a 24 
week, double-blind, randomized Phase 3 trial. Int J Cardiol 2014;176(1):55-61. 
Not relevant population 
("hypercholesterolemic 
patients at moderate 
cardiovascular risk not 
receiving statins or other 
lipid-lowering therapy") 
Roth EM. Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and 
US FDA approval indications. Future Cardiol 2016 Mar;12(2):115-28. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy 
and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 
2015 Mar 15;372(16):1500-9. 
Not relevant population 
(mixed populations from 
other Amgen trials) 
Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients 
with type 2 diabetes mellitus: a pooled meta-analysis of randomized placebo-
controlled clinical trials. Int J Cardiol 2010;141(2):157-66. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients 
with type 2 diabetes mellitus - a pooled meta-analysis of randomized placebo-
controlled clinical trials. Int J Cardiol 2010;141(2):157-166. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Sanofi, Genzyme. A study of the safety and efficacy of two different regimens of 
mipomersen in patients with familial hypercholesterolemia and inadequately controlled 
low-density lipoprotein cholesterol. NCT01475825. In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2014 [accessed 29.5.14]. Available 
from: http://ClinicalTrials.gov/show/NCT01475825 
Not relevant population - 
mipomersen trial not in 
HoFH 
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Sanofi, Regeneron Pharmaceuticals. Evaluation of alirocumab SAR236553 
(REGN727) when co-administered with atorvastatin in patients with primary 
hypercholesterolemia and LDL-cholesterol ≥ 100 mg/dL. NCT01288469. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2013 
[accessed 29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT01288469 
Not relevant trial design 
(8wks treatment period) 
Sanofi, Regeneron Pharmaceuticals. Open label study of long term safety evaluation 
of alirocumab. NCT01954394. In: ClinicalTrials.gov [Internet]. Bethesda (MD): 
National Library of Medicine (US).  2015 [accessed 19.3.15]; Available from: 
http://ClinicalTrials.gov/show/NCT01954394. 
Not relevant study design 
(Not RCT); Not relevant 
comparator 
Sanofi. Evaluation of efficacy and safety of AVE5530 co-administered with 
atorvastatin in primary hypercholesterolemia. NCT00741715. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2009 [accessed 
29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00741715 
Not relevant population 
(not receiving or willing 
and able to discontinue 
ongoing lipid-lowering 
therapy) 
Sanofi. Evaluation of safety and efficacy of AVE5530 as add-on to ongoing high 
doses of statins in patients with primary severe hypercholesterolemia. NCT00766688. 
In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 
2009 [accessed 29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00766688 
Not relevant population 
(unclear population and 
trial was terminated) 
Sanofi-Aventis Recherche & Développement. A multicenter, double-blind, 
randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, 
safety and tolerability of AVE5530 25 mg/day and 50mg/day when added to ongoing 
stable statin therapy (HMG-CoA reductase inhibitors) in patients with primary 
hypercholesterolemia. EUCTR2008-001550-41-FR.  In: WHO International Clinical 
Trials Registry Platform (ICTRP) [Internet]. Geneva: World Health Organization 
(WHO). 2008 [accessed 2.6.14]. Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-
001550-41 
Not relevant 
intervention/comparator 
(AVE5530) 
Sanofi-aventis Recherche & Développement. Efficacy and Safety of SAR236553 
(REGN727) Versus Ezetimibe in Patients with Hypercholesterolemia. EUCTR2011-
001424-38-BE. In: EU Clinical Trials Register (EUCTR) [Internet]. London: European 
Medicines Agency (EMA). 2012 [accessed 27.10.14]. Available from: 
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-
001424-38 
Not relevant population 
("hypercholesterolemic 
patients at moderate 
cardiovascular risk not 
receiving statins or other 
lipid-lowering therapy") 
Sanofi-Aventis Recherche & Développement. Phase III Study To Evaluate Alirocumab 
in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE 
II). EUCTR2013-002659-14-BE. In: EU Clinical Trials Register (EUCTR) [Internet]. 
London: European Medicines Agency (EMA). 2013 [accessed 27.10.14]. Available 
from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2013-002659-14 
Not relevant population 
(statin naive) 
Sanofi, Regeneron P. Efficacy and Safety of Alirocumab in Patients With 
Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying 
Therapy or the Lowest Strength of Statin.  2016; Available from: 
https://ClinicalTrials.gov/show/NCT02584504. 
Not relevant population 
(patients must have taken 
non-statin or low statin 
therapy only, not on 
maximally tolerated statin) 
Sanofi-Aventis G. A Randomized, Open-Label, Parallel Group Study 
to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care 
in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High 
Cardiovascular Ris.  2016; Available from: 
https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2015-001934-19. 
 
Not relevant population 
(inclusion based on non-
HDLC not adequately 
controlled with maximally 
tolerated statin therapy) 
Santanu G, Suhrita P, Mookerjee S, Tania K, Mita S, Pramit G, et al. Lipid modifying 
action of atorvastatin in comparison to combination of atorvastatin and nicotinic acid in 
patients with ischaemic heart disease. Indian Heart J 2011;63(5):434-7. 
Not relevant population 
Sattar N, Preiss D, Robinson JG, Djedjos CS, Elliott M, Somaratne R, et al. Lipid-
lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 
2 diabetes: a meta-analysis of individual patient data. Lancet Diabetes Endocrinol 
2016 May;4(5):403-10. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
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Sahebkar A, Simental-Mendia LE, Guerrero-Romero F, Golledge J, Watts GF. 
Efficacy and Safety of Evacetrapib for Modifying Plasma Lipids: A Systematic Review 
and Meta-Analysis of Randomized Controlled Trials. Curr Pharm Des 2016;22(5):595-
608. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Schering Plough, Merck Sharp Dohme Corp. Comparison of co-administration of 
ezetimibe plus simvastatin versus simvastatin alone in primary hypercholesterolemia 
(P03476)(Study P03476)(completed). NCT00651274. In: ClinicalTrials.gov [Internet]. 
Bethesda (MD): National Library of Medicine (US). 2008 [accessed 29.5.14]. Available 
from: http://ClinicalTrials.gov/show/NCT00651274 
Not relevant trial design 
(6wk treatment period) 
Schering Plough, Merck Sharp Dohme Corp. Comparison of ezetimibe added to 
ongoing statin therapy versus doubling the dose of statin in the treatment of 
hypercholesterolemia (P04355)(completed). NCT00652327. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2010 [accessed 
29.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00652327 
Not relevant trial design 
(8wks treatment period) 
Schering Plough, Merck Sharp Dohme Corp. Ezetimibe plus atorvastatin versus 
atorvastatin alone in subjects with primary hypercholesterolemia (Study 
P03406)(completed). NCT00651404. In: ClinicalTrials.gov [Internet]. Bethesda (MD): 
National Library of Medicine (US). 2010 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00651404 
Not relevant trial design 
(6wk treatment period) 
Schering Plough. A multicenter, randomized, parallel-groups, double-blind placebo 
controlled study comparing the efficacy, safety, and tolerability of co-administration of 
ezetimibe 10 mg with ongoing treatment with simvastatin 20 mg versus doubling the 
dose of simvastatin in subjects with primary hypercholesterolemia diabetes mellitus 
type 2 and coronary heart disease. EUCTR2004-002236-26.  In: EU Clinical Trials 
Register (EUCTR) [Internet]. London: European Medicines Agency (EMA). 2005 
[accessed 14.7.14]. Available from: https://www.clinicaltrialsregister.eu/ctr-
search/search?query=eudract_number:2004-002236-26 
Not relevant trial design 
(<12 wks) 
Schering Plough. The effects of ezetimibe/simvastatin 10/20 mg versus simvastatin 40 
mg in high cholesterol and coronary heart disease study (P04039AM2)(completed). 
NCT00423579. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2009 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00423579 
Not relevant trial design 
(6wk treatment period) 
Schulte KL, Beil S. Efficacy and tolerability of fluvastatin and simvastatin in 
hypercholesterolaemic patients: a double-blind, randomised, parallel-group 
comparison. Clin Drug Investig 1996;12(3):119-126. 
Not relevant population; 
not relevant outcomes; not 
relevant trial design 
(<12wks treatment period) 
Schwartzkopff W, Bimmermann A, Schleicher J. [Comparison of the effectiveness of 
the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in 
hypercholesterolemia]. Arzneimittelforschung 1990;40(12):1322-7. 
Not relevant population 
Seehusen DA. Statins for primary cardiovascular prevention. Am Fam 
Physician 2011;84(7):767-769. 
 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Shankar PK, Bhat R, Prabhu M, Reddy BP, Reddy MS, Reddy M. Efficacy and 
tolerability of fixed-dose combination of simvastatin plus ezetimibe in patients with 
primary hypercholesterolemia: Results of a multicentric trial from India. J Clin Lipidol. 
2007 Aug;1(4):264-70. 
Not relevant population 
(mixed statin history, 
numbers and separate 
data NR) 
Shankar PK, Bhat R, Prabhu M, Reddy BPS, Reddy MS, Reddy M. Efficacy and 
tolerability of fixed-dose combination of simvastatin plus ezetimibe in patients with 
primary hypercholesterolemia: results of a multicentric trial from India. J Clin Lipidol 
2007;1(4):264-270. 
Not relevant population 
(statin naive) 
Shaywitz AJ, Dias C, Smith B, Gao B, Gibbs J, Emery M, et al. AMG 145, a fully 
human monoclonal antibody against PCSK9, reduces LDL-C in healthy volunteers 
and patients on stable doses of statins. Presented at Annual Scientific Sessions of the 
National Lipid Association, NLA; 31 May - 3 Jun 2012; Scottsdale, AZ: United States. 
J Clin Lipidol 2012;6(3):286-287. 
Not relevant trial design 
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Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. 
AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary 
and other atherosclerotic vascular disease: 2011 update: a guideline from the 
American Heart Association and American College of Cardiology Foundation. 
Circulation 2011;124(22):2458-2473. 
Not relevant trial design 
(guidelines/guidance) 
Smulders YM, Burgers JS, Scheltens T, van Hout BA, Wiersma T, Simoons ML. 
Clinical practice guideline for cardiovascular risk management in the Netherlands. 
Neth J Med 2008;66(4):169-174. 
Not relevant trial design 
(guidelines/guidance) 
Soomro AY, Ediger M, Pandya B, Raza MR, Khan Z, Meghani M, et al. Efficacy and 
safety of proprotein convertase subtilisin/kexin type 9 inhibitors treatment in familial 
hypercholesterolemia: A comprehensive meta-analysis of all randomized clinical trials. 
J Am Coll Cardiol. 2016;67(13 SUPPL. 1):1984. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Sponseller CA, Morgan RE, Kryzhanovski VA, Campbell SE, Davidson MH. 
Comparison of the lipid-lowering effects of pitavastatin 4 mg versus pravastatin 40 mg 
in adults with primary hyperlipidemia or mixed (combined) dyslipidemia: a phase IV, 
prospective, US, multicenter, randomized, double-blind, superiority trial. Clin Ther 
2014;36(8):1211-22. 
Not relevant population 
(mixed statin history, 
numbers and separate 
data NR) 
Stein EA, Bergeron J, Gaudet D, Weiss R, Dufour R, Du Y, Yang F, Andisik M, Torri 
A, Pordy R, Gipe D. One year open-label treatment with alirocumab 150 mg every two 
weeks in heterozygous familial hypercholesterolemic patients. Presented at 63rd 
Annual Scientific Session of the American College of Cardiology and i2 Summit: 
Innovation in Intervention; 29-31 Mar 2014; Washington: United States. J Am Coll 
Cardiol 2014;63((12 SUPPL 1)):A1371. 
Not relevant comparator; 
not relevant study design 
(single arm extension 
study) 
Stein EA, Dufour R, Gagne C, Gaudet D, East C, Tribble D, et al. A randomized, 
double-blind, placebo-controlled study to assess efficacy and safety of mipomersen as 
add-on therapy in heterozygous familial hypercholesterolemia patients with coronary 
artery disease. Presented at European Society of Cardiology, ESC Congress; 28 Aug 
- 1 Sept 2010; Stockholm: Sweden. Eur Heart J 2010;31:898. 
Not relevant population - 
mipomersen trial not in 
HoFH 
Stein EA, Giugliano RP, Koren MJ, Raal FJ, Roth EM, Weiss R, Sullivan D, 
Wasserman SM, Somaratne R, Kim JB, Yang J, Liu T, Albizem M, Scott R, Sabatine 
MS, Investigators P. Efficacy and safety of evolocumab (AMG 145), a fully human 
monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background 
lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 
2014;35(33):2249-59. 
Not relevant study design 
(pooled analysis of four 
trials, which have already 
been considered in the 
review as separate 
studies) 
Stein EA, Koren M, Honarpour N, Kurtz C, Yang J, Wasserman S, et al. Clinical 
equivalence of Evolocumab 140 mg every two weeks and 420 mg monthly dosing 
regimens: a pooled analysis of 3146 patients in phase 3 studies (1107-103). Abstract 
presented at American College of Cardiology (ACC); 14-16 March 2015; San Diego, 
US. [Internet].  2015 [accessed 30.4.15]; Available from: 
http://www.abstractsonline.com/pp8/#!/3658/presentation/33655. 
Not relevant study design 
(Pooled data) 
Stein EA, Ose L, Retterstol K, Tonstad S, Schleman M, Harris S, et al. Further 
reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition 
of ezetimibe to maximum-dose rosuvastatin in patients with severe 
hypercholesterolemia. J Clin Lipidol 2007;1(4):280-286. 
Not relevant population; 
not relevant trial design 
Stein EA. Low-density lipoprotein cholesterol reduction by inhibition of PCSK9. Curr 
Opin Lipidol 2013;24(6):510-517. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Stein E. PCSK9 Inhibitors for Hyperlipidemia - Represented in NEJM by the OSLER 
and ODYSSEY trials. Presented at ESC Congress 2015; 29 Aug-2 Sep 2015; 
London: United Kingdom. 2015. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Stender S, Budinski D, Hounslow N. Pitavastatin demonstrates long-term efficacy, 
safety and tolerability in elderly patients with primary hypercholesterolaemia or 
combined (mixed) dyslipidaemia. Eur J Prev Cardiolog 2013;20(1):29-39. 
Not relevant population 
(statin status unclear) ; Not 
relevan trial design (not 
RCT) 
Stender S, Hounslow N. Robust efficacy of pitavastatin and comparable safety to 
pravastatin. Presented at 15th International Symposium on Atherosclerosis; 14-18 Jun 
2009; Boston, MA: United States. Atheroscler Suppl 2009;10(2). 
Not relevant population 
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Strony J, Hoffman R, Hanson M, Veltri E. Tolerability and effects on lipids of ezetimibe 
coadministered with pravastatin or simvastatin for twelve months: results from two 
open-label extension studies in hypercholesterolemic patients. Clin Ther 
2008;30(12):2280-97. 
Not relevant trial design; 
not relevant comparator 
Sturmer W, Kromer EP, Riegger AJ, Kochsiek K. [Lipid status and basal steroid 
hormone level following 16 weeks of lovastatin therapy in primary 
hypercholesterolemia]. Klin Wochenschr 1991;69(7):307-12. 
Not relevant population; 
not relevant trial design 
Sun Pharmaceutical Industries Ltd. A clinical trial to study the effects of rosuvastatin 
and fenofibrate in patients with primary hypercholesterolemia not adequately 
controlled with statin or fibrate monotherapy. CTRI/2009/091/001061. In: WHO 
International Clinical Trials Registry Platform (ICTRP) [Internet]. Geneva: World 
Health Organization (WHO). 2010 [accessed 2.6.14]. Available from: 
http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=1191 
Not relevant comparator; 
not relevant trial design 
Superko HR, Krauss RM, DiRicco C. Effect of fluvastatin on low-density lipoprotein 
peak particle diameter. Am J Cardiol 1997;80(1):78-81. 
Not relevant population 
(statin status unclear) 
Swergold G, Smith W, Mellis S, Logan D, Webb C, Wu R, et al. Inhibition of proprotein 
convertase subtilisin/kexin type 9 with a monoclonal antibody REGN727/SAR236553, 
effectively reduces low-density-lipoprotein cholesterol, as mono or add-on therapy in 
heterozygous familial and non familial hypercholesterolemia. Presented at American 
Heart Association's Scientific Sessions; 12-16 Nov 2011; Orlando, FL: United States. 
Circulation 2011;124(21 suppl 1). 
Not relevant population; 
Not relevan trial design 
(<12 wks) 
Takagi H, Umemoto T. Atorvastatin decreases lipoprotein(a): a meta-analysis of 
randomized trials. Int J Cardiol 2012;154(2):183-6. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Takeda. Efficacy of lapaquistat acetate and simvastatin in subjects with primary 
dyslipidemia. NCT00256178. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National 
Library of Medicine (US). 2012 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00256178 
Not relevant population; 
not relevant comparator 
Taskinen M-R. Consistent reductions in atherogenic lipid parameters with the PCSK9 
inhibitor alirocumab in patients not receiving background statin. Presented at ESC 
Congress 2015; 29 Aug-2 Sep 2015; London: United Kingdom. 2015. 
Not relevant study design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, Davey Smith G, et al. 
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst 
Rev 2011, Issue 1. Art. No.: CD004816. DOI: 
DOI:10.1002/14651858.CD004816.pub4. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, et al. Statins for the 
primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2013 
[accessed 20.5.14], Issue 1. Art. No.: CD004816. DOI: 
DOI:10.1002/14651858.CD004816.pub5. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Teramoto T, Takeuchi M, Morisaki Y, Ruotolo G, Krueger KA. Efficacy, safety, 
tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy 
or in combination with atorvastatin in Japanese patients with dyslipidemia. Am J 
Cardiol 2014;113(12):2021-9. 
Not relevant population 
(mixed statin history; 
separate data and 
numbers of participants 
NR) 
Thomas GS, Cromwell WC, Ali S, Chin W, Flaim JD, Davidson M. Mipomersen, an 
apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with 
severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, 
placebo-controlled trial. J Am Coll Cardiol 2013;62(23):2178-84. 
Not relevant population 
(HeFH and HoFH 
population for 
mipomersen. No evidence 
for HoFH only) 
Thompson PD, MacDougall DE, Newton RS, Margulies JR, Hanselman JC, Orloff DG, 
et al. Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL 
cholesterol in hypercholesterolemic patients with or without statin intolerance. J Clin 
Lipidol. 2016 May-Jun;10(3):556-67. 
Not relevant intervention/ 
comparator - ETC-1002, 
new potential lipid lowering 
therapy but unlicensed and 
still in development 
Tikkanen MJ, Helve E, Jäättelä A, Kaarsalo E, Lehtonen A, Malbecq W, et al. 
Comparison between lovastatin and gemfibrozil in the treatment of primary 
hypercholesterolemia: the Finnish Multicenter Study. Am J Cardiol 1988;62(15):35J-
43J. 
Not relevant population 
(mixed statin history) 
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Tomassini JE, Lin J, Polis AB, Shah A, Brudi P, Tershakovec A, et al. Variability of the 
ldl-c lowering response to ezetimibe and ezetimibe 1 statin therapy in 
hypercholesterolemic patients. Presented at nnual Scientific Sessions of the National 
Lipid Association, NLA; 30 May - 2 Jun 2013; Las Vegas, NV: United States. J Clin 
Lipidol 2013;7(3):281-282. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Toth P, Martin SS, Joshi P, Jones S, Massaro J, D'Agostino R, Sponseller C. 
Pitavastatin 4 mg provides significantly greater reduction in remnant lipoprotein 
cholesterol compared to pravastatin 40 mg: results from the prevail trial. 
Atherosclerosis 2014;235(2):e261-e262. 
Not relevant population 
(mixed statin history, 
numbers and separate 
data NR) 
Toth PP, Barter PJ, Palmer MK, Carlson BW. Achievement of atp iii combined ldl-c 
and non-hdl-c goals of ,100 and ,130 mg/dl or <70 and ,100 mg/ dl with 3 different 
statins: results from voyager. Presented at Annual Scientific Sessions of the National 
Lipid Association, NLA; 30 May - 2 Jun 2013; Las Vegas, NV: United States. J Clin 
Lipidol 2013;7(3):284-285. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Toth PP, Catapano A, Farnier M, Foody J, Tomassini J, Jensen E, et al. Effects of 
ezetimibe, ezetimibe coadministered with statins and statin therapies on fasting 
glucose changes in patients with hypercholesterolemia. Presented at Annual Scientific 
Sessions of the National Lipid Association, NLA; 30 May - 2 Jun 2013; Las Vegas, 
NV: United States. J Clin Lipidol 2013;7(3):277-278. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Toth PP, Hamon S, Jones SR, Joshi PH, Martin SS, Pordy R, et al. Alirocumab, a 
proprotein convertase subtilisin/kexin type 9 monoclonal antibody, reduces cholesterol 
concentrations of all serum low-density lipoprotein cholesterol fractions. Presented at 
American Heart Association Scientific Sessions and Resuscitation Science 
Symposium; 16-20 Nov 2013; Dallas, TX: United States. Circulation 2013;128(22 
suppl 1). 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Toth PP, Morrone D, Weintraub W, Hanson M, Lowe R, Lin J, et al. Safety profile of 
statins alone or combined with ezetimibe: a pooled analysis of over 21,000 patients. 
Presented at Annual Scientific Sessions of the National Lipid Association, NLA: 19-22 
May 2011; New York, NY: United States. J Clin Lipidol 2011;5(3):204. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Toth PP, Morrone D, Weintraub WS, Hanson ME, Lowe RS, Lin J, et al. Safety profile 
of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including 
over 22,000 patients treated for 6-24 weeks. Int J Clin Pract 2012;66(8):800-812. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Triscari J, Chen E, Johnson-Levonas AO, Mitchel YB, Ruck RA, MacLean A, et al. 
Effects of extended-release niacin/laropiprant on apolipoprotein B, LDL-Cholesterol, 
and non-hdlcholesterol targets in patients with type 2 diabetes. Presented at Annual 
Scientific Sessions of the National Lipid Association, NLA; 31 May - 3 Jun 2012; 
Scottsdale, AZ: United States. J Clin Lipidol 2012;6(3):285. 
Not relevant comparator 
(niacin/laropiprant) 
Tsimikas S, Witztum J, Catapano A. Effect of mipomersen on lipoprotein(A) in patients 
with hypercholesterolemia across four phase iii studies. Presented at 61st Annual 
Scientific Session of the American College of Cardiology and i2 Summit: Innovation in 
Intervention, ACC; 24-27 Mar 2010; Chicago, IL: United States. J Am Coll Cardiol 
2012;59(13 suppl 1):E1494. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Tunceli K, Lawson RW, Sibbring GC, McCormick AL, Tershakovec AM, Davies GM, et 
al. Comparative efficacy of ezetimibe-statin combination therapy and statin 
monotherapy in patients with hypercholesterolemia: systematic review and 
metaanalysis of randomised controlled trials. Presented at ISPOR 13th Annual 
European Congress; 6-9 Nov 2010; Prague: Czech Republic. Value Health 
2010;13(7):A342. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Ueda S. [Randomised controlled trial in Japanese patients with atherosclerotic 
disease]. Japanese Journal of Clinical Pharmacology and Therapeutics 
2008;39(5):143-146. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Uemura Y, Watarai M, Ishii H, Koyasu M, Takemoto K, Yoshikawa D, et al. 
Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on 
the lipid profile in Japanese patients with abnormal glucose tolerance and coronary 
artery disease. J Cardiol 2012;59(1):50-6. 
Not relevant trial design 
(crossover without 
washout) 
 by guest on O
ctober 20, 2017
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Toth et al | Network Meta-Analysis Lipid-Lowering Therapies | Supplemental Appendix 
S66 
Publication citation Reason(s) for exclusion 
University Medical Centre Ljubljana. Niacin/laropiprant and endothelial function. 
NCT01126073. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of 
Medicine (US). 2011 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT01126073 
Not relevant population 
(already reached LDL-C at 
baseline) 
University of California San Diego, Merck Sharp Dohme Corp. Ezetimibe in patients 
hypo-responsive to statins. NCT00965055. In: ClinicalTrials.gov [Internet]. Bethesda 
(MD): National Library of Medicine (US). 2013 [accessed 29.5.14]. Available from: 
http://ClinicalTrials.gov/show/NCT00965055 
Not relevant outcome 
(early termination) 
University of Pennsylvania, Chestnut Hill Health System. Safety of red yeast rice for 
high cholesterol in individuals with statin intolerance. NCT00639223. In: 
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2009 
[accessed 30.5.14]. Available from: http://ClinicalTrials.gov/show/NCT00639223 
Not relevant 
intervention/comparator 
(red yeast rice vs. placebo) 
University of Roma La Sapienza. Cholesterol-lowering effects of nutraceuticaLs 
versus ezetimibe in statin-intolerant patients. NCT01807078. In: ClinicalTrials.gov 
[Internet]. Bethesda (MD): National Library of Medicine (US). 2013 [accessed 
30.5.14]. Available from: http://clinicaltrials.gov/show/NCT01807078 
Not relevant population; 
not relevant comparator 
(nutraceutical) 
Uusitupa M, Ebeling T, Happonen P, Voutilainen E, Turtola H, Parviainen M, et al. 
Combination therapy with lovastatin and guar gum versus lovastatin and 
cholestyramine in treatment of hypercholesterolemia. J Cardiovasc Pharmacol 
1991;18(4):496-503. 
Not relevant comparator 
Vallés F, Anguita M, Anglada J, Aguirre C, Fabiani F, Plaza L, et al. A multicenter 
double-blind study comparing lovastatin and gemfibrozil in the treatment of primary 
hypercholesterolemia. Atherosclerosis 1991;91 Suppl:S3-9. 
Not relevant population 
Van Dam MJ, Penn HJAM, Den Hartog FR, Kragten HA, Trip MD, Buirma RJA, et al. 
A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin 
and fluvastatin: a randomized, double-blind study in adult patients at moderate to high 
risk for cardiovascular disease. Clin Ther 2001;23(3):467-478. 
Not relevant population 
(mixed) 
van der Harst P, Asselbergs FW, Hillege HL, Bakker SJL, Voors AA, van Veldhuisen 
DJ, et al. Effect of withdrawal of pravastatin therapy on C-Reactive protein and low-
density lipoprotein cholesterol. Am J Cardiol 2007;100(10):1548-1551. 
Not relevant trial design 
(trial looking at effects of 
withdrawal after a RCT) 
Vergani C, Stefanoni P. Efficacy and tolerability of gemfibrozil in hypercholesterolemic 
patients previously treated with simvastatin. Adv Ther 1993;10(4):189-196. 
Not relevant population; 
not relevant trial design 
(<10pts per arm) 
Villasis-Keever MA, Rendon-Masias ME, Pineda-Cruz R, Escamilla-Nunez A, Mould-
Quevedo JF. A meta-analysis of efficacy of atorvastatin in comparison to pravastatin, 
simvastatin and rosuvastatin for the control of dyslipidemia and cardiovascular events 
prevention. Presented at 15th Annual International Meeting of the International 
Society for Pharmacoeconomics and Outcomes Research, ISPOR; 15-19 May 2010; 
Atlanta, GA: United States. Value Health 2010;13(3):A150. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Visser M, Akdim F, Basart D, Kastelein J, Nederveen A, Kwoh T, et al. Effect of 
mipomersen treatment on hepatic triglyceride content in subjects with familial 
hypercholesterolemia. Presented at 15th International Symposium on Atherosclerosis; 
14-18 Jun 2009; Boston, MA: United States. Atheroscler Suppl 2009;10(2). 
Not relevant population (no 
HoFH for mipomersen) 
Visser M, Wagener G, Baker B, Geary R, Donovan J, Beuers U, et al. A randomized, 
double-blind, placebo-controlled trial to evaluate the effect of weekly subcutaneous 
injections of mipomersen, an apolipoprotein B-100 synthesis inhibitor, on low density 
lipoprotein cholesterol in high-risk statin-intolerant patients with hypercholesterolemia. 
Presented at American Heart Association's Scientific Sessions; 12-16 Nov 2011; 
Orlando, FL. Circulation 2011;124(21 suppl 1). 
Not relevant population (no 
HoFH for mipomersen) 
Visser ME, Kastelein JJP, Stroes ESG. Apolipoprotein B synthesis inhibition: results 
from clinical trials. Curr Opin Lipidol 2010;21(4):319-323. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Visser ME, Wagener G, Baker BF, Geary RS, Donovan JM, Beuers UHW, et al. 
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein 
cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-
controlled trial. Eur Heart J 2012;33(9):1142-9. 
Not relevant population - 
mipomersen trial not in 
HoFH 
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Wan H, Gumbiner B, Joh T, Udata C, Forgues P, Garzone PD. Effects of RN316 (pf-
04950615), a humanized igg2a monoclonal antibody binding proprotein convertase 
subtilisin kexin type 9, on lipoprotein particles in hypercholesterolemic subjects. 
Presented at 62nd Annual Scientific Session of the American College of Cardiology 
and i2 Summit: Innovation in Intervention, ACC; 9-11 Mar 2013; San Francisco, CA: 
United States. J Am Coll Cardiol 2013. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Watts G, Lambert G, Hamilton S, Chew G, Jenkins A, Chan D. Plasma proprotein 
convertase subtilising/KEXIN type 9 (PCSK9) concentrations are decreased by 
fenofibrate in statin-treated type 2 diabetic patients. Presented at 15th International 
Symposium on Atherosclerosis; 14-18 Jun 2009; Boston, MA: United States. 
Atheroscler Suppl 2009;10(2). 
Not relevant trial design 
(crossover trial with only 
12pts so <10pts per arm) 
Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the 
therapeutic equivalence of statins. J Clin Pharm Ther 2010;35(2):139-151. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Weng TC, Yang YHK, Lin SJ, Tai SH. A systematic review and meta-analysis on the 
therapeutic equivalence of statins. J Clin Pharm Ther 2010;35(2):139-51. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Wensel TM, Waldrop BA, Wensel B. Pitavastatin: a new HMG-CoA reductase 
inhibitor. Ann Pharmacother 2010;44(3):507-14. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Willich SN, Englert H, Sonntag F, Völler H, Meyer-Sabellek W, Wegscheider K, et al. 
Impact of a compliance program on cholesterol control: results of the randomized 
ORBITAL study in 8108 patients treated with rosuvastatin. Eur J Prev Cardiolog 
2009;16(2):180-7. 
Not relevant intervention; 
not relevant comparator 
(compares with or without 
compliance intervention 
Worthy G, Gandra SR, Bridges I, Worth G, Dent R, Forbes CA, et al. A systematic 
review and network meta-analysis on the efficacy of evolocumab and other lipid-
lowering therapies for the management of lipid levels in hyperlipidemia. Value Health. 
2016;19(3):A53. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Yamasaki T, Iwashima Y, Jesmin S, Ohta Y, Kusunoki H, Hayashi S, et al. 
Comparison of efficacy of intensive versus mild pitavastatin therapy on lipid and 
inflammation biomarkers in hypertensive patients with dyslipidemia. PLoS One. 
2014;9(2):e89057. 
Not relevant study design 
(Not RCT); Not relevant 
population (statin status 
unclear) 
Yamagishi T. [Efficacy and safety of ezetimibe added on to rosuvastatin (2.5 mg) 
compared with uptitration of rosuvastatin (5 mg) in hyperlipidemic patients]. Jpn 
Pharmacol Ther 2010;38(3):305-311. 
Duplicate of publication 
already assessed 
Yan F, Tian L, Xiao Z, Li S, Fu M, Tian H. Comparison of the efficacy of fenofibrate 
and acipimox on plasma lipoprotein subclasses distribution in the Chinese population 
with Type 2 diabetes mellitus and hypertriglyceridemia. Clinical Lipidology 
2014;9(2):171-177. 
Not relevant population 
(statin history unclear and 
"None had taken lipid-
lowering drugs….for at 
least 3mths") 
Ye Y, Zhao X, Zhai G, Guo L, Tian Z, Zhang S. Effect of high-dose statin versus low-
dose statin plus ezetimibe on endothelial function: a meta-analysis of randomized 
trials. J Cardiovasc Pharmacol Ther 2012;17(4):357-65. 
Not relevant trial design; 
review/meta-
analysis/pooled analysis 
for reference checking 
Zema MJ. Add-on therapy for hypercholesterolemia: a pilot comparison of two 
gastrointestinally-acting agents in statin-treated patients. J Clin Lipidol 2009;3(2):119-
124. 
Not relevant trial design 
(crossover trial with only 
12pts so <10pts per arm 
and treatment duration of 
only 6wks) 
Zou X, Si QJ. Is combined lipid-regulating therapy safe and feasible for the very old 
patients with mixed dyslipidemia? J Geriatr Cardiol. 2013 Dec;10(4):349-54. 
Not relevant study design 
(Not RCT) 
Zubareva M, Tripoten M, Rozhkova T, Solovieva E, Balakhonova T, Rogoza A, et al. 
Effects of Ezetimibe, intial doses of statins, and its combination on lipids in high risk 
patients with hyperlipideamia. Presented at 78th EAS Congress; 20-23 Jun 2010; 
Hamburg: Germany. Atheroscler Suppl 2010;11(2):189. 
Not relevant trial design 
(6wk treatment period) 
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C. List of unobtainable trials (12 trials) 
Publication citation 
[No authors listed]. [Hypercholesterolemia: when statins are not enough or not tolerated with 
combination therapy to LDL cholesterol target goal]. MMW Fortschr Med 2012;154(13):86-7. 
Kulev BD, Ageev FT. [Effect of various approaches to therapy with statins in high risk patients 
from the point of view of vascular endothelium]. Kardiologiia 2009;49(5):4-10. 
Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, et al. [Reduction of 
cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of 
the Pravastatin Atherosclerosis Intervention Program]. Fortschr Med 1996;114(8):91-8. 
Liakishev AA, Kukharchuk VV, Titov VN, Volkova EI, Konstantinov VO, Lipovetskii BM, et al. [An 
evaluation of the hypolipidemic effects of lovastatin in primary hypercholesterolemia. A 
multicenter study]. Kardiologiia 1993;33(11):48-54. 
Bays HE, MacLean A, Shah A, Sisk CM, Dong Q, Maccubbin D. The lipid-altering effects of 
extended-release niacin/laropiprant among different patient subgroups. Presented at Annual 
Scientific Sessions of the National Lipid Association, NLA; 13-16 May 2010; Chicago, IL: United 
States. J Clin Lipidol 2010;4(3):215. 
Yamagishi T. [Efficacy and safety of ezetimibe added on to rosuvastatin (2.5 mg) compared with 
uptitration of rosuvastatin (5 mg) in hyperlipidemic patients]. Jpn Pharmacol Ther 
2010;38(3):305-311. 
Gao RL. [The efficacy and safety of rosuvastatin on treating patients with hypercholesterolemia 
in Chinese: a randomized, double-blind, multi-center clinical trial]. Zhonghua xin xue guan bing 
za zhi [Chinese journal of cardiovascular diseases] 2007;35(3):207-211. 
Tao P, Wu XS, Yu XJ, Zhu J, Tao SQ. Efficacy and safety of cerivastatin 0.1 mg, 0.2 mg and 0.3 
mg in Chinese patients with primary hypercholesterolaemia: a multicentre, randomised, double-
blind, placebo-controlled study. Journal of Clinical Research 2000;3:29-40. 
Carmena R, De Oya M, Gomez-Gerique J, Mata P, Serrano S, Franco M, et al. Pravastatin, 
cholestyramine, and bezafibrate in patients with heterozygous familial hypercholesterolemia: the 
Spanish Multicenter Pravastatin Study. Cardiovascular Risk Factors 1996;6(1):55-61. 
Behounek BD. [Pravastatin in patients with cardiovascular risk factors. Effects of pravastatin in 
patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two 
additional atherosclerotic risk factors]. Fortschr Med 1994;112(5):45-54. 
Merck Co Inc. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to 
ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in 
hypercholesterolaemic patients with atherosclerosis or coronary heart disease: Merck Protocol 
Number: 0806-00, 2004  
Roth EM, McKenney JM. ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously Q2W 
as monotherapy versus ezetimibe over 24 weeks. Future Cardiol. 2015;11(1):27-37. 
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Supplemental Figures 
Figure S1. Treatment Difference in Percent LDL-C (95% Credible Interval) Change from 
Baseline, Evolocumab 140 mg Q2W (Panel A) or Evolocumab 420 mg QM (Panel B) at Week 
12 vs Comparator at Week 12 
 
 
LDL-C indicates low-density liprotein cholesterol; Q2W, every 2 weeks; QM, every month. 
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Figure S2. Risk of Bias Assessed in 69 Trials 
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Figure S3. Direct Meta-analyses of LDL-C Reduction (Following 2 Pages).  
Sensitivity analyses indicated via footnote. aExcluding YUKAWA studies1, 2: −71.45 (95% CI 
−75.33, −67.57); I2: NA (only LAPLACE-2). bExcluding YUKAWA studies1, 2: −71.24 (−75.16, 
−67.33); I2: 24.5%, P=0.25. cAlirocumab was titrated to 150 mg at week 12 for patients whose 
LDL-C did not reduce sufficiently.These results are for 12 weeks before titration for ODYSSEY 
COMBO I and ODYSSEY JAPAN and for 24 weeks for ODYSSEY CHOICE I. dExcluding 
ODYSSEY JAPAN3: −48.96 (−53.80 to −44.12); I2: 0%, P=0.420. eExcluding YUKAWA  
studies1, 2: −68.13 (−72.03 to −64.23); I2: NA (only LAPLACE-2). fExcluding YUKAWA studies1, 2: 
−60.21 (−64.86 to −55.55); I2: 67.4%, P=0.047. 
CI indicates confidence interval; LDL-C, low-density lipoprotein cholesterol; NA, not applicable; 
Q2W, every 2 weeks; QM, every month. Study acronym definitions are available in the source 
references. 
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Evolocumab 140 mg vs. placebo: 10-12 weeks Q2W
LAPLACE-2 39.86 -71.45 (-75.33, -67.57)
YUKAWA-1 34.61 -71.70 (-76.80, -66.60)
YUKAWA-2 25.52 -81.71 (-89.16, -74.26)
Overall (I-squared = 67.3%, P = 0.047) 100.00 -74.16 (-79.51, -68.80)
Evolocumab 140 mg vs. placebo: 12 weeks Q2W
LAPLACE-2 31.35 -72.89 (-77.12, -68.66)
LAPLACE-TIMI 26.64 -68.82 (-74.31, -63.33)
YUKAWA-1 24.78 -72.25 (-78.27, -66.23)
YUKAWA-2 17.23 -83.17 (-91.79, -74.55)
Overall (I-squared = 60.6%, P = 0.055) 100.00 -73.42 (-78.07, -68.77)
Alirocumab 75 mg vs. placebo: ≥12 weeks Q2W
ODYSSEY COMBO I 33.19 -47.40 (-53.55, -41.25)
ODYSSEY CHOICE I 30.59 -51.50 (-59.34, -43.66)
ODYSSEY JAPAN 36.22 -61.50 (-65.30, -57.70)
Overall (I-squared = 88.0%, P = < 0.001) 100.00 -53.76 (-63.39, -44.14)
Alirocumab 150 mg vs. placebo: ≥12 weeks Q2W
ODYSSEY HIGH FH 29.76 -40.30 (-51.35, -29.25)
ODYSSEY Long-term 37.77 -64.80 (-67.20, -62.40)
McKenney 2012 32.47 -67.30 (-76.04, -58.56)
Overall (I-squared = 89.3%, P = 0.001 100.00 -58.32 (-71.10, -45.54)
Evolocumab 140 mg vs. ezetimibe: 10-12 weeks Q2W
LAPLACE-2  -44.59 (-50.42, -38.76)
Evolocumab 140 mg vs. ezetimibe: week 12 Q2W
LAPLACE-2  -46.14 (-52.24, -40.04)
Alirocumab 75 mg vs. ezetimibe: ≥12 weeks Q2W
ODYSSEY COMBO II 51.48 -29.40 (-33.70, -25.10)
ODYSSEY OPTIONS I 29.63 -23.40 (-30.50, -16.30)
ODYSSEY OPTIONS II 18.89 -22.30 (-31.95, -12.65)
Overall (I-squared = 35.3%, P = 0.213) 100.00 -26.28 (-31.00, -21.56)
Ezetimibe vs. placebo: 10-12 weeks Q2W
LAPLACE-2 49.38 -26.87 (-33.15, -20.59)
Masana 2005 50.62 -27.00 (-33.20, -20.80)
Overall (I-squared = 0.0%, P = 0.977) 100.00 -26.94 (-31.35, -22.53)
Ezetimibe vs. placebo: week 12 Q2W
LAPLACE-2 46.76 -26.75 (-33.36, -20.14)
Masana 2005 53.24 -27.00 (-33.20, -20.80)
Overall (I-squared = 0.0%, P = 0.957) 100.00 -26.88 (-31.41, -22.36)
  
Study Weight Mean Difference (95% CI)
Direct Meta-analyses Q2W
Change From Baseline in LDL-C (% [95% CI])
-100 -75 -50 -25 0 25 35
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Evolocumab 420 mg vs. placebo: 10-12 weeks QM
LAPLACE-2 35.35 -68.13 (-72.03, -64.23)
YUKAWA-1 31.46 -68.70 (-73.80, -63.60)
YUKAWA-2 33.19 -76.82 (-81.39, -72.25)
Overall (I-squared = 78.0%, P = 0.011) 100.00 -71.19 (-76.74, -65.65)
Evolocumab 420 mg vs. placebo: 12 weeks QM
LAPLACE-2 21.70 -62.31 (-66.68, -57.94)
LAPLACE-TIMI 57 18.81 -54.36 (-60.14, -48.58)
YUKAWA-1 17.79 -66.08 (-72.37, -59.79)
YUKAWA-2 18.93 -70.21 (-75.93, -64.49)
DESCARTES 22.77 -62.67 (-66.51, -58.83)
Overall (I-squared = 74.5%, P = 0.003) 100.00 -63.06 (-67.56, -58.57)
Alirocumab 300 mg vs. placebo: ≥12 weeks QM
McKenney 2012 47.68 -42.60 (-51.33, -33.87)
ODYSSEY CHOICE I 52.32 -58.70 (-64.19, -53.21)
Overall  (I-squared = 89.3%, P = 0.002) 100.00 -51.02 (-66.78, -35.26)
Evolocumab 420 mg vs. ezetimibe: 10-12 weeks QM
LAPLACE-2  -48.33 (-54.38, -42.28)
Evolocumab 420 mg vs. ezetimibe: week 12 QM
LAPLACE-2  -42.74 (-49.20, -36.28)
Ezetimibe vs. placebo: 10-12 weeks QM
LAPLACE-2 49.11 -19.80 (-26.28, -13.32)
Masana 2005 50.89 -27.00 (-33.20, -20.80)
Overall (I-squared = 59.6%, P = 0.116) 100.00 -23.46 (-30.52, -16.41)
Ezetimibe vs. placebo: week 12 QM
LAPLACE-2 47.62 -19.57 (-26.53, -12.61)
Masana 2005 52.38 -27.00 (-33.20, -20.80)
Overall  (I-squared = 59.0%, P = 0.118) 100.00 -23.46 (-30.73, -16.19)
   
Study Weight Mean Difference (95% CI)
Direct Meta-analysis QM
-100 -75 -50 -25 0 25 35
Change From Baseline in LDL-C (% [95% CI])
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Figure S4. Network for Comparing Other Lipids With Evolocumab 140 mg Q2W vs Other 
Therapies. AliMab indicates alirocumab; ApoB, apolipoprotein B; EvoMab, evolocumab; EZE, 
ezetimibe; HDL-C, high-density lipoprotein-cholesterol; Lp(a), lipoprotein(a); non-HDL-C, non-
high–density lipoprotein-cholesterol; Q2W, every 2 weeks; QM, every month. Study acronym 
definitions are available in the source references. 
A. Sensitivity Analysis Combining Evolocumab Q2W and QM Dosing 
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B. Evolocumab 140 mg Q2W With any Background Therapy 
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C. HDL-C and Non-HDL-C 
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D. ApoB 
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E. Lp(a) 
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Figure S5. Treatment Difference in Percent LDL-C (95% Credible Interval) Change: Panel A, 
Evolocumab 140 mg Q2W and 420 mg Every Month Combined at the Mean of Weeks of 10 and 
12 vs Comparator at ≥ 12 Weeks; Panel B, Evolocumab 140 mg Q2W at the Mean of Weeks of 
10 and 12 vs Comparator at ≥ 12 Weeks With Any Background Therapy 
 
LDL-C indicates low-density liprotein cholesterol; Q2W, every 2 weeks; QM, every month. 
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Figure S6. Sensitivity Analysis: Treatment Difference in Percent LDL-C (95% Credible Interval) 
Change from Baseline, Evolocumab 140 mg Q2W at the Mean of Weeks 10 and 12 vs 
Comparator at ≥ 12 Weeks: Panel A, Excluding Japan Studies; Panel B, ODYSSEY HIGH FH. 
Evolocumab 420 mg Every 4 Weeks at Weeks 10 and 12 vs Comparator at ≥ 12 Weeks: Panel 
C, Excluding Studies Conducted in Japan. 
 
aOne study of alirocumab 75 mg Q2W did not report 12-week results for secondary lipid endpoints, so 24-week 
results were used. Therefore data labelled alirocumab 75 mg includes data from those who were titrated to 
alirocumab 150 mg from week 12. LDL-C indicates low-density liprotein cholesterol; Q2W, every 2 weeks; QM, every 
month. 
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Figure S7. Treatment Difference in Percent (95% Credible Interval) Change from Baseline, 
Evolocumab 140 mg Q2W at the Mean of Weeks of 10 and 12 vs Comparator at ≥ 12 Weeks: 
Panel A, HDL-C; Panel B, Non-HDL-C; Panel C, ApoB; Panel D, Lp(a). 
 
LDL-C indicates low-density liprotein cholesterol; Q2W, every 2 weeks; QM, every month. 
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Supplemental Tables 
Table S1. Methodology and Characteristics of Included Studies 
Characteristic No. of trials out 
of 69 (%) 
Type of hyperlipidemia  
Primary  24 (34.8) 
Secondary 19 (27.5) 
Primary and secondary 23 (33.3) 
NR/unclear 3 (4.4) 
HeFH/HoFH status  
HoFH 2 (2.9) 
HeFH 9 (13.0) 
Mixed HoFH and HeFH 4 (5.8) 
HoFH excluded 8 (11.6) 
FH excluded 7 (10.2) 
NR/unclear 39 (56.5) 
Overall risk category of population  
Population with previous CVD events 
and/or at high risk 
17 (24.6) 
Population without previous CVD events 4 (5.8) 
Mixed population with and without previous 
CVD events/high risk of CVD 
29 (42.0) 
NR/unclear 19 (27.5) 
Type 2 diabetes status  
Type 2 diabetic population 7 (10.2) 
Non-diabetic population 2 (2.9) 
Mixed type 2 and non-diabetic population 35 (50.7) 
NR/unclear 25 (36.2) 
Ethnicity  
Predominantly (>90%) White 7 (10.2) 
Japanese 12 (17.4) 
South Asian Canadian 1 (1.5) 
Mixed 22 (31.9) 
NR/unclear 27 (39.1) 
Smoking status  
Smokers and nonsmokers 17 (24.6) 
Smokers, nonsmokers, and ex-smokers 7 (10.2) 
Nonsmokers and ex-smokers 1 (1.5) 
NR/unclear 44 (63.8) 
Gender  
Mixed gender 66 (95.7) 
Males only 1 (1.5) 
NR/unclear 2 (2.9) 
Obesity status  
Normal (BMI 18.50-24.99 kg/m2) 3 (4.4) 
Overweight (BMI ≥ 25.00 kg/m2) 12 (17.4) 
Obese (BMI ≥ 30.00 kg/m2) 2 (2.9) 
Mixed (normal, overweight and obese) 8 (11.6) 
NR/unclear 44 (63.8) 
Hypertension status  
Hypertensive patients included 36 (52.2) 
NR/unclear 33 (47.8) 
CVD indicates cardiovascular disease, HeFH, heterozygous familial hypercholesterolemia; HoFH, homozyqous 
familial hypercholesterolemia; NR, not reported. 
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Table S2. Studies Retrieved by the Systematic Review but Excluded From the Network Meta-
Analysis 
Study Details Reason 
Abbott/NCT00300430 
3 different statin + fenofibrate 
comparisons 
No comparison of interest for NMA 
Abbott/NCT01674712/ 
EUCTR2011-005924-16-CZ 
Fenofibrate monotherapy or in 
combination with simvastatin 
No comparison of interest for NMA 
ACCORD Lipid Trial Fenofibrate vs placebo No comparison of interest for NMA 
Arai 2016 Anacetrapib vs placebo No comparison of interest for NMA 
ARBITER 2 Required data not available Data not available 
ARBITER 6-HALTS/ 
NCT00397657 
Required data not available Data not available 
Bando 2016 Statin vs statin (switching agent) No comparison of interest for NMA  
Chen 2013 Required data not available Data not available 
DEFINE Anacetrapib vs placebo No comparison of interest for NMA 
EASEGO 
No common switching of statin dose in 
placebo group (some moderate to 
moderate, some moderate to high) and 
some subjects in ezetimibe group 
switched from moderate to low dose 
statin 
Unstable or low statin dose 
 
ENHANCE 
24-month outcomes and different run-in 
period 
Ineligible study design 
 
ESSENTIAL Required data not available Data not available 
Ezetimibe Study Group  
In placebo group atorvastatin went from 
moderate to high.  Dose doubling / 
quadrupling was common in both arms 
Unstable or low statin dose 
 
Farnier 2010 (pravastatin trial) Low-dose statin Unstable or low statin dose 
Farnier 2011 (simvastatin trial) Statin dose not stable Unstable or low statin dose 
Farnier 2012 Statin dose not stable Unstable or low statin dose 
GAUSS/Amgen 20090159 
Evolocumab vs ezetimibe in statin-
intolerant patients 
No background statin 
therapy/Ineligible patient population 
GAUSS-2/Amgen 20110116 
Evolocumab vs ezetimibe in statin-
intolerant patients 
No background statin 
therapy/Ineligible patient population 
GAUSS-3/Amgen 20120332 
Evolocumab vs ezetimibe in statin-
intolerant patients 
No background statin 
therapy/Ineligible patient population 
Gelabert 2004 Required data not available Data not available 
Goshima 2010 Low-dose statin Unstable or low statin dose 
INFINITY 
Statin subjects: 40% switched from 
moderate to high atorvastatin and 60% 
from high to high.  Dose doubling was 
common in both arms post randomization 
Unstable or low statin dose 
Kastelein 2015 
Required data not available (trial of 
LY3015014) 
Data not available 
Kei 2013 Low statin dose, no SD/SE Unstable or low statin dose 
Kersting 2000 Required data not available Data not available 
Kowa Research 
Europe/NCT00344370 
Statin vs statin No comparison of interest for NMA 
Kush 2009 
54% not on statin at baseline and no 
details of statin intensity (Asian 
population) 
Ineligible population 
McClean 2011 Some statin naïve subjects Ineligible population 
Nadaraia 2011 Unknown statin intensity Data not available 
Novartis/NCT01551173 Statin vs statin No comparison of interest for NMA 
ODYSSEY ALTERNATIVE 
Alirocumab vs placebo in statin-intolerant 
patients 
No background statin therapy 
ODYSSEY FH I Alirocumab vs placebo in FH only 
Ineligible background therapy 
(prinicipally statin+ezetimibe) 
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Study Details Reason 
ODYSSEY FH II Alirocumab vs placebo in FH only 
Ineligible background therapy 
(prinicipally statin+ezetimibe) 
Okada 2011 
Statin dose not stable, included some low 
dose 
Unstable or low statin dose 
PEAS Low dose statin Unstable or low statin dose 
Pfizer/NCT01592240 Bococizumab vs placebo No comparison of interest for NMA 
RADICHOL 1 Mipomersen vs placebo in HoFH Ineligible population 
REALIZE/NCT01524289 Anacetrapib vs placebo No comparison of interest for NMA 
RESEARCH 
Japanese diabetic patients, some on low 
dose statin 
Unstable or low statin dose 
RUTHERFORD/ 
Amgen 20090158 
Evolocumab vs placebo in HeFH patients 
Ineligible background therapy 
(prinicipally statin+ezetimibe) 
RUTHERFORD-2/Amgen 
20110117 
Evolocumab vs placebo in HeFH patients 
Ineligible background therapy 
(prinicipally statin+ezetimibe) 
Sanofi NCT01812707 Low dose statin, no SD/SE Unstable or low statin dose 
Sawayama 2011 Required data not available Data not available 
Scott 2010 
Fenofibrate vs placebo (simvastatin 
background) 
No comparison of interest for NMA 
SEACOAST II 
Required data not available (median at 
24 weeks) 
Data not available 
SEARCH/ISRCTN74348595 
Required data not available (no change 
or % change in LDL-C) 
Data not available 
Simvastatin To Atorvastatin 
switch Trial (STAT) 
Required data not available and 
comparison of moderate to high intensity 
statin 
No comparison of interest for NMA 
Six Cities Study 
Patients were previously treated with 
statin but discontinued statin prior to the 
start of the trial consequent baseline lipid 
values were from a no statin baseline. 
Ineligible population 
Stein 2008/NCT00125125 Required data not available Data not available 
Study P06027 Included 2.5 mg rosuvastatin Unstable or low statin dose 
TESLA/Amgen 20110233 Evolocumab vs placebo in HoFH Ineligible population 
Torimoto 2013 Included 2.5 mg rosuvastatin Unstable or low statin dose 
TREAC/NCT00203476 Required data not available Data not available 
TRIPLE Required data not available Data not available 
Wink 2002 Required data not available Data not available 
Yamagishi 2010 Low-dose rosuvastatin (2.5 mg) Unstable or low statin dose 
Yamazaki 2013 Required data not available Data not available 
ZETELD Low-dose atorvastatin (10 mg) Unstable or low statin dose 
Shaded rows are included in a sensitivity analysis but not in the main analyses. SD indicates standard deviation; SE, 
standard error. Study acronym definitions are available in the source references. 
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